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Radiotherapy (RT), the mainstay treatment for head & neck cancer (HNC), is associated with 
salivary gland dysfunction. Intensity-modulated radiotherapy (IMRT) helps mitigate the 
severity of side effects. This is of particular note with oral mucositis being a very frequent side 
effect of head and neck cancer radiation therapy treatment having a clinical impact on 
patients being a limiting factor for cancer treatment, compromising its effectiveness. In 
addition, there is a lack of adequate treatment to reverse, control or prevent this side effect 
The aim of this study was to analyse and evaluate the longitudinal nature of IMRT oral side 
effects and changes in nine salivary protein composition, as well as their possible associations, 
in order to develop a clinical and laboratory-based model, built on these connections, for the 
prediction of the incidence and severity of oral mucositis.  
Samples were obtained from 40 head and neck cancer patients prior to IMRT (T0) at Guy’s 
Hospital London in the Special Dental Care Unit, afterwards they were seen at six months post 
IMRT (T1) and 12 months post IMRT (T2). Unstimulated whole saliva samples were used to 
quantify flow rate and were analysed for total protein content using the Bicinchoninic Acid 
Assay (BCA), Periodic Acid Schiff (PAS) staining determined glycoprotein concentration, 
including mucin 5B and mucin 7, α-amylase activity was determined by kinetic assay, targeted 
Enzyme-Linked Immunosorbent Assays (ELISA) were used to quantified IgA, albumin cystatin 
S, acidic proline-rich peptides and statherin. Coomassie Brilliant blue was employed to detect 
carbonic anhydrase VI protein (CA VI) band.  
In agreement with previous studies using conventional RT, IMRT resulted in decreased saliva 
flow rate and composition, along with xerostomia, taste variation reported by patients and 
oral mucositis score showed a significant, transient alteration.  
Significant reductions in total protein secretion rate were identified for individuals on IMRT 
compared to baseline. Protein concentration for mucin 5B and mucin 7 were significantly 
elevated, concentration levels of IgA did not vary at any time point following IMRT. α-amylase 
activity and cystatin S were statistically decreased post-IMRT. Albumin concentration was 
significantly increased at T1, PRP and statherin reduction was not significant post IMRT.  
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There were reported significant associations among protein composition, secretion rate and 
this reduced flow rate as well as dry mouth feeling reported by patients and taste acuity. 
Additionally, it was observed significant association between oral mucositis onset /severity 
and saliva total protein concentration and secretion rate along with specific salivary proteins 
mucin 5B, mucin 7 and IgA as a part of the mucosal protection barrier and hydration layer, as 
well as amylase that play a role in bacterial colonization, cystatin S as an antibacterial  protein 
and part of pellicle, and albumin as marker of inflammatory processes. These associations 
between clinical and biochemical data allowed the determination of potential cases that can 
serve as a reference for monitoring oral response to therapy. The current study proposed the 
use of novel salivary protein predictive model for the early diagnosis and potential severity of 
oral mucositis in head and neck cancer patients based on the analysis of ROC curves. The 
specific proteins concentration and secretion rate cut off points were selected regarding their 
sensitivity and specificity to target this condition and classify patients susceptible to develop 
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1.1 Introduction  
 
In the treatment of advanced head and neck cancer, radiotherapy (RT) remains a 
mainstay, either as a monotherapy to control tumour size prior to surgery, or in conjunction 
with chemotherapy. Despite the high efficacy of localised radiotherapy in the treatment of 
tumours, adjacent tissues and structures can suffer significant injury resulting in off-target 
effects, that may be severe, debilitating and treatment-limiting. The salivary glands are 
among the normal tissues often affected in patients with head and neck cancers (HNC) as the 
RT beam path, in most instances, must traverse these sensitive tissues with high radiation 
weighting (absorption and susceptibility of tissues). One of the most significant long-term 
complication of radiotherapy is a progressive loss of salivary gland function, leading to 
quantitative and qualitative losses in saliva, recognised clinically as radiation-induced 
xerostomia (dry mouth)(Vissink et al., 2010; Baskar et al., 2012; Duarte et al., 2014; Almståhl 
et al., 2019).   
In addition to injury to the major glands, oral complications may be related to permanent cell 
damage induced by the toxic effects of radiation. DNA of cells in the tissues surrounding the 
tumour site is affected, impairing cell division and resulting in cell death or deterioration of 
functional characteristics. For instance, cumulative doses >30Gy will produce degeneration of 
salivary gland acinar cells along with inflammation and fibrosis. Even though cells have slow 
turnover rates (circa 60 to 120 days) the changes in volume and composition start 
immediately after RT. Further RT is known to produce modification of connective tissues 
causing acute apoptosis of fibroblasts and vascular tissues preceding the damage in the 
epithelial cells resulting in induced mucosal injury and reduction of healing particularly in 
mucosal tissue (Sonis, 2004a; Rieger et al., 2012; Turner et al., 2013).  
All of these complications are interconnected; salivary gland hypofunction induces a 
significant reduction in salivary flow rate, causing xerostomia, which will hamper speech, 
swallowing and altering taste perception as well as producing nocturnal oral discomfort 
(Wijers et al., 2002; Vissink et al., 2003; Nutting et al., 2011; Vissink et al., 2015).  A reduced 
salivary flow rate is usually accompanied by an altered saliva composition, leading to an 
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increased risk of oral diseases and hastening progression of dental caries. It is well established 
that along with healthy diet and oral hygiene, saliva is important in maintaining tooth integrity 
through mineral and bacterial homeostasis acquired enamel pellicle and antibacterial activity 
and host protection (Hannig et al., 2017; Pitts et al., 2017).  
Intensity modulated radiation therapy (IMRT) was developed to mitigate the toxic effects of 
RT on the tissues surrounding the tumour site, minimising salivary gland hypofunction.  
Studies found lower instances of xerostomia reported by patients as well as improvements in 
salivary flow rate and quality of life parameters related to xerostomia in head and neck cancer 
patients (Nutting et al., 2011). However, around 40 % of head and neck cancer patients still 
experience moderate to severe sensations of xerostomia along with a reduced salivary flow 
rate  following IMRT (Vissink et al., 2010; Belstrøm et al., 2016; Janus et al., 2017).  
In addition to these chronic oral manifestations, one of the most acute side effects of IMRT is 
oral mucositis, which may be life threatening and requires intensive treatment. Studies 
established that approximately 80% of patients undergoing RT will develop oral mucositis, 
characterized by the presence of extensive, deep and painful ulcers affecting any oral mucosal 
surface. This intense inflammatory response may severely impair or prevent eating, 
swallowing, drinking and speaking. Clinical management is targeted towards the 
managements of symptoms, such as opiate-based analgesics and parenteral feeding through 
nasogastric tubes. No effective treatment to prevent or eliminate oral mucositis has been 
found to date. Severe cases of oral mucositis will need hospitalisation which can delay cancer 
treatment and lead to dose / fractioning alteration, thus limiting the effectiveness of the 
cancer therapy (Logan et al., 2007; Sonis, 2011; Epstein et al., 2012; Duarte et al., 2014; Villa 
and Sonis, 2015; Franco et al., 2017; Maria et al., 2017; Jung et al., 2019). Much of the 
literature assessing RT side effects have been observational, documenting only the oral status 
of a small number of head and neck cancer patients after RT from a quality of life perspective. 
Even though salivary flow rate was measured in some studies it was used only to determine 
hyposalivation and xerostomia(Nutting et al., 2011; Memtsa et al., 2017; Almståhl et al., 
2019).  Only a small number of investigations evaluated pH and buffer capacity in saliva after 
RT, albeit without a benchmark (Möller et al., 2004; Sim et al., 2018) and to date there has 
been no saliva biochemical components analysis or link to clinical oral complications  
 20 
It is not possible to draw any definitive conclusions on salivary biochemical composition 
changes post-RT due to the limited number of longitudinal studies (short follow-up period) 
which have been mostly retrospective, observational and cross sectional with a smaller 
number of patients recruited. Further each study has used a different saliva collection 
technique and collection time along with a lower quantity of biochemical components 
analysed (Funegård et al., 1994; Almståhl et al., 2001; Eliasson et al., 2005; Hannig et al., 2006; 
Vidotto et al., 2010; Dijkema et al., 2012; Laheij et al., 2015).  
Thus, the long-term nature of the changes in salivary protein composition and correlations 
between individual salivary proteins and their corresponding clinical xerostomia, taste 




Overcoming limitations of previous studies, the following research project will assess the 
most significant acute and long-term complications of RT that affect HNC patients: oral 
mucositis, dry mouth feeling, taste alteration and carious lesion incidence, all of which 
negatively affect cancer treatment outcomes and the quality of life of cancer survivors.  This 
project was developed with an aim to study any possible correlations / links between the oral 
sequelae of RT and the negative clinical outcomes listed, in order to help the development of 
clinical management protocols for HNC patients to mitigate the effect on care and patient 
comfort and its delivery in healthcare systems.  
The project comprises of a longitudinal cohort study of HNC patients correlating biodata of 
biochemical salivary parameters, clinical outcomes and oral health status over a period up to 
12 months post-RT, focusing on baseline pre-IMRT (T0), 6 months post-IMRT (T1) and up to 
12 months post–IMRT treatments (T2). The ultimate goal is to identify possible predictive 
markers in the saliva at T0 to assist with evaluation of oral mucositis severity in individual HNC 
patients prior to start of treatment so that treatment can be adapted for such high-risk 
patients individually, to either prevent or minimise the severity of this consequence of RT.   
The study was performed in accordance with the Declaration of Helsinki. Patients were 
recruited at Guy’s Dental Hospital, London, UK in the Special Dental Care Unit from the pool 
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of diagnosed HNC patients prior to undergoing IMRT, having gained full written consent. Forty 
patients were seen pre-IMRT (T0). From this cohort, 38 were seen at six months post IMRT 
(T1) and 33 at 12 months post IMRT (T2). 
The first results chapter includes the oral and dental assessments performed on all participant 
including DMFT(S) indices, dry mouth feeling taste change reported from a simplified 
questionnaire and oral mucositis severity. Severity of any mucositis present was assessed 
using the WHO oral mucositis scale. Unstimulated whole mouth saliva was collected at each 
time point by passive drooling for 10 minutes. Flow rate was measured by weighing the 
sample tube before and after collection. Saliva samples were labelled and frozen at -80º C on 
the 17th floor laboratory at Guy’s Dental Hospital.  
The discussion of the results in this chapter looks at whether salivary flow rate was statistically 
significantly affected following IMRT, any correlation with reported of xerostomia and taste 
changes, any significant reduction in number of teeth present in the mouth and variations in 
the quantity of carious lesions at T1 and T2, compared to T0.  The results obtained from the 
clinical assessment showed clear links between UWMS flow rate, dental assessments of oral 
health, dry mouth sensation and taste perception, to salivary gland dysfunction. On the other 
hand, oral mucositis presence was related to a reduced UWMS flow rate at T1 and T2 as well 
as to a dry mouth feeling reported by patients at both time points.  
The second results chapter provides insight into the RT effects on salivary proteins chosen 
due to their previously established roles in mucosal protection from desiccation, provision of 
lubrication and microbial protection as well as maintaining enamel integrity. The saliva 
samples were used to quantify total protein concentration and secretion rate, in order to 
assess the amount of protein entering the oral cavity. Nine specific salivary proteins were 
investigated, all of which are directly associated with oral health, mucosal and teeth 
protection, antibacterial, rheological properties, remineralisation and microbial homeostasis. 
They can act as possible markers of the two most common acute and late RT side effects - 
oral mucositis and radiotherapy caries, as well as other oral symptoms such as dry mouth and 
taste perception. Total protein concentration was quantified by BCA assay. Periodic Acid 
Schiff staining determined glycoprotein concentration, including mucin 5B (MUC5B) and 
mucin 7 (MUC7). Coomassie brilliant blue determined Carbonic Anhydrase VI pixel intensity, 
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ELISA assays quantified IgA, cystatin S, statherin, acidic proline-rich peptides and albumin. α-
amylase activity was determined by kinetic assays.  
Significant alteration was observed in composition and secretion rate, starting with total 
protein, as well as mucins, amylase, albumin, cystatin S and carbonic anhydrase following 
IMRT T1 and T2 in comparison with baseline results recorded at T0. This chapter analyses any 
association between radiation-induced changes in salivary composition with the clinical 
dental assessment, taste alteration and xerostomia reported by patients. The total number 
of teeth present, and number of surfaces affected visibly by caries were significantly affected, 
in association with changes in total protein concentration and secretion rate, mucin 5B and 
7, amylase and cystatin S at T1 and T2. Dry mouth feeling was significantly associated to a 
reduced total protein secretion rate, and to an increased mucin 5B and 7 concentration in 
saliva, these changes alter saliva viscosity reducing its lubrication capacity impeding to reach 
oral mucosa and be retained on it, this will make mucins uncapable of forming a gel and 
covering oral epithelium to protect it from dehydration, resulting in to an altered mouth feel. 
Taste alteration reported by patients was only significantly associated to CAVI concentration 
and secretion rate.  
The clinical relevance of changes in salivary quantity and quality are those that salivary 
properties directly influence lubrication of the oral cavity, hydration of the oral mucosa, alter 
normal mouth feel and contribute to overall homeostasis.  
 
The final chapter studies the possible relationship between salivary proteins content and 
specifically those responsible for mucosal pellicle protection, lubrication, hydration and the 
onset and severity of oral mucositis. In order to achieve this, aim a longitudinal regression 
panel was used. Subsequently, statistical analytical ROC curve model was applied. This 
statistical model evaluates the sensitivity and specificity of the marker proteins to define their 
capacity to predict the risk and severity of oral mucositis in head and neck cancer patients 
undergoing IMRT, prior starting the treatment.  
These analyses revealed that specific salivary proteins amylase unit and secretion rate 
assessed at T0 may be a possible predictive marker for mucositis development during 
radiotherapy.  
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 Regarding severity of oral mucositis mucin 5B concentration/secretion rate as well as total 
protein concentration and secretion rate analysed at T0 may be a possible determining factor 
of high severity of oral mucositis occurrence during the cancer treatment.  
It is important to remark that there is no report in the literature studying the longitudinal 
correlation between IMRT induced changes in salivary proteins with oral mucositis 
development and severity. Therefore, this study is first of its kind that has attempted to find 
these correlations in forty head and neck cancer patients across twelve months post IMRT. 
 
These findings highlight the potential importance of a patient cantered approach as a clinical 
endpoint focusing on improving preventive management regimes for HNC at risk of 
developing severe oral mucositis. Identifying HNC patients at high risk of severe mucositis and 
consequently informing the oncology and health care team could possible play a major role 
in improving their quality of life.  
Oral mucositis represents a significant clinical challenge and causes major burden for HNC 
patients as mentioned earlier. 
 The relevance of these finding is regarding patient morbidity and suffering, both of which 
have not substantially improved in the past decades, patients continue receiving only 
palliative care due to a lack of an effective treatment to reverse oral mucositis. Thus, the 
prevention, early management and control of oral mucositis is vital, so that the incidence and 
degree of this condition can be reduced (Sonis, 2004a, 2011; Epstein et al., 2012; Duarte et 
al., 2014; GB et al., 2015; Franco et al., 2017; McCullough, 2017; Almståhl et al., 2019).  
 
On the other hand, the impact in the cost of care may be substantial due to repetitive 
hospitalization for pain management, parenteral feeding and secondary infection treatment. 
Ultimately resulting in unplanned cancer treatment interruption, delays or cancellations 
linked to recurrence of disease and a subsequent lowering of survival rates (Sonis, 2011; Villa 
and Sonis, 2015; McCullough, 2017; Münstedt et al., 2019).   
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By having a possible indicator of the severity of oral mucositis, might have imperative impact 
on patient care, involving fewer hospital visits, decreasing number of emergency room visits, 
reducing the health care practitioners additional time managing of mucositis-related issues 
consequently reducing significant costs for the NHS. 
 
1.3 Aim and Objectives  
 
Saliva quantity and quality performs a substantial role in oral homeostasis, constantly 
covering oral mucosa and teeth to ensure lubrication, hydration and microorganism 
colonization. Therefore, altered protein composition as well as a reduced flow rate are 
associated with frequency and severity of various oral and mucosal diseases, fungal infections 
and dental caries.  
It has been reported in literature, the effects of radiotherapy in the oral cavity regarding to 
patient’s quality of life, however not many researchers have focused on salivary gland 
function regarding salivary protein composition and secretion rate. Therefore, long term 
effects of IMRT on saliva composition and potential associations with oral side effects remains 
unclear.  
The aim of this project is to perform a well-controlled and integrated longitudinal study of 
HNC patients correlating biodata of biochemical parameters, clinical parameters and oral 
health status, to overcoming the limitations of previous studies, that examined the different 
side effects of radiotherapy of HNC patients (reduced number, retrospective, observational, 
short term follow up, lack of detailed clinical assessment, focused into treatment of side 
effects). 
The first objective of this study will be to perform quantitative analysis of oral/ dental status 
of HNC patients pre and post IMRT and analyse the possible associations between the clinical 
outcomes.   
Followed by assessing salivary gland function of HNC patients pre and post IMRT by analysing 
protein concentration and secretion rate and investigate the possible associations between 
these proteins and clinical outcomes. 
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Next objective is to determine the possible association between selected proteins 
concentration and secretion rate and oral mucositis outcomes after IMRT, and therefore, the 
final objective is to evaluate whether protein concentration or secretion rate of saliva is a 
reliable predictor of mucositis presence and severity.  
 
1.4 Null Hypothesis  
 
There will be no correlation between salivary biochemical composition and oral side effects 
of radiotherapy in the HNC patients before and after radiotherapy. 
1.5 Literature Review  
1.5.1 Saliva  
 
 1.5.1.1 Physiological Role of Saliva and Composition 
 
Saliva can be said to affect all functions of the mouth; the complex biofluid that makes up 
saliva is an important component of several processes including homeostasis, maintenance 
of the symbiotic balance in the oral cavity, as well as other vital functions of oral physiology.  
Saliva has been defined as a complex matrix containing proteins, enzymes and electrolytes, 
including an important sink of ions maintaining tooth regeneration and repair (Hunter, 2013; 
Hannig et al., 2017; Pedersen et al., 2018) 
A key characteristic of saliva is its ability to envelop oral surfaces as a non-Newtonian fluid, 
without being easily washed off. Teeth and mucosal surfaces are immediately covered by 
salivary proteins, forming a functional barrier via the adsorption of these components (Kilian 
et al., 2016; Pedersen et al., 2018).  
Saliva is composed mainly of water (99.5%) and inorganic substances (0.2%), such as 
electrolytes, whereas proteins represent only 0.3% of salivary composition. However, the 
composition may vary depending on flow rate, circadian rhythms, systemic diseases and other 
factors such as during eating and drinking (Vidotto et al., 2010; Proctor, 2016).  
Total protein concentration represents approximately 1 - 2 milligrams per ml of saliva, the 
main constituents of this group are glycoproteins, enzymes, immunoglobulins and peptides, 
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which are responsible for multiple protective functions(Denny et al., 2008; Schuurhuis et al., 
2016).  
Alterations in salivary secretion rates are associated strongly with changes in oral 
homeostasis, as a result of ageing, systemic diseases, medication and medical treatments 
(Pedersen et al., 2018; Proctor, 2016). 
 
1.5.1.2 Saliva Flow Rate 
 
The average daily volume of saliva secreted is between 500 - 600 ml (Proctor, 2016). The 
major salivary glands (parotid, submandibular and sublingual) secrete 90% of the total saliva, 
with the remaining 10% being secreted by minor salivary glands (Tschoppe et al., 2010).  
Unstimulated Whole Mouth Saliva (UWMS) is a mixed secretion that comes from every 
salivary gland. The contribution of each salivary gland without stimulation is approximately 
60% via submandibular glands, 25% from parotid glands, with the sublingual and minor 
salivary glands combining to contribute 7 – 8% of the total salivary composition (Hunter, 2013; 
Pedersen et al., 2018). UWMS flow rate is an indicator of salivary gland function, being 0.2 - 
0.3 ml/min. (NAVAZESH, 1993; Tschoppe et al., 2010; Chaudhury et al., 2015; Pedersen et al., 
2018).  
A reduction that goes below these baseline levels is defined as “hyposalivation” – a functional 
loss where the salivary flow is reduced, ultimately leading to an altered chemical composition 
of the saliva (Tschoppe et al., 2010; Chaudhury et al., 2015)(Tschope et al., 2010; Chaudhury 
et al., 2015). 
 
1.5.1.3 Salivary Glands 
  
Salivary glands are exocrine glands developed from epithelial cells, major salivary glands 
proliferating from the epithelial buds developing into mesenchymal tissue. This process is 
guided by molecular signals during embryonic development (Proctor 2016). 
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Salivary glands are composed of two types of epithelial cells: acinar and ductal cells. Most 
salivary proteins are secreted by acinar cells, whereas ductal cells only represent a minor 
contribution regarding the total protein secretion rate (Carpenter, 2013a; Proctor, 2016; de 
Paula et al., 2017).  
Within acini, different cell types determine which of the two types of salivary proteins are 
synthesised by each gland, mucin or non-mucin content.  Serous cell acini secrete a watery 
fluid that is rich in salivary enzymes, via exocytosis(Humphrey and Williamson, 2001). Mucous 
cells secrete viscous glycoproteins and mucins that form mucus, which serous cells lack (de 
Paula et al., 2017).  
Parotid glands are purely serous in nature, while submandibular and sublingual glands contain 
both mucous and serous cells. This cellular conformation helps determine the main type of 
saliva secreted by each gland (Denny et al., 2008). Parotid glands secrete saliva which contains 
mainly water, enzymes (α-amylase) and a small concentration, if any, of mucin glycoproteins 
(these glycoproteins are responsible for its viscoelastic properties). This parotid saliva is 
capable of moistening both hydrophobic and hydrophilic surfaces, which is important for 
mastication, moistening and swallowing of different types of food with diverse properties. 
Submandibular glands are seromucous glands, comprising 10% mucous cells and 90% serous 
cells (Hunter, 2013; Schipper et al., 2007). Finally, sublingual and minor salivary glands are 
formed mainly by mucin producing acinar cells, secreting approximately 80% of total mucins 
present in saliva, a high viscosity fluid that prevents mucosal dehydration. At the same time 
this saliva presents a high elasticity and low shear rate which permits retention and adhesion 
to oral mucosa. Additionally, minor salivary glands and parotid produce secretory 
immunoglobulin A (IgA). The minor mucous salivary glands are located in the submucosa, 
distributed throughout the oral cavity excluding the hard palate and gingivae. Their main 
function is mucosal protection and lubrication given their specific protein production. They 
also have an important role in preventing bacterial infections in teeth such as caries lesion.  
The secretory products of the salivary glands, after being synthesized intracellularly, are 
secreted into the ductal system via intercalated ducts, striated ducts, interlobular and main 
excretory ducts in each salivary gland. This complex network is capable of modifying 
hypotonic saliva into isotonic fluid before of conducting this into the oral cavity (de Paula et 
al., 2017; Carpenter, 2013a). 
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1.5.1.4 Salivary Gland Innervation 
  
Salivary secretions, in humans, are controlled by the parasympathetic and sympathetic nerves 
that reach acinar cells, ductal cells, myoepithelial cells and blood vessels. Sympathetic nerves 
reach mainly parotid and submandibular glands, whilst sublingual and minor salivary glands 
are reached by adrenergic innervation. Animal studies have revealed that different 
neurological stimulation can vary salivary composition and volume via the nervous system. 
The parasympathetic system is responsible of electrolyte secretion and normal salivary flow 
rate, protein secretion is preferentially activated by sympathetic stimulation, however there 
is a substantial cross-talk and synergism between the two regulatory pathways. 
Parasympathetic stimulation and peptidergic stimulation can regulate the levels of 
production of mucin-rich saliva from sublingual and minor salivary glands(de Paula et al., 
2017; Proctor, 2016; Mandl and Ekberg, 2019; Castro et al., 2013). Sympathetic innervation is 
related to the amount of protein secreted under reflex taste stimulation which is responsible 
for the dry mouth feeling(Proctor and Carpenter, 2007). Finally, adrenergic stimuli from the 
sympathetic system can cause changes to protein secretion levels in parotid and 
submandibular glands (Mandl and Ekberg, 2019; Castro et al., 2013; Hunter, 2013; Schipper 
et al., 2007; Proctor, 2016).  
There are different mechanisms for certain proteins and specific immunoglobulins, such as 
IgA, which is secreted by plasma cells present inside salivary glands. IgA is carried across the 
cells into the lumen of the acinus and an epithelial polymeric immunoglobulin receptor is 
added to this molecule on the basolateral membrane of acinar and ductal cells. This receptor 
works as a transporter, dividing this complex when gets saliva (Proctor, 2016; Brandtzaeg, 
2009). Certain proteins are released by vesicular secretion, without any external stimulus, 
which may result in accumulation of these molecules in the ductal system. Other proteins are 





1.5.1.5 Salivary Proteins 
 
Salivary protein composition and flow rate are crucial in oral health, being involved in a wide 
range of functions in order to maintain homeostasis. Proteins can be related to rheological 
properties of saliva, antimicrobial activity as well as probiotic activity, all of which form a 
system that defends the oral cavity (Schipper et al., 2007; Pinna et al., 2015; Pedersen et al., 
2018).   
Moreover, salivary flow rate and biochemical composition are important in the clearance of 
nutrients and bacteria (Dawes et al., 2015). Any changes to the flow rate affect the 
concentrations of mucin content, glycoproteins or Proline-Rich Proteins (PRP), which have 
been directly associated with carious lesion development, diminishing the protective effect 
of tooth mineralization homeostasis (Zussman et al., 2007; Peros et al., 2011;Hemadi et al., 
2017; Cardoso et al., 2017).  
Salivary mucins are high molecular weight glycoproteins that are essential in determining 
saliva’s viscoelastic properties, which in turn, regulates the lubrication and hydration of oral 
mucosa creating a membrane (Proctor, 2016) mucin 5B (MUC 5B) (2-4 x 104 kDa) and mucin 
7 (MUC 7) (130-180kDa) both comprise almost 25% of the total protein concentration. Both 
mucins are secreted mainly by minor and sublingual glands (>70%), with submandibular 
glands contributing only 20% of total production (Chaudhury et al., 2015; Frenkel and Ribbeck, 
2015). Structurally, mucin 5B and mucin 7 are negatively charged, highly glycosylated 
proteins. Their protein backbone contains serine and threonine amino acid sequences, 
capable of binding to sialylated or sulphated oligosaccharides (O-glycosilated tandem repeat 
attached to the protein core). These carbohydrate chains give mucins the capacity of being 
hydrophilic polymers capable of binding to water, preventing desiccation, providing anti-
proteolytic properties and specific attachment sites for pathogens (Castro et al., 2013; Hannig 
et al., 2017).   
Furthermore, mucin 5B is the primary gel-forming mucin in the oral cavity (Frenkel and 
Ribbeck, 2015) due to its high amino acid content along with multiple glycan chains. 
Specifically, mucin 5B can bind calcium as well as interacting with proline-rich proteins, 
statherins, and histatins. In contrast, mucin 7 lacks gel-forming properties (Xu et al., 2016) 
and exists essentially as monomers or dimers. Mucin 7 is capable of attaching secretory IgA 
 30 
at sites close to the mucosal pellicle, increasing its concentration close to the oral epithelium. 
Additionally, it is capable of binding antibacterial proteins in order to increase protein 
concentration levels in different locations throughout the oral cavity, as well as playing an 
important role in preserving the viscoelastic properties of saliva together with the ability to 
contribute to bacterial clearance (Dawes et al., 2015; Vijay et al., 2015; Frenkel and Ribbeck, 
2015; Hemadi et al., 2017).  
These protective barriers play an important role in preventing demineralisation, stimulating 
remineralisation, maintaining a neutral pH, protecting opposite surfaces from abrasive forces 
during mastication, speaking and swallowing ( Castro et al., 2013; Gibbins et al., 2014; Dawes 
et al., 2015 ;Hemadi et al., 2017; Mandl and Ekberg, 2019). On soft tissue surfaces, the barriers 
form a level of protection against dehydration, whilst keeping tissues lubricated and 
protecting underlying tissues from proteolytic attack (Gabryel-Porowska et al., 2014; 
Ligtenberg and Almståhl, 2015; Hemadi et al., 2017).  
MUC7 can also play a part in maintaining oral cavity homeostasis by binding with antibacterial 
elements, such as acidic and basic PRPs, statherins and histatin 1. It is believed that mucins 
may act as carriers for these antibacterial molecules transporting them to different locations 
within the oral cavity, increasing their concentration in mucosal or acquired enamel pellicle 
or forming a protective system around these proteins in order to inhibit the proteolytic 
degradation of these molecules (Frenkel and Ribbeck, 2015).  
Certain studies have shown the potential capability of mucins to aggregate bacteria in order 
to increase their chance of removal during swallowing, as well as determining bacterial 
colonization on oral surfaces, by attaching certain microbial species on specific glycans, such 
as sialic acid and blood-group antigens, even though these studies do not distinguish between 
MUC5B and MUC7 (Levine et al., 1978; Frenkel and Ribbeck, 2015). Additionally, it is 
specifically known that MUC5B is capable of binding specific bacteria in a biofilm formation 
in order to reduce their virulence (Frenkel and Ribbeck, 2015; Hemadi et al., 2017). Others 
have studied the spectrum of antimicrobial and antifungal activity of MUC7, due to a non-
glycosylated region at the N-terminus of the apomucin molecule. The presence of O-glycans 
forms a large protease-resistant region providing binding spots for commensal bacteria and 
pathogens (Xu et al., 2016), even finding it capable of interacting directly with them to 
facilitate their removal from the oral cavity (Frenkel and Ribbeck, 2015; Hemadi et al., 2017). 
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It also has potent killing capabilities against a variety of fungi and both gram-positive and 
gram-negative bacteria, including Escherichia coli, Staphylococcus aureus, Candida albicans 
and Cryptococcus neoformans(Frenkel and Ribbeck, 2015; Hemadi et al., 2017). MUC5B is 
only capable of modulating the virulence of Candida albicans pathogens without killing them 
and this could potentially be the reason why candida can be present in the oral cavity without 
causing candidiasis (Frenkel and Ribbeck, 2015). 
MUC5B is capable of creating a highly concentrated network across oral surfaces in order to 
keep the mouth lubricated, suggesting a possible relation between dry mouth feeling and 
mucin 5B concentration (Lee et al., 2007). Further studies have correlated this mucin 
concentration with xerostomia, concluding that mucin 5B is an effective lubricant in the 
mouth, rather than only correlating this symptom with the amount of whole mouth saliva 
present in the mouth (Dijkema et al., 2012). 
Both mucins are among the main components of mucosal pellicle, along with secretory IgA, 
as their presence is found in a higher concentration than in saliva(Hannah L. Gibbins et al., 
2014; Dawes et al., 2015; Hemadi et al., 2017). Mucins are related to mucosal tissue 
protection against injuries along with Epidermal growth factor (EGF) (Pedersen et al., 2018). 
Moreover, MUC7 and MUC5B, along with other proteins such as statherin, histatin, acidic 
proline-rich proteins, α-amylase and lysozyme are part of the acquired enamel pellicle 
(Hannig et al., 2017).  These findings all suggest that mucins are a vital component for 
preventing carious lesion development, whether it be via oral defence binding, reducing 
bacterial virulence, or maintaining opportunistic pathogens in the oral environment without 
causing diseases (Frenkel and Ribbeck, 2015).  
Albumin, produced in the liver and carried into the mouth as an ultra-filtrated serum, 
represents more than 50% of all plasma proteins (Meurman et al., 2002). Albumin is well-
established as an indicator of plasma leakage in the oral cavity, typically as a result of 
inflammatory processes; therefore it can act as a marker for oral mucositis in relation to 
radiation therapy in head and neck cancer patients  (Schenkels et al., 1995; Almståhl et al., 
2001; Meurman et al., 2002; Chiappin et al., 2007; Messana et al., 2008). Additionally, it is 
capable of binding to hydroxyapatite forming part of enamel acquired pellicle and coats soft 
oral surfaces playing an important role in lubrication (Schenkels et al., 1995; Chiappin et al., 
2007; Cone, 2009; Messana et al., 2008; Hannig et al., 2017). α-Α-amylase, secreted by parotid 
 32 
glands, is one of the most abundant enzymes in the mouth and considered to be a marker of 
parotid gland function (Almståhl et al., 2001). Its primary function is starch digestion by 
catalysing the hydrolysis of glycogen starch- related polysaccharides(Granger et al., 2007). 
Similarly, to MUC5B, it is also capable of binding oral bacteria, such as Streptococcus gordoni, 
S. mitis and S. oralis (Dawes, 2008). α-amylase binds to the membrane of bacteria in order to 
aid their clearance from the oral cavity, therefore decreasing the risk of dental caries (Borghi 
et al., 2017; Picco et al., 2017). 
α-Amylase is capable of selectively binding to bacterial colonies in the oral cavity (Nikitkova 
et al., 2013; Gao et al., 2016; Borghi et al., 2017; Cardoso et al., 2017), providing additional 
glucose for the formation of tooth biofilm that maintains the normal flora (Gao et al., 2016; 
Borghi et al., 2017; Cardoso et al., 2017). This biofilm production and caries formation is linked 
to this binding of α-amylase to bacteria and teeth, as α-amylase enables the necessary starch 
hydrolysis for microorganisms, metabolism and lactic acid.  
Carbonic Anhydrase VI (CAVI) is an enzyme secreted by parotid and submandibular glands 
that plays a fundamental role in controlling taste sensation and taste bud growth, as well as 
development and/or maintenance, especially fungiform papillae. CAVI facilitates the 
interaction between food particles and taste buds (Denny et al., 2008; Hunter, 2013). In order 
to counteract the excessive acidity of the tooth surface biofilm, CAVI is activated and catalyses 
the most important buffer reaction in the oral environment; the carbonic dioxide equilibrium 
in saliva (Öztürk et al., 2008; Frasseto et al., 2012; Zwier et al., 2013; Cardoso et al., 2017; 
Pedersen et al., 2018), in order to increase bicarbonate salivary levels especially with acidic 
foods. Moreover, this enzyme plays a role in reducing tooth demineralization by activating 
this buffer mechanism that neutralizes the acidic pH of biofilm (Kimoto et al., 2006; Cardoso 
et al., 2017).  
Statherin is a phosphoprotein secreted from parotid, submandibular and sublingual glands, 
which plays a multifunctional role in the oral cavity, maintaining calcium homeostasis, 
preventing its precipitation and crystal growth, as well as keeping saliva supersaturation in 
order to stimulate the remineralisation process. It is an acquired enamel pellicle early 
precursor, also playing an important role in promoting the initial microbial colonization of 
tooth surfaces and present antifungal properties (Niemi and Johansson, 2004; Li et al., 2004; 
Proctor et al., 2005; Gorr, 2009; Vergeer et al., 2009; Izumi et al., 2015; Vukosavljevic et al., 
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2014; Dawes et al., 2015). In addition, Statherin has lubricating properties, preventing teeth 
from chipping and wearing down during mastication (Schipper et al., 2007; Carpenter, 2013a).  
Acidic PRPs secreted by parotid and submandibular glands contain between 25-42% of proline 
amino-acids (Carpenter, 2013a).  
Acidic PRP, statherin and other phosphorus-containing proteins are capable of binding 
calcium, thereby maintaining a higher concentration than teeth (supersaturated saliva), in 
order to prevent dissolution of teeth and to avoid its precipitation, especially at the cervical 
margins of teeth causing calculus (Carpenter, 2013a; Hemadi et al., 2017). Acid and basic PRPs 
are part of the acquired enamel pellicle due to their calcium hydroxide-binding properties. 
These proteins participate in oral bacterial clearance, binding bacteria, fungi and viruses 
towards the stomach. Furthermore, these proteins have a polyphenol binding affinity, acting 
as polyphenol precipitators (tannins included) in the perception of astringency (Fábián et al., 
2015).   
Cystatins are a family of seven low molecular weight proteins secreted primarily by 
submandibular glands. Cystatins can act as a form of microorganism control, whether it be 
control of lysosomal cathepsins, inhibition of bacterial cysteine proteases, binding bacterial 
lipopolysaccharides, adenovirus or herpes simplex 1 infectivity and viral replication (Messana 
et al., 2008; Fábián et al., 2012; Magister and Kos, 2013; Aroonsang et al., 2014; Fábián et al., 
2015; Hemadi et al., 2017; Martini et al., 2017). Cystatins also are a part of the acquired 
enamel pellicle formation and play an important role in tooth remineralisation processes (Gao 
et al., 2016; Martini et al., 2017; Hemadi et al., 2017). More specifically, cystatin S inhibits the 
action of endogenous, bacterial and parasitic protozoan proteases, binds bacterial 
lipopolysaccharides and seems to exert direct immunomodulatory effects(Martini et al., 
2017; Fábián et al., 2012).   
Secretory IgA is the main antibody of saliva and is secreted by plasma cells located inside the 
glands under conditions of stress, disease or inflammation. Healthy oral cavities would 
typically find minimal to no diffusion of IgA into saliva. On the oral epithelium it is highly 
concentrated forming part of the mucosal pellicle (Carpenter, 2013a; H. L. Gibbins et al., 2014; 
Hannah L. Gibbins et al., 2014). IgA plays an antibacterial role by interfering with the 
adherence of microbial flora to tooth surfaces, inhibiting bacterial metabolism, neutralizing 
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bacterial toxins and enzymes as well as the agglutination of bacteria. These all aid in 
strengthening the anti-microbial action of saliva (Fábián et al., 2012; H. L. Gibbins et al., 2014; 
Gao et al., 2016; Hemadi et al., 2017).  
Additionally, secretory IgA and α-amylase are resistant to bacterial proteolytic enzymes 
(Schipper et al., 2007) and some studies have identified IgA as a protective mechanism in 
children with early childhood caries (Hemadi et al., 2017). Immunoglobulin A (IgA) 
concentration increases in elderly people in UWMS as well as this non stimulated whole saliva 
secretion rates were reduced with age (Eliasson et al., 2006). 
 
1.5.1.6 Salivary Interaction with Oral Tissues  
 
Saliva protective functions are related directly to its capacity of interact with soft and hard 
tissues in the oral cavity by forming a complex layer that is capable of moisten and lubricate 
these surfaces along with being capable to remain on the surfaces (Hannig et al., 2017). 
Residual saliva (RS) is a term used to refer to a salivary film covering oral structures and 
preventing the oral mucosa from feeling dry. Its composition is dependent on a mixture of 
saliva from every gland coating all the surfaces in the mouth, with each location’s thickness 
varying and with its wetting capacity a determinant of the dry mouth feeling in correlation 
with protein concentration levels (Pramanik et al., 2010; Chaudhury et al., 2015). Perception 
of dry mouth has been correlated to insufficient mucosal wetting and altered unstimulated 
whole saliva composition (Lee et al., 2007; Pramanik et al., 2010; Chaudhury et al., 2015). The 
mucosal pellicle is a thin layer (70-100 micrometres) covering soft tissues of the oral cavity in 
order to aid with lubrication and moisturizing. Mucosal pellicle attachment to the epithelial 
cell surface results in it not being able to be cleared with water or other ionic washes (H. L. 
Gibbins et al., 2014; Hannah L. Gibbins et al., 2014; Hannig et al., 2017). It is formed by a 
complex network layer of salivary proteins that are structurally different from enamel pellicle. 
It is capable of retaining high volumes of water due to its composition which is mainly a 
glycoprotein protein (MUC5B, MUC7 and secretory IgA) hydrogel (H. L. Gibbins et al., 2014; 
Dawes et al., 2015; Hannig et al., 2017; Hemadi et al., 2017). Further in-vitro studies have also 
found more proteins, such as cystatin S and PRPs included in its structure (Dawes, 2008; H. L. 
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Gibbins et al., 2014; Hannig et al., 2017). Still inconclusive, (Lee et al., 2007; H. L. Gibbins et 
al., 2014; Hannig et al., 2017) some studies have found that subjects with a dry mouth 
sensation experience a decreased thickness of this pellicle, (less than 10um) (Dawes, 2008).  
This protective layer regulates the early adhesion and colonization of bacteria on the oral 
mucosa as well as regulating oral microbiota conformation (Pedersen et al., 2018). Saliva 
contact with hard tissues is mainly by the interaction between specific proteins and teeth 
surfaces in order to create a protective layer to ensure a high concentration of calcium, 
buffering capacity and lubrication. It is well established that the main function of the enamel 
pellicle is the protection of teeth from erosion and abrasion (Kielbassa et al., 2006; Hannig et 
al., 2017). The structure and thickness of acquired enamel pellicle changes depending on the 
location and time of formation, composed typically by a two-phase structure of an electron-
dense basal layer and a globular overlying structure. These structures are formed by salivary 
proteins, the main components being MUC5B, statherin, acidic proline-rich proteins, 
histatins, α-amylase and lysozyme; that are therefore crucial for re-
mineralisation/demineralisation of the enamel (Meurman et al., 2002; Hannah L. Gibbins et 
al., 2014). MUC5B, PRPs, histatin and statherin are the first proteins to bind to enamel due to 
the negative charges that come from the acidic side-chains. The main function of the pellicle 
is the regulation of the calcium phosphate concentration in the oral cavity, impeding crystal 
growth, keeping calcium supersaturated in saliva close to the tooth surface thereby 
controlling dental erosion. Acquired enamel pellicle promotes the adhesion of different 
bacteria to hydroxyapatite on tooth surfaces (Buzalaf et al., 2011; Magalhães et al., 2011; 
Vukosavljevic et al., 2014; Hannah L. Gibbins et al., 2014; Hannig et al., 2017; Hemadi et al., 
2017; Mutahar et al., 2017). In the mature enamel pellicle, more protein-protein interactions 
are observed, where MUC7 and MUC5B are capable of binding α-amylase to this layer 
(Mutahar et al., 2017; Hannig et al., 2017).  
It is well established that lubrication is one of the most important functions of saliva, reducing 
the friction between two surfaces during movement. A lack of this property will lead to 
irritation and ultimately, destruction of soft and hard tissues. This function is directly related 
to salivary films, enamel and mucosal pellicle and the presence of saliva (H. L. Gibbins et al., 
2014; Hannig et al., 2017). Literature has suggested that lubrication properties of saliva 
depends on its viscosity as well as on the physical characteristics of the adsorbed surface. It 
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has been proposed that viscosity is more important in soft tissue lubrication than in hard 
surfaces. Glycoproteins and proteins are responsible of lubrication properties of saliva such 
as the mucins, especially 5B. Its viscoelastic and protective properties are vital in coating and 
wetness of oral surfaces. In addition, statherin, α-amylase, proline-rich glycoproteins and 
acidic proline-rich proteins are involved in this process ( Hahn Berg et al., 2004; Proctor et al., 
2005; Schipper et al., 2007).  
 
1.5.2 Head and Neck Cancer (HNC) 
 
Head and neck cancers are the sixth most common cancer in the world representing 4-5% of 
all malignancies (Joshi, 2010; Gualtero and Suarez Castillo, 2016). These cancer varieties 
include oral, nasal cavity, salivary glands, paranasal sinus, oropharynx and larynx cancers, 
however approximately 90% of oral and oropharyngeal cancer is squamous cell carcinoma, 
representing the most common cancer in the head and neck region (Chi et al., 2015). Primarily 
affected by risk factors such as drinking or smoking habits, human papillomavirus (HPV) is 
considered an aetiologic factor for oropharyngeal squamous cell carcinoma, more specifically 
HPV 16 (Chi et al., 2015).  
Reduced quality of life is common among these cancer sufferers, not only with the direct side 
effects associated with radiation therapy (RT), but also their psychological, emotional and 












1.5.3 Radiotherapy  
 
Radiotherapy (RT) is a physical and localized treatment to control tumours. As the first choice 
of treatment for the majority of head and neck cancer patients, RT is mainly delivered by an 
external beam in a fractioned dose in order to preserve the normal tissues exposed (Baskar 
et al., 2012; Duarte et al., 2014; Almståhl et al., 2019). More than 50% of patients receive 
treatment delivered in fractions of 2 Grays (Gy) daily for 5 days per week until the end of their 
therapy dosage (mean cumulative dose 55-77 Gy) (Chao et al., 2001; Springer et al., 
2005;Sennhenn-Kirchner et al., 2009; De Siqueira Mellara et al., 2014; Gao et al., 2015). 
Ionising radiation creates its therapeutic effect by interacting with the water molecules within 
cells to create free radicals that cause chemical damage, altering a cell’s structure, chemical 
composition and functions (Breneman, 1994). By affecting cells directly, they can alter the 
DNA, therefore diminishing the division rate of tumour cells, eventually leading to autophagy 
causing cell death (Baskar et al., 2012; Strojan et al., 2017). Radiation effectiveness depends 
on total dose fractionation and radio sensitivity of targeted cells.  
RT has been proven to induce late side effects to the head and neck, including salivary gland 
hypofunction (Richards et al., 2017) and results in dry mouth (xerostomia), reduced salivary 
flow rate and altered saliva composition (Nutting et al., 2011).  
 
1.5.4 Radiotherapy Side Effects 
 
Conventional radiotherapy is the cause of a wide range of adverse oral tissue reactions, such 
as permanent damage to the major and minor salivary glands, modification of connective and 
vascular tissues, chronic inflammation and its resulting effects. Side effects of radiotherapy 
can be categorised into two types, depending on the time of appearance (acute and late), 
that result in several oral pathologies during and after radiotherapy. Acute effects occur from 
the very beginning of treatment, whereas late effects occur after treatment has concluded to 
produce long term effects (3 months or more) (Vissink et al., 2003; Meurman and Grönroos, 
2010; Walker et al., 2011; Gonçalves et al., 2014; De Siqueira Mellara et al., 2014; Lieshout 
and Bots, 2014; Laheij et al., 2015). Acute effects include mucositis, salivary gland 
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hypofunction and taste alterations, whereas late adverse effects are permanent salivary gland 
damage, caries and periodontal pathology, amongst others.  
Salivary gland hypofunction induces a reduced salivary flow rate causing xerostomia, which 
not only affects speech and swallowing, but can also hasten the progression of dental caries 
(Wijers et al., 2002; Nutting et al., 2011; Belstrøm et al., 2016; Janus et al., 2017). Chronic 
inflammation and its cytotoxic effects on epithelial tissue also leads to mucositis, presenting 
large, irregular and deep ulcers within the mouth (Rieger et al., 2012; Turner et al., 2013; Gao 
et al., 2015). Hyposalivation after RT is a common side effect due to irradiation of salivary 
glands, producing acini cell or blood vessel damage. However, it is not clear whether the 
damage is caused by direct cytotoxic effects of radiation on secretory and ductal cells or 
indirectly affecting the vascular flood in the salivary gland by chronic inflammatory infiltration 
(Klein et al., 2014). Radiation doses and the volume of irradiated tissue have been directly 
correlated with salivary gland hypofunction, whereby cumulative doses exceeding 30 Gy have 
even caused permanent tissue damage (Klein et al., 2014).  
Moreover, xerostomia, disrupted salivary gland function and altered biochemical composition 
of the saliva can be observed separately, but are usually interrelated as a side effect of RT. 
Altogether, in the long run, they will contribute to the increase in caries risk in these groups 




Xerostomia affects more than 80% of head and neck radiotherapy patients (Tschoppe et al., 
2010; Pinna et al., 2015; Villa and Sonis, 2016). A diminished salivary output results in an 
altered salivary biochemical composition along with a change in salivary viscosity (Tschoppe 
et al., 2010; Vissink et al., 2010; Riley et al., 2017; Pedersen et al., 2018). Unstimulated whole 
mouth saliva flow rate lower than 40-50% of its normal value is indicative of xerostomia and 
probably more than one salivary gland is affected by hypofunction. However, xerostomia may 
be a result of salivary composition changes specially mucins that are responsible of lubrication 
functions(Pedersen et al., 2018).  
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Such changes in saliva affect a patient’s ability to chew and swallow, deteriorating their 
quality of life due to their inability to distinguish different food preferences, types, quality of 
nutrients and finally, to differentiate safe and dangerous foods (Tschoppe et al., 2010;Rieger 
et al., 2012; Pinna et al., 2015). Even though the prevalence of changes in taste after cancer 
treatment has been described, the mechanism involved is not well understood and there is a 
lack of literature to support the subjective changes in taste before and after radiotherapy, 
affecting threshold and or producing an alteration of taste perception (Epstein et al., 2016; 
Spotten et al., 2016; Epstein et al., 2019).  
Taste requires an appropriate saliva flow rate to be perceived by taste buds throughout the 
oral cavity, oropharynx and dorsal surface of the tongue in order to evaluate the content of 
food and distinguish it from toxic elements and proper nutrients, preventing ingestion of 
these substances, making the food consumption a satisfactory experience connected 
positively with the ability to enjoy the flavour and texture of food (Epstein et al., 2019).  
Dysgeusia or alteration in taste perception and loss of taste (ageusia) has been associated 
with damage in the gustatory system, ageing, xerostomia and Sjögren’s syndrome. Head and 
neck cancer patients suffer loss of taste acuity and a metallic or bitter taste during the 
radiotherapy, ranging from 75-100% and may be related to the onset of mucositis. Over 90% 
of the patients that received a dose of 60Gy developed a relative taste loss. Taste impairment 
is related to radiation dose fraction size, volume and technique, starting during the first week 
of radiotherapy and progressing during the treatment reaching the maximum point in the 
fourth week. This taste dysfunction has been studied using survey methods by patient-
reported outcomes. Additionally, hyposalivation and saliva quality may increase the taste 
disturbance, negatively affecting the quality of life of these patients, reducing treatment 
compliance, altering food intake, food choice, desire to eat, distress and interfering with daily 
functions. After radiotherapy, taste dysfunction may continue indefinitely due to damage to 
receptors and/or hyposalivation which will result in a reduced food particles dissolution, 
decreasing the molecule number able to reach taste receptors (Ruo Redda and Allis, 2006; 
Bressan et al., 2016; Epstein et al., 2016, 2019; Jham et al., 2009).  
Furthermore, it can make the mouth feel dissimilar, with oral mucosa becoming dry and sticky 
increasing the risk of mucosal ulceration and injuries (Chao et al., 2001; Vissink et al., 2010; 
Pinna et al., 2015; Strojan et al., 2017) and food being difficult to swallow, which in the long 
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run, creates a nutritional deficiency that affects general health. Additionally, the lack of 
lubrication properties and wettability of saliva will result in speech problems, creating 
difficulties in communication. The resulting lack of social interaction has a negative impact on 
the general health and well-being of these patients (Vissink et al., 2010; Pinna et al., 2015; 
Chaudhury et al., 2015).  Subjects with hyposalivation caused by radiation therapy showed 
differences in oral microflora composition compared with age-gender control patients 
(Almståhl et al., 2001), increasing its susceptibility to bacterial and yeast infection (Chaudhury 
et al., 2015). Hyposalivation subjects presented a similar number of tooth surfaces covered 
with plaque during the dental examination. The difference in bacterial composition was 
associated with an altered salivary protein concentration (Almståhl et al., 2001) reduced 
salivary flow rate, increased sugar intake and poor oral hygiene raising the risk of an 
unbalanced oral microbiome mainly dominated by the microorganisms associated with oral 
diseases (Kilian et al., 2016). 
In addition, reduced flow rate leads to a reduced food clearance altering bacteria composition 
that can impact taste acuity (Epstein et al., 2016).  
All the above will result in serious consequences for oral homeostasis, reducing important 
protective saliva functions, increasing caries risk leading to a tooth destruction and oral 
mucositis.  
 
1.5.4.2 Radiation Therapy Related to Hyposalivation In Head and Neck Cancer 
 
It is well established that there are many different causes for hyposalivation including a 
variety of systemic diseases; chronic autoimmune conditions, such as Sjögren’s syndrome, 
lupus erythematosus, rheumatoid arthritis, scleroderma, hormonal causes (diabetes 
mellitus), neurologic causes (Parkinson’s disease), anorexia, alcohol abuse, infections and 
depression. Additionally, there are more than 400 types of medications capable of reducing 
the salivary flow rate (Tschoppe et al., 2010).  
Patients will develop signs of atrophic mucosa, erythema, angular cheilitis and oral ulcers, 
conditions that are  associated with pain and changes in taste perception that may affect oral 
functions, thus leading to nutritional impairment, weight loss, isolation and depression, 
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stopping the treatment all together (Tschoppe et al., 2010; Osailan et al., 2012; Sroussi et al., 
2017).  
Roesink et al., (2001), studied 108 head and neck cancer patients before and after they were 
treated with conventional radiotherapy in order to correlate dose/volume/parotid gland 
function. The stimulated parotid flow rate was measured before radiotherapy, then 6 weeks, 
6 months, and 1 year after radiotherapy. After 6 weeks of radiotherapy the salivary flow rate 
was significantly reduced compared with the base line (0.12mL/min), after 1 year the mean 
flow rate reached 0.20 mL/min still remaining under the base line mean flow (0.34 mL/min). 
A reduced flow rate was associated with increasing fraction of the irradiated parotid gland. 
There was no information regarding the general health of the patients, nor an oral assessment 
and the salivary flow rate before the cancer treatment was not compared with a control 
group.  
Möller et al., (2004), studied 39 patients treated with radiotherapy alone or with surgery 
(n=36), where unstimulated and stimulated salivary flow rate, pH and buffering capacity were 
measured. Smoking and alcohol habits were recorded as well.  
Unstimulated whole mouth saliva for all patients decreased gradually during irradiation from 
45% to 21%, compared with the mean baseline. Similarly, for stimulated whole mouth saliva, 
the rate decreased from 39% to 14% showing a faster and steeper decrease in flow rate 
compared with unstimulated saliva. Stimulated whole mouth saliva mean flow rates 
decreased statistically and significantly during the entire study compared with unstimulated. 
The pH dropped after 1 week of radiotherapy, then started to increase until the end of the 
treatment reaching 7.05 for WSS, lower than the baseline. WRS pH was 6.97, marginally 
higher than before the cancer treatment. The buffering capacity of saliva dropped 
significantly from the first week of irradiation, reaching the minimum value after 3 weeks of 
treatment, maintaining this decrease until the end of RT. After 12 months, the buffering 
capacity was still significantly lower than baseline. It was concluded that radiotherapy induces 
severe hyposalivation, alteration of salivary pH, and a significant loss in salivary buffering 
capacity. There is a lack of analysis regarding the salivary components of saliva, there was no 
control group to compare before RT, no oral assessment of this group, nor oral disease and 
dry mouth reports.  
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Dijkema et al., (2008), evaluated 221 head and neck cancer patients treated with IMRT and 
conventional RT in a retrospective study. Stimulated parotid flow rates were measured before 
as well as 6 weeks, 6 months and 1 year after radiotherapy in order to evaluate the 
relationship between the mean dose and the parotid gland and the probability of 
complications for CRT and IMRT. Thus, a complication was defined as “stimulated parotid flow 
ratio <25% of the pre-treatment flow rate”. Parotid gland complication after 6 weeks and 6 
months was 1.4 times higher when IMRT was used, compared with CRT. One year after the 
radiotherapy was completed, there was no difference between the two types of RT. This 
retrospective study associated radiotherapy effects to parotid gland hypofunction, only 
measuring the flow rate. There was no analysis of the quality of saliva after radiotherapy.  
 Dijkema et al., (2010)multicentre study analysed 222 H&N cancers treated with conventional 
and intensity-modulated RT.  Stimulated parotid gland flow rates were measured before the 
treatment and 1 year after RT. A flow ratio <25% of pre-treatment was defined as a 
complication. The aim was to assess the normal tissue complication probability (NTCP) of the 
parotid gland 1 year after radiotherapy. It was found that the Mean doses of 25–30 Gy were 
associated with 17–26% NTCP. Like the previous study, there was no sialochemistry analysis 
in order to assess the side effects of radiotherapy in parotid gland function.  
Nguyen et al., (2018) compared conventional RT and IMRT in 96 patients with head and neck 
cancer, assessing hyposalivation by comparing stimulated flow rate before and after 
treatment, then correlating this with time, total dose received and  unilateral and bilateral 
conventional RT. Additionally, the amount of RT received by the parotid gland was evaluated 
using Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC criteria), in order 
to predict the severity of hyposalivation after cancer treatment and to predict the risk of oral 
diseases and reduce the number of teeth extractions before radiotherapy. Patients that 
received bilateral conventional RT presented with a significantly reduced salivary flow rate 
compared with unilateral and IMRT after radiotherapy when contrasted with baseline 
measurement. At 12 months, the three groups showed a trend of salivary flow recovery, being 
the bilateral radiotherapy group the smallest compared with their baseline flow rate.  
IMRT groups were not divided into bilateral and unilateral. There was no oral assessment 
before and during the follow-up to correlate with the hyposalivation in order to measure the 
risk of oral diseases. Additionally, only stimulated saliva was collected. 
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Memtsa et al., (2017), studied salivary flow rate and xerostomia in 60 head and neck cancer 
patients treated with conventional radiotherapy to correlate this with quality of life. The 
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-
Core 30 (QLQ-C30), the Quality of Life Questionnaire Head and Neck Module (QLQ‑H&N35) 
and the Greek version of the XQ questionnaire were applied at 4 timepoints before and after 
radiotherapy. Unstimulated and stimulated whole mouth saliva were collected and pH was 
measured, xerostomia was graded using Radiation Therapy Oncology Group (RTOG). Quality 
of life decreased significantly at 6 months after radiotherapy, XQ questionnaire scores were 
significantly lower when correlated with salivary flow rate. Salivary flow rate was 20% lower 
than baseline at 12 months after RT. Xerostomia was correlated with quality of life scores, but 
not with flow rate measures at 12 months. There was no analysis of protein composition of 
saliva before and after radiotherapy related with xerostomia. The study of salivary 
biochemical composition related with mucosal hydration is important in patients that present 
signs and symptoms of xerostomia.  
Sim et al., (2018) evaluated xerostomia scores, stimulated salivary flow rates, pH and 
buffering capacity before, during and after radiotherapy (IMRT) in 15 head and neck cancer 
patients. Xerostomia scores were determined using the Radiation Therapy Oncology 
Group/European Organization for the Research and Treatment of Cancer (RTOG/EORTC). 
Unstimulated and stimulated saliva were collected pre and post radiotherapy. Xerostomia 
scores were significantly higher 2 years after radiotherapy, stimulated and unstimulated 
salivary flow rate decreased significantly after radiotherapy, together with pH and buffer 
capacity. Even though the variation of flow rate and pH was analysed before and after 
radiotherapy, the number of patients included in this study was low and there was no report 
of salivary composition.  
Similarly, Almståhl et al., (2019) analysed the quality of life of 29 head and neck cancer 
patients pre and up to 24 months post-radiotherapy related to stimulated saliva secretion. 
Patients completed the European Organisation for Research and Treatment of Cancer Quality 
of Life questionnaires (EORTC QLQ‐C30 and H&N35) and the Hospital Anxiety and Depression 
scale (HADS) at four time points: pre-treatment and at 6, 12- and 24-months post-
radiotherapy. Stimulated saliva was collected for 3 min at every time point. Patients that 
showed signs of hyposalivation showed significant differences in their quality of life at every 
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time point after radiotherapy, presenting signs of insomnia, difficulties in swallowing, reduced 
social eating, reporting dry mouth and sticky saliva. Hyposalivation groups experienced poor 
everyday functioning and reported more symptoms related to salivary flow rate at 24 months, 
especially regarding eating and drinking impairments which resulted in social isolation. 
Additionally, this group had a reduced sense of taste at 24 months, describing that food is 
tasteless or different.  
Salivary flow rate and composition are both related to oral health, due to all the protective 
functions of saliva in order to maintain integrity of soft and hard tissues.  
As a side effect of radiotherapy, hyposalivation and an altered saliva composition are going 
to impair the antimicrobial, remineralising and buffering capacity of saliva, as well as the 
lubrication and hydration properties of saliva increasing the risk of developing oral diseases.   
Most of the studies performed presented with an absence of information about participants, 
regarding systemic diseases, medication, oral diseases, caries risk, carious lesion numbers, 
localization, teeth/surface and dental treatment received. Only the salivary flow rate was 
assessed to determine salivary hypofunction as a result of radiotherapy and correlate with 
quality of life of head and neck cancer patients. None of the studies mentioned above 
performed any analysis of the total protein component or specific proteins regarding salivary 
microbial and host protection and viscoelastic / lubrication properties which could affect the 
capability of saliva to humectify the oral mucosa. 
 
1.5.4.3 Radiotherapy Related to Taste Disturbance 
 
Taste requires an appropriate saliva flow rate to be perceived by taste buds throughout the 
oral cavity, oropharynx and dorsal surface of the tongue in order to evaluate the content of 
food and distinguish it from toxic elements and proper nutrients, preventing ingestion of 
these substances, making the food consumption a satisfactory experience connected 
positively with the ability to enjoy the flavour and texture of food (Epstein et al., 2019).  
A reduced salivary flow rate may affect the intensity of taste acuity as a result of a reduced 
capacity for dissolving food molecules, which reduces the number of these particles reaching 
taste receptors. Additionally, oral diseases such as carious lesions and candidiasis may 
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influence gustatory changes, especially in head and neck cancer patients who present 
xerostomia (Epstein and Barasch, 2010; Irune et al., 2014; Epstein et al., 2019).  
Taste dysfunction is related to the development of mucositis and dysphagia during cancer 
treatment. These are acute side effects of radiotherapy which are dose-limiting, affecting care 
plan compliance, extension and results in increasing mortality and morbidity. In addition, 
these complications will affect nutritional status, appetite and food consumption, altering 
daily routine and leading to a reduced quality of life (Ruo Redda and Allis, 2006; Irune et al., 
2014; Epstein et al., 2016, 2019). It is important to identify the side effects of radiotherapy in 
order to help cancer survivors to comprehend and manage these sequelae and thereby 
maximize the functions post-treatment and improve their quality of life.  
Spotten et al., (2016), focused on assessing the prevalence and severity of distorted taste and 
smell perception and sensitivity after cancer treatment using a ‘Taste and Smell Survey’ 
(Heald et al.,1998) and nutritional status using versions of the scored Patient-Generated 
Subjective Global Assessment (abPG-SGA). Fourty non-head and neck cancer patients were 
assessed, 19 reported at least one sense affected after radiotherapy, along with dry mouth. 
Many patients reported anxiety about poor food variety and some of them reported reduced 
social activity due to these side effects which were significantly associated with quality of life 
in this group.  
Similar results were obtained by (Zabernigg et al., 2010) taste alterations (TAs) and the 
association with quality of life in 197 non-head and neck cancer patients. Taste alteration was 
found in many patients and was associated positively to various aspects of quality of life such 
as fatigue and appetite loss. Additionally, a loss of eating pleasure was reported, which was 
associated with weight loss and diminished social interaction.  
Both studies were performed in non-head and neck cancer patients, without any information 
related to oral status, hygiene habits, medication, systemic diseases, salivary flow rate and 
protein composition before and after radiotherapy.  
Jin et al., (2018) studied the relationship between weight loss and taste alteration in 114 head 
and neck cancer (HNC) patients who were treated with intensity modulated radiotherapy. 
Using a scale to measure subjective taste alteration, weight and body mass index (BMI) were 
assessed at baseline, mid-treatment, post-treatment and two months after radiotherapy. The 
 46 
prevalence of subjective taste alteration after radiotherapy was more than 75%, along with 
discomfort during food intake and weight loss as well as mean BMI. Although there was no 
correlation between weight lost and taste alteration. Similarly, to the previous studies, 
salivary flow rate and protein composition were not measured together with the oral and 
dental status of this group of patients after the radiotherapy. In addition, there was no report 
of dry mouth feeling.  
Epstein et al., (2019) evaluated only five subjects with hematologic malignancy and nine head 
and neck cancer patients, who reported taste changes after treatment from 1-6 months. In 
order to test taste, a chemical gustometry for the primary taste qualities of sweet, sour, salty 
and bitter was used and umami flavour was assessed by using a modified Henke test. Patients’ 
answers were selected from the following choices: sweet, salty, sour, bitter, spicy, and tasty, 
or no taste. Dry mouth was assessed using the NCI Common Terminology Criteria for adverse 
Events (CTCAE) 4.0 and the Scale of Subjective Total Taste Acuity (STTA) was used to describe 
the loss of taste function (from 0 to 4). Stimulated and unstimulated salivary flow rate was 
measured, defining hyposalivation in 0.1ml/min for unstimulated and 0.5-0.7 ml/min for 
stimulated. Head and neck cancer patients’ taste function was reported as follows: grade 2 
taste disturbance was 44%, grade 3 was 44%, and one patient reported grade 1.  Regarding 
the gustometry test, four patients (44%) described no taste, three (33%) described an 
abnormal taste and two (22%) described moderate to severe reduction in sweet taste. Dry 
mouth was reported by all the patients in this group, showing grade 2 in 66% and grade 1 in 
33%. A reduced salivary flow rate was observed in 67% of the patients. Some patients 
reported improvement in taste after treatment, but all had dry mouth. Despite the low 
number of subjects included in this study of taste acuity after radiotherapy, salivary flow rate 
was measured, and dry mouth was reported by patients in order to associate these factors. 
There is no information of oral status, smoking and drinking habits, oral diseases such as 
carious lesions, mucositis and candida during and after radiotherapy. In addition, salivary 
protein composition before and after radiotherapy was not analysed.  
Martini et al., (2019)examined 31 head and neck cancer patients undergoing radiotherapy 
only or with chemotherapy. Taste changes were assessed using the (CT)-induced taste 
alteration scale (CiTAS), a scale based on 18 items to assess qualitative, quantitative and diet-
related toxicities before and after radiotherapy (1w, 1month and 6 months), pain was 
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evaluated using a visual analogue scale from 0 to 10. A statistically significant difference (p < 
0.05) was observed for reduced taste perception from baseline and at every time point, 
similarly for discomfort, metallic taste and presence of an unpleasant taste and for general 
taste alterations score.  
Ogama et al., (2010) studied 117 head and neck cancer patients receiving radiation therapy. 
The relationship between radiation treatment at different dosages and adverse effects like 
dysgeusia, xerostomia, and oral mucositis resulting in appetite changes were analysed. 
Fluctuations in saliva production, analgesic use, frequency of oral care, subjects’ 
characteristics and appetite were studied during the cancer treatment at 20, at 30, and 50 
Gy. Xerostomia was assessed by observing the amount of saliva and patients reported saliva 
production. Mucositis was evaluated using 5-point Common Terminology Criteria for Adverse 
Events (CTCAE), v3.0. Appetite survey was applied and analgesic intake. At 50 Gy, it was seen 
that xerostomia, sensitivity of taste and oral mucositis influenced appetite. Xerostomia is 
related to a reduced flow rate and oral care. Mucositis is affected by analgesic use. At 50 Gy 
all patients presented dysgeusia. This shows the importance of controlling xerostomia, 
dysgeusia and oral mucositis through the proactive use of analgesics for pain in order to 
prevent appetite reduction, to increase patients’ comfort, radiation therapy tolerance, QOL, 
and cancer treatment success. It is important to maintain oral care at this radiotherapy 
dosage.  
Flavour is a complex interaction between many sensorial factors including a normal salivary 
flow rate, taste and it is connected to emotions evoking a sense of well-being. After 
radiotherapy, hyposalivation may contribute to taste impairment due to a lack of dissolution 
of the food particles. Additionally, altered saliva viscosity impedes the correct transport of 
the molecules to the taste receptors (Epstein and Barasch, 2010; Irune et al., 2014; Epstein et 
al., 2019). Taste is related to energy intake, water consumption, nutrients and protection from 
toxins and poison. Macro and micronutrients are vital in the maintenance of health and tissue 
repair, especially after oncology treatments. The capacity to appreciate food affects the 
quality of life of head and neck cancer patients (Epstein et al., 2016).  
Taste alteration mainly influences the quality of life of head and neck cancer survivors 
regarding food selection, content evaluation, desire and oral intake of food, which leads to 
weight loss and nutritional implications. Changes in taste which have been evaluated by 
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patients are related mainly to quality of life. It is important to assess the changes in taste 
perception after radiotherapy and associate this with salivary gland hypofunction, examining 
the quality and quantity of saliva in order to correlate these outcomes with the possible role 
of saliva in taste changes in head and neck cancer patients in a long term follow-up.  
There are a lack of studies that include patient evaluation and analysis of the salivary 
production and protein content from unstimulated whole mouth saliva related to taste 
disturbances reported by the patients. There is a deficiency of information about oral 
examination of this group of patients, reporting carious lesions, dental treatment, mucositis, 
candida, smoking and drinking habits, oral hygiene in head and neck cancer patients 
undergoing radiation therapy. Finally, microbial analysis would add valuable information 
related to infections which alter the oral homeostasis and influence taste disfunctions. 
 
 
1.5.4.4 Radiotherapy Related to Xerostomia   
 
Diminished salivary flow rate has been one of the most common acute side effects leading to 
a dry mouth feeling or xerostomia. Xerostomia affects more than 80% of head and neck 
radiotherapy patients (Tschoppe et al., 2010; Pinna et al., 2015; Villa and Sonis, 2016). A 
diminished salivary output results in an altered salivary biochemical composition along with 
a change in salivary viscosity (Tschoppe et al., 2010; Vissink et al., 2010; Riley et al., 2017; 
Pedersen et al., 2018).  
However, xerostomia may be a result of salivary composition changes especially mucins that 
are responsible for lubrication (Pedersen et al., 2018). 
Xerostomia is a common side effect after radiotherapy in head and neck cancer patients, 
associated to hyposalivation and altered composition of saliva, which may lead to oral 
mucosal dehydration and cause a dry mouth feeling (Wiener et al., 2010; Nguyen et al., 2018). 
Altered flow rate and composition increase the risk of tooth demineralization and reduce 
remineralization due to the lack of calcium and phosphate increasing the caries risk and tooth 
extractions, post-extraction osteoradionecrosis, candidiasis and mucosal ulcerations (Jensen 
et al., 2010; Epstein et al., 2012). Additionally, xerostomia is associated to functional 
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impairments in chewing, swallowing, speaking and mucosal sensitivity (Murphy and Deng, 
2015).  
Chao et al., (2001), prospective clinical study before and after 6 months of radiotherapy in 41 
H&N cancer patients, objective and subjective xerostomia was tested in patients with head-
and-neck cancers treated with intensity-modulated radiation therapy (IMRT) (n 27) and three-
dimensional radiation therapy (n=14). Stimulated and unstimulated parotid saliva was 
collected before radiotherapy and 6 months after. Quality of life (QOL) was assessed with five 
questions regarding the patients’ oral discomfort and eating/speaking problems. A 
correlation was seen between parotid mean dose and reduction of stimulated saliva flow rate 
after 6 months of RT.  Also, stimulated and unstimulated saliva flow showed a significative 
correlation with eating/speaking functions at 6 months. The use of RT that is capable of 
sparing parotid glands showed an objective and subjective improvement of both xerostomia 
and QoL scores in head-and-neck cancers patients. The patients assessed for salivary flow rate 
were not compared with a control group and there was no analysis of the protein content to 
relate with xerostomia. 
 Vergeer et al., (2009), compared patient-rated xerostomia in 241 head and neck squamous 
cell carcinomas (HNSCC) treated with intensity-modulated radiation therapy (IMRT) and 
three-dimensional conventional radiotherapy (3D-CRT) using Radiation Therapy Oncology 
Group (RTOG) acute and late xerostomia and health-related quality of life (HRQOL). IMRT 
group resulted in both observer-rated and patient-rated xerostomia that was significantly 
lower than the two-dimensional radiotherapy, improving quality of life. However, 40% of 
patients still complained of xerostomia. No saliva was collected and there was no assessment 
of the salivary flow rate before and after the cancer treatment, nor was there any biochemical 
analysis of saliva.  
Hawkins et al., (2018) studied patient-reported xerostomia related to quality of life in head 
and neck cancer patients using patient-reported outcome measures (PROMs) including 
patient-reported xerostomia (PRX). Xerostomia (XQ) and head-and-neck quality of life 
(HNQOL) questionnaires were answered by 252 head and neck cancer patients treated with 
bilateral IMRT at 8 time points until 60 months after IMRT.  
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Before radiotherapy, there was no register of these parameters.  A positive correlation was 
shown between QOL and patient reported xerostomia and the radiation dose received by 
each gland.  
Kawamoto et al., (2018) studied retrospectively the incidence of late subjective xerostomia 
(severe xerostomia, grade >=2) in 71 oropharyngeal and hypopharyngeal cancer patients 
undergoing conformal radiotherapy (3D-CRT) and contralateral superficial lobe parotid-
sparing IMRT (CSLPS-IMRT). Xerostomia was assessed longitudinally at 3, 6, 12, 18 and 24 
months based on the PARSPORT trial this is a phase III multi-centre randomised controlled 
trial of parotid sparing IMRT in patients with head and neck cancer. The efficacy of both 
treatments was similar, whereas the incidence of xerostomia was significantly lower in CSLPS-
IMRT showing improvements in salivary function recovery and dry-mouth specifically 
increasing global quality of life score.  
These last two studies only measured the severity of xerostomia reported by the patients in 
order to assess its influence on the quality of life of head and neck cancer patients after 
radiotherapy. There was no information related to the salivary flow rate (stimulated or 
unstimulated) and composition regarding dry mouth. In addition, systemic diseases, smoking 
and drinking habits were not measured, nor was there any information related to oral or 
dental assessment which could dramatically influence the quality of life of these patients. 
Nutting et al., (2011) developed a multicentre study to compare side effects in 73 head and 
neck cancer patients using IMRT and conventional radiotherapy, in order to assess the 
incidence of severe xerostomia (grade 2) before starting the therapy and at week 4, 3 6 12 
and 24 months, using Late Effects of Normal Tissue (LENT SOMA) scales. The European 
Organization for Research and Treatment of Cancer ‘s (EORTC) QLQC30 quality-of-life 
questionnaire was used and the associated head and neck specific module HN35. For the 
assessment of xerostomia, the modified xerostomia questionnaire was applied. Unstimulated 
and stimulated parotid saliva from each parotid gland were collected. After 12 months of RT, 
grade 2 xerostomia was significantly lower in the IMRT group than in the conventional 
radiotherapy group. At 24 months the same pattern of therapy was given and salivary flow 
rate, dry-mouth and global quality of life outcomes in this group improved. Despite the fact 
that they collected saliva and recorded the flow rate, the specific values showing the variation 
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in time were not given, only an expression of the results and whether the salivary flow rate 
was able to be measured or not at every time point.  
Ghosh-Laskar et al., (2016), studied 59 patients with head and neck cancer treated with 
intensity modulated radiotherapy (n=30) or three-dimensional conformal radiation therapy 
(n=29). A clinical exam and salivary scintigraphy were performed, before and after 
radiotherapy. Grade 2 or worse acute xerostomia was evaluated at 8 weeks after 
radiotherapy, showing a significantly lower incidence in the IMRT group, the other acute 
toxicities not being significantly different. After radiotherapy, late radiation toxicity was 
measured every 6-months until complete 2 years. It was shown that grade 2 xerostomia in 
patients with HNSCC and treated with IMRT was reduced significantly in early (8 weeks) and 
late stages (24 months) after the treatment. Patients treated with 3D conformal RT showed 
an increased weight loss compared to IMRT group. In this study salivary flow rate was not 
measured clinically by sample collection. Therefore, there was no analysis of salivary 
biochemical composition after radiotherapy.  
Chen et al., (2017) ran a retrospective study of 855 nasopharyngeal carcinoma (NPC) patients 
treated either with three-dimensional conformal radiation therapy (3DCRT) or with intensity-
modulated radiation therapy (IMRT) between 2004 and 2009. Late toxicities were measured 
using Radiation Therapy Oncology Group (RTOG) criteria. Three years after radiotherapy, it 
was concluded that late toxicities occurred more frequently in patients treated with 3DCRT 
than in those treated with IMRT and salivary gland dysfunction was very similar in both 
groups. All the side effects were measured using the Radiation Therapy Oncology Group 
(RTOG) criteria. Salivary gland dysfunction was based on the observation of dry mouth and 
response to stimulation. Again, there was no report of clinical measurements or sample 
collection such as salivary flow rate and salivary composition in these two studies that 
compared the side effects of radiotherapy.  
As a conclusion, after radiotherapy, head and neck cancer patients have a deteriorated quality 
of life related to xerostomia as reported by patients.  
Dry mouth has been associated with a decreased quantity of saliva and as a result of altered 
protein composition (hyposalivation-independent dryness ranging from 4% to 50% in patients 
with dry mouth) (Närhi et al., 1994; Chaudhury et al., 2015, 2016). This subjective sensation 
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of oral dryness is a common side effect in head and neck cancer patients as well as salivary 
gland hypofunction caused by the cumulative dose > 20 Gy. An altered salivary production 
and quality due to radiotherapy may lead to changes in oral environment which in turn will 
Increase the risk of developing oral diseases, such as carious lesions and infections, along with 
reducing protective saliva functions such as hydration and lubrication of oral tissues 
(Chaudhury et al., 2015; Pedersen et al., 2018; Lynge Pedersen and Belstrøm, 2019).  
Xerostomia affects the basic daily functions that are associated with quality of life of this 
group of patients producing discomfort when eating and swallowing and speech problems. 
Studies conducted are mainly based on patient reports after radiotherapy. Therefore, it is 
important to measure the variations in saliva production and salivary protein composition in 
order to correlate the results with xerostomia reported by patients before and after 
radiotherapy. Saliva protein composition has a direct influence on the normal hydration and 
protection of mucosal surfaces by its gel-forming capacities and lubrication properties. 
Altered salivary protein composition will change viscoelastic saliva properties leading to a 
reduced coating or wetness of mucosal surfaces. Specially mucins composition which are 
responsible of viscosity, elasticity and stickiness properties that influence directly in 
lubrication and mucosal covering. Therefore, not only the amount of saliva produced is 
important, but also protein composition is vital in keeping the integrity of the oral surface.  
Finally, in the previous studies, there is a lack of information related with the subjects’ habits 
(smoking and drinking), oral assessment in order to correlate xerostomia with the number of 







1.5.4.5 Radiation Therapy Related to Salivary Protein Content in Unstimulated Whole Mouth 
Saliva in Head and Neck Cancer Patients 
 
Radiotherapy produces major salivary gland hypofunction which leads to salivary flow 
reduction from the beginning of treatment and results in a long-term or permanent dry 
mouth, especially when the cumulative doses of radiotherapy are higher than 30 Grays  
(Chao et al., 2001; Jawad et al., 2015). All salivary glands may be affected directly by 
radiotherapy during the cancer treatment. However, it has been well-established that serous 
acini cells are more radiosensitive than mucosal acini cells. Irradiation will cause cell death 
and inflammatory infiltration into the salivary glands leading to reduced saliva secretion and 
altered biochemical content (Jensen et al., 2003; SHAO et al., 2011; Hunter, 2013; de Paula et 
al., 2017).  
Moreover, nasopharyngeal and oropharyngeal cancer radiation directly affects the acinar 
cells of parotid glands due to their proximity to the tumour, thereby receiving a higher dose 
of radiation which will damage cell membranes impeding their normal function (Dijkema et 
al., 2008). 
After cancer treatment, rheological saliva properties will alter, becoming stickier and more 
viscous. It will also turn from transparent to white, yellow or brown (Jensen et al., 2003; 
Hunter, 2013; de Paula et al., 2017). Additionally, it has been stated that the concentration of 
salivary components depends on saliva flow rate. Thus, a diminished salivary gland function 
results in a reduced salivary flow rate. Therefore, saliva composition will be altered reducing 
its properties (Tschoppe et al., 2010; Dawes et al., 2015; Pinna et al., 2015; Gao et al., 2016; 
Riley et al., 2017).  
It has been proposed that there may be a association between elevated caries prevalence, 
incidence and activity with salivary gland dysfunction (Dawes et al., 2015; Pinna et al., 2015; 
Gao et al., 2016). Specifically, the composition of proteins in saliva, their concentration and 
secretion rate are all responsible for oral health, maintaining saliva’s rheological properties in 
order to maintain oral tissue integrity, function and oral homeostasis. Additionally, many 
other proteins are balancing the microbiome into symbiotic relationships, controlling 
opportunistic pathological bacterial/fungal growth through the power of altering 
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microorganism metabolism, increasing agglutination and clearance of particular bacteria 
species. Finally, these macromolecules are capable of maintaining optimal pH levels, reducing 
the acid moments and promoting the remineralization process over demineralization.  
Salivary proteins, as a part of the enamel and mucosal pellicle, play an important role in 
biofilm development, promoting initial bacterial colonization and adhesion to all oral 
surfaces, modulating bacterial attachment, controlling its growth and metabolic activity. All 
of the above results in a healthy bacterial community, excluding pathogens or keeping these 
opportunistic microbes in a non-pathological state (Schenkels et al., 1995; Almståhl et al., 
2001; Chiappin et al., 2007; Carpenter, 2013; Laheij et al., 2015; Dawes et al., 2015; Kilian et 
al., 2016). An increased concentration of IgA in saliva after RT has been related to mucosal 
damage and/or to cellular damage in the parotid gland (Richards et al., 2017). 
Mucins form a protective, slimy and viscoelastic layer over the oral mucosa. It has been shown 
that mucin 5Bin particular is closely related to xerostomia in H&N cancer patients (Dijkema et 
al., 2012; H. L. Gibbins et al., 2014). 
It is important to emphasise the protective effect of saliva on oral mucosa, which is not only 
related to the volume of saliva present in the oral cavity, but also to its quality. This helps to 
reduce the potential damage when a hot or cold drink is consumed, or from eating hard foods 
by lubricating them. This buffering capacity depends on the bicarbonate reaction and 
carbonic anhydrase VI action in converting carbonic acid into water and carbonic dioxide to 
neutralize acids (Dawes et al., 2015).  
Salivary proteins are capable of forming a functional network, clustering different proteins. 
This network capacity will improve antibacterial, antifungal and antiviral properties, attracting 
beneficial microorganisms, protecting the oral environment from pathological bacteria and 
other harmful substances in order to preserve normal and beneficial flora which include 
around 700 species (Prodan et al., 2015).  
Quality and quantity of proteins in saliva are associated with frequency and severity of oral 
diseases, indeed it has been suggested that many of these molecules are related to the 
aetiology of mucosal diseases, fungal infections and dental caries (Hemadi et al., 2017).  
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It has been established that a reduced flow rate in head and neck cancer patients treated with 
radiotherapy is linked to an increased caries risk and candida infections (Frenkel and Ribbeck, 
2015).  
 Valdez et al., (1993)studied salivary flow rates from both unstimulated and stimulated saliva 
of the parotid and SM/SL glands, total protein content, lysozyme, lactoferrin, sodium, 
chloride, and potassium concentration.  Fifty H&N cancer patients, with xerostomia after 
conventional radiotherapy, were compared with controls subjects. SFR in both stimulated and 
unstimulated saliva was reduced significantly compared with controls. Total protein 
concentration was similar in both groups, whereas secretion rate was lower in the irradiated 
patients. Lactoferrin was significantly elevated in parotid saliva as well as levels of lysozyme.  
Funegård et al., (1994) analysed stimulated saliva from both parotid glands in 16 head and 
neck cancer patients before, during and post-RT for up to 18 months. They assessed α-
amylase, hexosamine, sialic acid, salivary peroxidase, bacteria aggregating glycoprotein 
(BAGP) and IgA concentration in order to determine the antibacterial properties of saliva and 
correlate this with the diminished salivary flow rate. During the treatment, there was a 
protein concentration fluctuation which returned to baseline levels after 18 months. 
However, there were only 16 patients studied and parotid gland saliva does not represent 
whole mouth saliva.  
 
It has been reported by Hannig et al., (2006) that total protein concentration did not show 
any variation in unstimulated whole mouth saliva of head and neck cancer patients compared 
to healthy subjects. It was reported that only the acidic proline-rich proteins were significantly 
lower in irradiated patients with hypo-salivation, following 6-12 months of radiotherapy. 
However, this group of ten patients showed variations in different salivary protein 
concentrations compared to healthy younger controls (34-44 years old). Without 
considerable differences, only with acidic PRP was a statistically significant decrease 
observed. Different proteins were assessed using a mass spectrometry with electrospray 
ionization (ESI-MS). There were no samples collected before cancer treatment and there was 
a lack of information regarding the oral health status of these groups of subjects. 
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Laheij et al., (2015) evaluated protein concentration using surface-enhanced laser 
desorption/ionization (SELDI-TOF-MS) in nine head and neck cancer patients treated with 
radiotherapy and ten healthy controls. Differences in concentration were found in 
antibacterial proteins, antifungal proteins related with oral infection, and proteins that 
maintain mineral homeostasis between both groups. Based on a small number of subjects 
with a wide age range, it was concluded that protein could be used as a biomarker of oral 
diseases related to RT in this group. Also, it was stated that oral health is associated with 
whole protein concentration, rather than a specific group of proteins. There was no systemic 
evaluation of the patients or medication intake. Moreover, an oral assessment could have 
been performed to correlate the results with existing carious lesions and a salivary protein 
composition assessment of the patients before radiotherapy.  
Almståhl et al., (2001) compared the protein concentration in stimulated whole saliva from 
irradiated patients, Sjögren’s Syndrome (SS) patients and those with hypo-salivation of 
unknown origin as well as healthy controls. The variation in protein in patients treated with 
radiotherapy was higher than the other hypo-salivation groups. The results were related with 
microbial species, salivary flow, periodontal disease and numbers of caries lesions found 
during the oral exam. Despite the fact that the groups were matched in terms of age, gender, 
number of teeth and periodontal characteristics, the number of subjects in the radiation 
group was half the number of the other groups. Furthermore, there was no information about 
the type of cancer, radiation dose received and habits of these patients. In addition, an oral 
assessment of these patients before their radiotherapy and treatments was not conducted. 
Consequently, further analysis is required to compare before and after RT and to follow up 
on the patients.  
Eliasson et al., (2005) studied the secretion rate and IgA, albumin and lactoferrin in minor 
gland saliva and unstimulated and stimulated whole mouth saliva in 20 subjects with hypo-
salivation due to Sjogren syndrome and radiotherapy compared with healthy, matched 
controls in gender, age and number of teeth. All patients were instructed to not clean their 
teeth inter-proximally for three days, not to brush their teeth the same day and not to eat or 
drink for at least 2h prior to the measurements. Flow rate from both minor and major salivary 
glands were diminished in patients with SS´s and the radiotherapy group compared with 
controls. All proteins in whole saliva were increased in comparison with controls; only 
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albumin was decreased in the SS´s group. Lactoferrin was significantly lower in the SS group 
compared with RT (p < 0.05). Minor salivary gland flow rate and secretion rate were 
diminished, and protein concentrations were higher in both groups compared with healthy 
controls. Additionally, the highest differences were observed in the RT group.  
Vidotto et al., (2010) performed a proteomic analysis of saliva (n=7) and serum (n=15) from 
head and neck cancer patients before and after radiotherapy (between 1 to 60 months). 
Proteins that may contribute to tumour growth (palate lung and nasal epithelium clone 
protein PLUNC and zinc-alpha-2-glycoprotein) were studied and compared with control 
subjects. After radiotherapy, the protein profile analysed was similar to controls (n=29), 
showing the potential of saliva and serum for diagnosing and monitoring health, disease and 
treatment outcomes. Unstimulated whole mouth saliva is an accessible fluid composed of a 
mix of major and minor salivary glands and a mix of proteins that have different functions. Its 
composition and flux can be affected by several factors, including radiotherapy. The flow rate 
was significantly reduced after RT and differences in 13 protein profiles and their pattern of 
expression were shown between patients and controls (proteins involved in cell adhesion, cell 
differentiation and epidermis development, metabolic processes, transport and immune 
response). However, before and after radiotherapy, protein concentration did not show a 
significant variation. Flow rate and saliva constituents could be used to observe different 
pathological conditions. There was no hygiene assessment, record of number of months after 
RT and oral assessment. 
Dijkema et al. (2012) studied mucin 5B (MUC 5B) concentration and total protein 
concentration (TPC) levels (mg/ml) in 29 head and neck cancer patients before and after 12 
months of cancer treatment. After using a xerostomia questionnaire, the patients were 
grouped, according to their conditions, in non/mild and severe groups in order to correlate 
the amount of protein with the oral signs and symptoms of this side effect in differing degrees. 
Indeed, MUC5B concentration was higher in patients with no or mild xerostomia than in 
patients with severe xerostomia. Additionally, in this group, MUC5B output (mucin 
concentration by SFR) levels were the lowest but even so, there was no significant difference.  
Regarding total protein content, there was no statistically significant difference after the 
treatment among the groups. Two separate saliva samples were collected, stimulated 
submandibular gland saliva using citric acid solution (5%), collected by suction with a 
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micropipette in the floor of the mouth, in close proximity to the Wharton duct and parotid 
stimulated saliva using a Lashley cup. In addition, the xerostomia questionnaire used in the 
study was not described (Granger et al., 2007; Rohleder et al.,2009; Jensen et al., 2010; 
Papacosta et al., 2011). 
Richards et al., (2017)assessed parotid function after 3 and 12 months of curative intensity-
modulated radiotherapy (IMRT) in 26 HN cancer patients, analysing saliva´s organic and 
inorganic composition and flow rate. Subjective and objective xerostomia measures were also 
collected in order to associate this with saliva composition. UWM saliva flow rate decreased 
significantly along with total protein secretion rate, phosphate concentration and only 
lactoferrin was increased. The same trend was seen in SMS with lactoferrin secretion rate. At 
12 months, lactoferrin was increased in both saliva samples. TPC secretion rate in UWMS was 
lower in the group with a high degree of xerostomia. This study was retrospectively planned 
and only included patients who had a determined flow rate >0.03ml/min.  
In summary, despite the fact that all of these studies collected different types of saliva 
(parotid, sublingual, submandibular and unstimulated whole mouth saliva) from a small 
number of cancer patients (the majority of the studies recruited between 9 and 20 subjects), 
all attempted to correlate protein concentration with radiation oral sequelae such as carious 
lesions and oral mucositis. Some of the studies also correlated results with the number of S. 
Mutans and lactobacillus colonies, in order to identify proteins as a biomarker of bacterial 
oral diseases. Salivary gland function is altered after radiation therapy, affecting saliva flow 
rate and biochemical composition regarding protein concentration. The majority of these 
studies were performed after the radiation therapy. Hence, further longitudinal clinical 
studies are required to correlate the variation in saliva protein content with the most 
prevalent oral sequelae in head and neck cancer survivors. It is necessary to compare the total 
protein concentration with specific proteins related to antimicrobial, bacterial and sugar 
clearance, mucosal protection, lubrication, buffer and remineralization which are important 
salivary functions before and after  cancer therapy, as well as age and gender-matched 
healthy controls, in order to identify potential protein associations and predict the oral and 
dental disease risk and finally provide a specialised individual dental care plan for each 
patient.  
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Finally, it would be interesting to associate the xerostomia induced by radiotherapy with the 
protein variation in saliva, especially the molecules that are part of mucosal pellicle.  
 It is important to establish the influence of salivary proteins on oral bacterial community as 
this will contribute to increase the pathogenic population and contribute among multiple 
factors such as diet, hygiene, mineral unbalance, to carious lesion onset. Thus, all the data 
obtained could be correlated in order to be able to predict the predisposition of caries 
development in this group. 
 
1.5.4.6 Oral Mucositis 
 
Oral mucosal inflammation produced by cancer therapy is one of the most common side 
effects in head and neck cancer therapy (Sonis, 2011; Epstein et al., 2012; Duarte et al., 2014; 
Franco et al., 2017; Jung et al., 2019). It is considered one of the most painful radiotherapy 
side effects strongly affecting quality of life of these patients (Franco et al., 2017).  
More than two-thirds of radiation and chemotherapy-treated head and neck cancer patients 
suffer oral mucositis, presenting large, irregular and deep ulcers which reach the submucosa, 
due to the cytotoxic effects of inflammation on epithelial tissue (Sonis, 2004b, 2011; Epstein 
et al., 2012; Villa and Sonis, 2015; GB et al., 2015; Vasconcelos et al., 2016; Richards et al., 
2017). As an acute effect, mucositis is influenced by tumour location, which is directly 
correlated to mucositis severity, cancer treatment (radiation dosage, size of the area and 
fractioning), genetic susceptibility and individual patient response, being described as a 
complex and multifactorial pathology. Additionally, other factors related with mucositis have 
been found, such as patients’ habits. Smoking may modify the dose-response curve. 
Additionally, patients related risk factors such as a microbial population shift, dental and 
periodontal general condition, poor oral hygiene, reduced salivary flow rate and composition 
of saliva will influence negatively occurrence, intensity, severity and length of mucositis in 
head and neck cancer patients the possibility of oral mucositis onset (Sonis, 2004b; Epstein et 
al., 2012; Sonis, 2013; Villa and Sonis, 2015, 2016; Normando et al., 2017; Franco et al., 2017; 
Orlandi et al., 2018). Salivary mucins, especially MUC5B, are important in mucosal hydration 
and lubrication. Mucins are capable of forming a gel and covering oral epithelium, constituting 
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a dynamic and semipermeable barrier, in order to protect this tissue from dryness, shear 
stress and controlling bacterial adhesion and colonization. A healthy mucosal barrier is vital, 
particularly in patients with diminished salivary flow rate and altered biochemical 
components. Altered mucin composition will alter salivary viscoelastic properties resulting in 
a reduced or defective mucosal layer that will lead to a reduced hydration, lubrication, 
protection and diffusion of molecules into the oral epithelial surfaces (Larhed et al., 1998; 
Cone, 2009). Additionally, saliva contains a wide range of proteins which are vital in the 
different stages of wound healing (Brand et al., 2014; Dawes et al., 2015).  
Oral mucositis is controlled by numerous molecules, inflammatory and non-inflammatory 
mediators, cytokines, growth factors and matrix metalloproteinases, such as epidermal 
growth factor (EGF) and tumour necrosis alpha (TNF-a) showing that this is not only an 
epithelium reaction to radiation, but rather a complex molecular chain of differing 
reactions(Villa and Sonis, 2016; Normando et al., 2017; Münstedt et al., 2019). 
Such severe complications can be a limiting factor for cancer treatment, as the resultant pain 
of oral mucositis can cause patients to drop the treatment, compromising its effectiveness. 
More advanced cases will even require hospitalization to manage pain as well as parenteral 
feeding in order to endure the pain while feeding, with secondary infection treatment to 
prevent the risk of systemic infection, bacteraemia and sepsis. This is due to the higher risk of 
systemic infection among patients that develop mucositis. Thus, the prevention, 
management and control of oral mucositis is vital, so that the incidence and degree of this 
condition can be reduced (Epstein et al., 2012; Duarte et al., 2014; Franco et al., 2017; 
Almståhl et al., 2019; Münstedt et al., 2019).  
There are five principle stages of mucositis progression. Initiation occurs in the basal 
epithelium and submucosa endothelium cells, despite the fact that the basal epithelium is the 
target of radiation toxicity and the site where cell injury and death start, by two mechanisms 
directly breaking DNA strands of cells and generating oxidative species. The radiation 
activates several pathways in endothelial fibroblasts and epithelium to initiate and modulate 
the damage response and tissue injury. Inducing immune cells (macrophages) to produce pro-
inflammatory cytokines, such as tumour-necrosis factor α (TNF-α) and interleukin 6, lead 
epithelial basal cell death and injury (Sonis, 2004b; Vasconcelos et al., 2016).  
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Furthermore, these mechanisms of damage also harm epithelial stem cells, reducing their 
regeneration capacity, resulting in a permanently thinner epithelium barrier and allowing 
mucositis symptoms to emerge. Signal amplification occurs, with macrophages that are 
activated by radiotherapy producing pro-inflammatory cytokines in response, which amplify 
the primary signal, causing a positive feedback to magnify the tissue damage, by activation of 
metalloproteinases 1 and 3 (MMP-1 and MMP-3). After approximately 10 days of treatment, 
ulcerating lesions may appear in the oral mucosa (Sonis, 2004b, 2011).  
Following this, spontaneous healing can begin 2 to 3 weeks after radiation, by migration of 
epithelial cells from the walls of the wound guided by proliferation, migration and 
differentiation signals from mesenchymal cells and extra cellular matrix (Sonis, 2004b).  
Additionally, mucositis is associated with nutritional deficits, resulting in rapid weight loss, 
with the pain also presenting chronic fatigue apathy and depression. According to some 
reports, this could be linked to systemic serum elevated cytokines levels, that is a result of an 
increased mucosal proinflammatory cytokines production caused by mucositis (Silva et al., 
2009; Franco et al., 2017; McCullough, 2017; Maria et al., 2017).  
Certain studies have focused on regulating the pathways of oral mucositis, such as TNF-α, IL-
6, IL-1β, IL-10, TGF-β, EGF, FGF, VEGF, specific tissue inhibitors and matrix metalloproteinases 
(MMP-2/TIMP-2 and MMP-9/TIMP-2 ( GB et al., 2015; Normando et al., 2017). However, 
despite these mechanisms being explored, there are presently no therapeutic agents to 
prevent or rapidly resolve this oral side effect. Oral mucositis still remains as a dose limiting 
factor in head and neck cancer patient treatment, interfering with the plan (McCullough, 
2017). 
Finally, oral mucositis leads to a high risk of developing bacterial and fungal infections, with 
oral candida along with microorganisms capable of colonisation surrounding the ulcerated 
mucosa and contributing to the mucositis process, stimulating polymorphonuclear leukocytes 
(PMNs) and macrophages’ chemotactic activities and pro inflammatory cytokines secretion. 
Ultimately, the bacterial colonies are capable of affecting the mucosal injury, severity and 
duration (Vanhoecke et al., 2015; Vasconcelos et al., 2016; Maria et al., 2017).  
Clinical evaluation of oral mucositis related to Intensity Modulated Radiotherapy is not well 
established in the literature, possibly because there are several scoring criteria to determine 
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mucositis prevalence and intensity. Some studies only report the highest severity (3 or 4) 
leaving the lowest out of their scope(Logan et al., 2007; Epstein et al., 2012; Sonis, 2013; Villa 
and Sonis, 2015, 2016; Normando et al., 2017; Franco et al., 2017).  
Oral mucositis diagnosis is based on clinical observation, with no scientific evidence of the 
superiority of one measuring criteria over the rest. These scales do not always meet the ideal 
criteria of being objective, sensitive, validated, reliable / easy to use, useful in different 
treatment modalities, asses mucosal damage and patients’ daily function (De Sanctis et al., 
2016).  
In order to assess oral mucositis, the World Health Organization (WHO) developed an oral 
toxicity scale to quantify oral mucositis severity. It is based on a clinical observation of oral 
mucosa symptoms, signs of damage, and functional disturbances based on diet of the subjects 
(World Health Organization, Handbook, 1979). This scale is used in research and daily health 
care of head and neck cancer patients. The WHO scale grading ranges from no change to mild 
and including severe mucositis (grades 3–4). The training and experience in using the scale 
will improve the accuracy and consistency of the outcomes (‘WHO handbook for reporting 
results of cancer treatment’, 1979; Sonis, 2004a, 2013).  
Oral mucositis monitoring is important, patients grade 3 or 4 are frequently reported because 
this group is more likely to delay their cancer treatment, reduce the radiotherapy dose (dose 
limiting toxicity), modifying fractionation or interrupting the cancer treatment continuity 
(approximately 30%), impairing the effectiveness of the therapy and affecting negatively the 
patients’ quality of life. Due to the associated symptoms of severe oral mucositis over 60% of 
these patients will need parenteral nutrition, opioid analgesia, antibiotics and hospitalization 
so increasing the healthcare costs.  Economic costs will increase as a result of prolonged 
cancer treatment and oral mucositis symptoms treatment(Sonis, 2004b; Maria et al., 2017).  
Hahn Berg et al., (2004) investigated 127 head and neck cancer patients with advanced 
squamous cell carcinoma (SCC) treated with radiotherapy and at least 2 cycles of cisplatin and 
5-FU. It was observed that 64% of patients developed mucositis, and 33% had grade 3–4 
mucositis. In addition, other gastrointestinal symptoms were described that could be due to 
mucositis including severe nausea, dehydration and electrolyte imbalance which required 
intravenous or enteral fluid replacement. 
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Orlandi et al., (2018), assessed mucositis grades in a retrospective study in 132 head and neck 
cancer patients treated with IMRT (70Gy) and chemotherapy, in order to predict a dose 
response association to prevent and manage this side effect. Clinical parameters were 
assessed: age, gender, body mass index (BMI), smoke history, histology, staging, 
hypertension, diabetes mellitus, as well as cardiological, haematological and oncological 
diseases other than NPC, RT technique, fractionation and overall treatment time and 
chemotherapy regimens. There was no information regarding oral health and dental care 
received by the patients before and after the cancer treatment. Additionally, there was also 
a lack of information related to salivary gland function before and after radiotherapy, 
assessing salivary flow rate and saliva composition.  
Jham et al., (2008) performed a retrospective oral assessment of cancer patients before, 
during and after RT to evaluate the oral side effects. Mucositis was the most prevalent side 
effect among subjects during RT, whereas after treatment completion it became the lowest 
in prevalence. Duarte et al., (2014)conducted a retrospective study of the prevalence of oral 
side effects in patients treated with IMRT and conventional RT. A complete oral evaluation 
was performed before treatment and patients with oral diseases were excluded. It was shown 
that there was a reduced number of mucositis and xerostomia cases among patients treated 
with IMRT compared with conventional RT. However, this group showed an increased number 
of caries lesions and fewer teeth remained in comparison to the other group. 
In a retrospective analysis of oral side effects during and after IMRT,78 patients were seen 
every month during the first year, every 2 months in the second year and every 3–6 months 
after. Radiotherapy doses varied from 60 Gy to 70 Gy. Twenty patients received inductive 
chemotherapy and 35 received concomitant chemotherapy. Using RTOG index it was shown 
that the majority of patients (82%) developed severe mucositis during therapy (RTOG Grade 
3 mucositis in 64 patients). Similar results were seen in 48 patients who had squamous cell 
cancer (SCC). It was shown that grade 3 mucositis was observed in 41 patients (85%). A 
median follow up was 18.7 months 34 patients presented xerostomia, 11 lost of taste, 7 neck 
fibrosis and 2 dysphagia (Van Gestel et al., 2011).  
Similar findings were reported by Vera-Llonch et al., (2007) in a retrospective study in head 
and neck cancer patients treated with radiation therapy. The data was collected from 154 
different oncologists, in order to determine the severity of oral mucositis. A non-validated 
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index was used, which categorised the patients in none, mild, moderate or severe mucositis. 
83% of patients developed mucositis, presenting the following distribution: mild in 19%, 
moderate in 35% and severe 28%  
It was also seen that patients who developed oral mucositis during treatment presented a 
higher risk of making unplanned breaks and hospitalizations, especially in the severe 
mucositis group. There is no record of any oral assessments or dental treatments given to 
these groups of patients before and after radiotherapy  
All these studies are retrospective evaluations of the mucosal condition in head and neck 
cancer patients, reporting the prevalence and severity of oral mucositis during and after the 
radiation therapy. There is a lack of information regarding the oral condition of the subjects 
(dental and periodontal), dental treatment received before and after radiotherapy, oral 
hygiene, drinking and smoking habits and food consumption as well as sugar intake. Finally, 
there was no information related to salivary flow rate quantity and quality which are all 
related to the development of this condition.  
Dodd et al.,(2003) studied the clinical efficacy of sucralfate (Carafate R) mouthwash for head 
and neck cancer patients (HNC) compared with salt & soda mouthwash in order to reduce the 
severity of the mucositis, the severity of mucositis-related pain and the time required to heal 
RT-induced mucositis. Habits like smoking and drinking were assessed. There were no 
significant differences in the number of days for mucositis to start, pain scores, grades and 
time of healing, during and one month after RT. The use of salt and soda was suggested 
because it is less expensive.  
Veness et al., (2006) evaluated the effect of topical misoprostol in reducing the severity of 
radiation-induced mucositis in patients receiving a radical dose of radiotherapy in a 
randomized, double-blind, placebo-controlled trial.  Forty-two patients received misoprostol 
and 41 received a placebo. No significant difference in the mean area under the mucositis 
curve (13.2 vs 16.6; P = 0.1) was noticed. The misoprostol group reported an increased 
soreness (7.6 vs 6.9; P = 0.04) and an increase in the use of analgesics. 12% of patients 
interrupted their treatment and the median time of interruption was 6 days. There was no 
difference between groups in the incidence of mucositis. 
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Diaz-Sanchez et al., (2015) evaluated the use of chlorhexidine gel 0.2% versus placebo in 7 
patients diagnosed with head and neck cancer, in order to prevent and treat oral mucositis 
induced by radiation therapy and chemotherapy. Patients were instructed to apply the gel 5 
times per day, from the initiation of radiotherapy until 2 weeks after the treatment finished.  
The grade of mucositis was measured using WHO score criteria, pain (visual analogue scale) 
and analgesic consumption was recorded by the patients, infectious complications were 
assessed in weekly reviews as well as treatment tolerance using a score from 0 to 5. After the 
treatment, mucositis pain and tolerance were similar in both groups and there was not any 
improvement with the use of chlorhexidine.  
Franco et al., (2017) showed the impact of oral mucositis in twenty-one head and neck cancer 
patients’ quality of life. All patients received intensity-modulated radiotherapy and they were 
using an oral mouthwash to prevent oral mucositis. A scale was used to assess the presence 
of ulcers and erythema in nine different places in the mouth. In order to appraise these 
patients’ wellbeing, an oral mucositis questionnaire for head and neck cancer was applied 
weekly, along with a functional assessment of cancer therapy which includes physical, 
emotional, social, family and functional well-being. Additionally, pain was evaluated using a 
visual analogue scale, at rest and during daily functions (speaking and swallowing). It was 
shown that oral mucositis increases along with the increase in the radiotherapy dose. This 
was directly correlated with pain at rest, speaking and swallowing during the treatment and 
it was shown to have a negative impact on patients’ quality of life in all the groups. This 
remained unchanged until two weeks after they finished their cancer treatment. This was a 
prospective study, there was no oral or dental assessment, salivary flow rate variation was 
not recorded, and composition was not assessed to correlate with dry mouth and taste acuity. 
Finally, regarding the impact of all these factors, together with the development of oral 
mucositis, it is also important to consider the influence of dietary advice and dental treatment 
received before and after radiotherapy in order to correlate with the data obtained.  
Dodd et al., (2003); Veness et al., (2006); Diaz-Sanchez et al., (2015) conducted randomized 
controlled trials to evaluate the effectiveness of different medical products in preventing and 
treating oral mucositis provoked by oral cancer treatment. All the groups studied developed 
mucositis during the cancer therapy and there was no difference between the medication 
administered and the placebo group. Moreover, there was a lack of information about the 
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oral health status before the radiotherapy started, as well as salivary flow rate variation and 
protein composition of saliva.  
Jham et al., (2009) assessed the effect of bethanechol administration in oral mucositis, 
candidiasis and taste loss before and during radiotherapy in 16 head and neck cancer patients 
randomly selected to use it. Mucositis was scored using the World Health Organization (WHO) 
method, candidiasis was diagnosed by clinical examination and taste loss was assessed by 
subjective report of absence of taste.  
There were no significant differences observed between groups in relation to frequency and 
severity of mucositis, frequency of candidiasis and taste loss. Candidiasis during RT presented 
in a smaller number of cases in the group using bethanechol (50%) than the one using saliva 
(70%). The number of subjects that reported loss of taste was lower in the bethanechol group 
(69%) during RT, in comparison to the saliva group (95%) (P=0.07). It was seen that in this 
group, bethanechol does not seem to reduce the occurrence of mucositis, candidiasis nor 
taste loss during RT. In this study, there was no information regarding oral health, hygiene 
habits nor oral assessment including dental treatment received before and after the 
radiotherapy.  Finally, there was no analysis of salivary flow rate nor composition which could 
affect the outcomes.   
Charalambous et al., (2018)studied the efficacy of thyme honey in oral mucositis treatment 
to reduce symptoms, grade and secondary complications, such as weight loss and oral 
problems, in order to assess the effect of mucositis development and quality of life of 
patients. Seventy two head and neck cancer patients treated with IMRT (50 and 60Gy) were 
recruited and divided into two groups; intervention group (thyme honey rinses) and control 
group (saline rinses). Oral mucositis grade was assessed once per week starting at the 4th 
week of radiotherapy and until 6 months after, by radiation oncologists using a scale adapted 
by Radiation Therapy Oncology Group (RTOG).  Quality of life was evaluated with the OM 
Questionnaire validated previously; a different questionnaire was considered to evaluate 
overall wellbeing. It was shown that in the intervention group, oral mucositis severity was 
less, patients maintained their weight and their overall health was better than control group 
increasing the Quality of Life index level in this group. However, the time it took to resolve 
lesions did not diminish in the intervention group compared with the control, taking between 
2 to 4 weeks after finishing radiotherapy. Similarly, to the previous study, there was a lack of 
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information and of proper assessment of the oral health, dental health, salivary flow rate, 
saliva composition and dietary intake of these patients before, during and after radiotherapy. 
Finally, it is important to remark that honey was given three times a day for seven weeks, thus 
increasing the sugar content in these patients’ diets. Also, the duration of every rinse was not 
given, and the oral hygiene habits were not assessed. All these factors may increase the risk 
of caries lesion development, which was also not assessed before and after radiotherapy. 
Similar results were found in a study developed by Rao et al. (2017), where 49 head and neck 
cancer patients were divided into two groups, one was asked to rinse their mouth with poli-
floral honey three times a day during and after the radiotherapy (mean dose received 62–70 
Gy), the other group was using betadine (povidone-iodine) . In this study, the subjects from 
the groups were examined in order to assess decayed teeth and ulcers/lesions in the oral 
mucosa by an oro-dental physician. Oral hygiene habits were recorded, and all patients 
received oral and dental care during the radiotherapy. A senior oro-dental pathologist 
assessed the mucositis grade once per week, using the same scale RTOG index (Radiation 
Therapy Oncology Group grading system) until 4 weeks after radiotherapy. The results 
showed that honey was more effective in reducing oral mucositis, thereby decreasing the 
number of patients with intolerable mucositis. The number of patients that had to stop the 
treatment was reduced as well as the number of these patients, but there was there was no 
analysis of salivary flow rate and there is no information regarding the outcomes of the oral 
assessment.  
Using RTOG index, Sun et al., (2019), studied the effect of two oral mouthwashes, one was 
pure vitamin B and the second was a mix of vitamin B and Gene Time VR (recombinant form 
of human epidermal growth factor capable of regulating cell-growth) to treat oral 
inflammation, in 100 head and neck cancer patients for 3 weeks after the radiotherapy (RT 
dose 50–70 Gy). The patients rinsed four times per day, 10 min after each meal and before 
going to bed, for a full five min and then swallowed slowly. The Radiation Therapy Oncology 
Group (RTOG) index was used to assess oral mucositis and the ulcer area was measured. The 
pain was recorded using a VAS scale. Almost all patients developed mucositis, but the mixed 
compounds group showed a significantly shortened ulcer healing time.  There was no oral 
assessment or hygiene habits recorded. There was no evaluation of saliva quality and quantity 
either.  
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The main agreement in all studies including retrospective and prospective assessments, is 
that oral mucositis is a frequent and painful complication during cancer therapy;  over 80% of 
oral cancer patients will develop this condition and it has been related to a reduced body 
mass index which will lead to dietary supplementation (Huang et al.,2019; Charalambus et 
al.,2018 ;Villa et al.,2016). 
Presently, many of the studies are focused on finding an effective topical treatment and trying 
to reduce the incidence or severity of mucositis using a large number of natural and 
pharmacological agents. However, there is not enough evidence confirming the efficacy of 
these agents over placebo, in preventing and reducing oral mucositis development and 
severity related to radiotherapy ( Riley et al., 2017 ;Huang et al., 2019). 
In previously described retrospective studies, the prevalence of mucositis among groups of 
patients treated with radiotherapy was assessed. However, there was no clear measurement 
of xerostomia, salivary flow rate and saliva composition to associate with oral mucositis 
severity. It is important to consider both salivary flow rate and saliva biochemical content 
variation before and after radiotherapy to assess the role of both in oral mucosal health and 
pathology development. It is well established that dry mouth feeling is a result of a diminished 
saliva secretion. It has also been associated with a change in its biochemical composition 
without a diminished salivary flow rate (Wang et al., 2016; Riley et al., 2017). This protein 
association with salivary flow rate determines the variation in protein secretion rate after 
radiotherapy.  
So far, there is no effective therapy to cure this side effect or reduce its severity and duration. 
Also, there are no drugs available to avoid or prevent radiation-induced mucositis, even 
though there are a large number of studies trying different products, such as promoting oral 
hygiene, food advice, reducing alcohol intake and quitting smoking. Recently, there have been 
studies focusing on antibody assessment, such as Interleukins 6 / 8 and TNF alpha, in HNC 
patients undergoing conventional radiotherapy to treat and prevent oral mucositis focusing 
on neutralizing the inflammatory response increasing defensive response (Villa and Sonis, 
2016; Normando et al., 2017).  
In summary, there is a lack of studies that analyse the protein content from unstimulated 
whole mouth saliva related to mucosal lubrication, hydration and protection in head and neck 
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cancer patients undergoing radiation therapy. Despite the fact that this is one of the most 
common complications of RT and dose limiting for HNC patients, usually causing intense pain, 
negative impact in QOL and a major economic and clinical impact along with the lack of 
effective drugs and treatments currently there is no biomarker to predict onset and severity 
of oral mucositis as well as early detection. Oral mucositis detection and diagnostic is limited 
to clinical manifestation of this side effect only. 
Evaluation is required of protein concentration related to mucosal pellicle in head and neck 
cancer patients before/after radiotherapy. Comparing these proteins to determine the 
possible variation and correlation with the clinical information is needed in order to develop 
predictive “biomarker” signatures to identify patients with a high risk of developing severe 
oral mucositis.  
Therefore, it would be important to develop a predictive model that could easily monitored 
and identify patients at risk of developing oral mucositis and severity, based on longitudinal 
quantification and identification of protein signatures present in UWMS associated with 
mucosal integrity in order to, help to improve prevention, management and increase overall 
treatment effectiveness.  
Also, there is little research focused on oral microbiome variation before and after 
radiotherapy associated with secondary infection in oral mucositis, particularly using high 
throughput sequencing techniques to determine the microbiota present longitudinally that 
may be related to the severity of this condition.  
Therefore, a prospective longitudinal study with a complete oral evaluation of head and neck 
cancer patients is necessary before, during and after cancer treatment which would help to 
identify and quantify clinical features that increase the risk of developing severe mucositis. 
There is a lack of information regarding salivary flow rate, protein secretion rate in order to 
correlate these factors with the onset and severity of oral mucositis.  
Finally, it would be helpful to assess patients related factors that may modify the individual 
response to radiotherapy. An accurate oral assessment is necessary before starting 
radiotherapy, including evaluation of dental status (DMFT), oral hygiene, oral diseases and 
habits such as smoking and drinking.  
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1.5.4.7 Effect of Radiotherapy on the Interaction between Dental Organic Matrix and 
Apatite Crystals related to an Increased Caries Risk / Incidence 
 
Patients with Head and Neck (H&N) cancer undergoing radiotherapy (RT) are at significantly 
higher risk of developing severe oral complications following treatment. These include rapidly 
progressive caries, which carry high risks of bone necrosis resulting in non-healing sites with 
extensive bone destruction should extractions be required. These are recognised as distinct 
disease entities related to H&N radiotherapy, termed “radiation caries” and “bone necrosis”, 
respectively.  
(Vissink et al., 2003; Meurman and Grönroos, 2010; Walker et al., 2011; De Siqueira Mellara 
et al., 2014; Lieshout and Bots, 2014; Laheij et al., 2015). 
Dental caries is the most common late side effect of radiation, however the nature of their 
origins or why the H&N patient cohort are particularly susceptible to them has not yet been 
fully established in literature. This susceptibility remains despite concomitant best 
preventative practice, comprising of frequent dental recall, regimes to improve acid 
resistance of teeth (0,05% sodium fluoride solution once per day, 5,000ppm fluoride 
toothpaste for use twice daily), pre-radiotherapy assessment performed by the dental team 
in order to identify pre-existing diseases and potential risk during and after RT, and preparing 
the patient for the possible side effects of cancer treatment. In addition, this increased 
susceptibility may persist throughout a H&N cancer patient’s lifetime, leading to a complete 
edentulousness in the years following the cancer treatment and affecting their quality of 
life.(Vissink et al., 2003; Meurman and Grönroos, 2010; Walker et al., 2011; De Siqueira 
Mellara et al., 2014; Lieshout and Bots, 2014; Laheij et al., 2015).  
Typically, dental caries are present a few months after radiotherapy, with a rapid onset as a 
result of a combination of factors including shifts in oral microbial community composition 
favouring acidophilic bacteria, poor oral hygiene due to potential mucositis, hypo-salivation, 
altered salivary composition and dietary alterations such as an increased sugar intake during 
and after the cancer treatment for weight maintenance (Springer et al., 2005; Kielbassa et al., 
2006; De Oliveira Mota et al., 2013; De Siqueira Mellara et al., 2014; Gonçalves et al., 2014; 
Pinna et al., 2015; Lu et al., 2019).  
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Histological analysis has revealed that the onset and development of post-radiation caries are 
similar to non-radiation-related caries, but the sites affected are different: radiation-related 
caries are more frequently located on the cervico-labial surface, incisal edge of canines and 
incisors (Walker et al., 2011) whereas non-radiated caries are more frequent in the 
interproximal and occlusal areas of the posterior teeth (molar and premolars) (Laheij et al., 
2015; Lu et al., 2019).  
Further patients with radiation-related caries often have little or no pain, even in the most 
severe cases(Walker et al., 2011). The clinical appearance and patterns of the radiation-
related caries are often different and typically observed as brown discoloration of the enamel 
on irradiated subjects. Although the reasons for such differences is not well-established, it 
has been suggested that this could be considered a sign that radiotherapy-related caries are 
uncavitated and should be treated as an incipient caries (Silva et al., 2009; Lu et al., 2019).  
First instances of radiation-related caries are characterised by localised lesions to the incisal 
or occlusal surfaces. Their development continues with a partial or total enamel delamination, 
which diffuses and progresses by developing an irregular and generalized erosion of the 
incisal edge of the tooth, ultimately resulting in dentine exposure and leaving tissues 
vulnerable to decay (Gomes-Silva et al., 2017). Furthermore, lesions with a half-moon 
demineralization pattern with rapid progression can be seen in root surfaces after radiation 
therapy, which may lead to tooth fracture (Silva et al., 2009).  
The delamination observed post-RT has been associated with a biomechanical breakdown of 
the dentinoenamel junction (DEJ) caused by radiation (De Siqueira Mellara et al., 2014; Lu et 
al., 2019). RT induces further changes in the organic composition (collagen) and increasing 
organic matrix degradation (MMPs), resulting in disruption of the DEJ area. In healthy 
patients, this area is not typically affected by mechanical failure and even with parafunctional 
loading, it is capable of impeding crack propagation. The DEJ keeps enamel and the underlying 
dentin firmly joined by collagen fibres (type I, IV and VII), allowing for increased stability, 
fracture resistance and a capacity to absorb energy and plastically deformation without 
fracturing (J. D. McGuire, Gorski, et al., 2014; Jacob D. McGuire, Walker, Mousa, et al., 2014; 
Jacob D. McGuire, Walker, Dusevich, et al., 2014).  
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The mechanisms that control enamel delamination and debilitated mechanical properties 
after RT have been explored in vitro, with results suggesting that RT alters mechanical 
properties, such as increasing elastic modulus and stiffening within the tooth 
structure(Kielbassa et al., 2000). RT also alters enamel microstructural organisation and 
protein / mineral compositions that affect normal teeth functions., This increases tooth 
fragility and susceptibility to fractures. Clinically, this would lead to rapid tooth destruction 
under physiological loading, increasing the wear of the incisal and occlusal areas during 
mastication and may ultimately lead to fracture of the crown (Santos-Silva et al., 2015).  
These aggressive types of caries represent one of the most severe consequences of RT for 
H&N cancer patients, with potential risks of complete edentulousness within 3 - 5 years after 
RT that has  a severe impact on the patients’ quality of life (Jansma et al., 1989; Kielbassa et 
al., 1999, 2006; Walker et al., 2011; Lieshout and Bots, 2014).  
Goncalves et al. (2014) and Fränzel and Gerlach, (2009) analysed the mechanical properties 
of irradiated molars, before, during and after RT. Fränzel and Gerlach, (2009) reported a 
significant reduction in hardness and elastic modulus in the enamel related to the RT dose, 
whereas Gonçalves et al., (2014) found an increased micro-hardness in the enamel surface 
after radiation. In line with finding by Reed et al., (2015) both studies reported a reduction in 
dentine micro-hardness. They observed that the elastic modulus and stiffness were increased 
in the enamel and dentine near the enamel dentine junction (EDJ) after RT. In addition, Raman 
spectroscopy showed that the protein/mineral ratio was significantly reduced in the whole 
enamel and superficial dentine towards the EDJ which could contribute to the enamel 
delamination that happens after the RT. However, the study sample number was only 7 teeth. 
This sadly is too few to draw definitive conclusions. Further the fractioning protocol was 
higher than the one used in treatment of H&N cancer patients.  
It has been suggested that irradiation itself does not affect micro-hardness in demineralized 
enamel, rather the oral hygiene habits of the study subjects affected the enamel properties 
indirectly  A difference in  mineral loss was observed in the two studies which has been 
attributed to the brushing habits of the five participants  in the first study and the 12 
participants in the second study, who were wearing the appliances with irradiated and non-
irradiated enamel slabs. It is important to state that the participants had similar oral 
conditions, caries risk, treatments and general health. Also, unstimulated whole mouth saliva 
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(UWMS) flow rate was measured with all participants using a fluoride-free toothpaste, but 
the technique and frequency of brushing was not described. On the other hand, the teeth 
were kept wet during  radiation (Kielbassa et al., 1999, 2000).  
However, subsequent studies have shown that RT reduced the tensile strength (UTS) in 
enamel and dentine, with and without the use of specific mouthwash. It is important to 
remark that the teeth were kept in artificial saliva during radiation (Soares et al., 2010; Soares, 
Roscoe, et al., 2011). Afterwards, the same group irradiated (60Gy) premolars divided in 
sound and endodontically treated and restored with resin or amalgam (mesio-occlusal-distal 
preparation) and compared fracture resistance and strain of cusp with non-irradiated 
premolars. It was observed that fracture resistance was significantly lower in sound irradiated 
premolars; also strain of cusps were significantly higher than the non-irradiated sound 
premolars (Soares, Roscoe, et al., 2011).  
Radiation caries is the main cause of tooth destruction in this specific population (Vissink et 
al., 2003). It may directly affect the chemical/molecular tissue content by altering the 
hydroxyapatite crystals in the prismatic structure and collagen fibres near the EDJ. These 
molecular changes may affect micro-hardness, stiffness and fracture resistance of teeth, 
facilitating caries development (Kielbassa et al., 1999; Soares, Neiva, et al., 2011; Soares, 
Roscoe, et al., 2011;De Siqueira Mellara et al., 2014; J. D. McGuire, Mousa, et al., 2014).  
Qualitative analyses of the irradiated teeth using different microscopy techniques to describe 
the caries zone and fracture patterns after loading, respectively have been performed 
(Kielbassa et al., 2000; Soares et al., 2010; Soares, Neiva, et al., 2011; De Oliveira Mota et al., 
2013). However, these studies give an anatomical description only (qualitative analysis) and 
there is a lack of information regarding the protein concentration, mineral molecular 
composition and chemical variation of irradiated hard tissues. . McGuire, Mousa, et al., (2014) 
investigated the protein composition in the EDJ in healthy teeth, concluding that the enamel 
near the EDJ contains collagen IV and VII as well as laminin. Collagen IV provides a molecular 
link between enamel and dentine, so the loss of this protein due to RT may produce instability 
in the EDJ, facilitating post-radiation enamel delamination. More recently, the same group (J. 
D. McGuire, Gorski, et al., 2014) performed an in-vitro assessment of collagen IV in non-
irradiated and irradiated teeth, using the same method of collagen detection, identifying this 
protein as a biomarker of the enamel dentine junction (EDJ) in mature teeth. In this study, 
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irradiated teeth showed a reduced staining pattern of this protein at the EDJ, indicating that 
in vivo radiation may possibly affect collagen IV. Conversely, Springer et al., (2005) did not 
find any difference in collagen fibre concentration in hard tissues of non-irradiated and 
irradiated teeth. Only the pulp tissue showed a shift in protein concentration after RT, which 
may affect odontoblast metabolism and impair the capacity of these cells, thus reducing their 
capacity to produce reactionary and reparative dentin as a barrier protecting them from 
injury. However, this study only involved samples of teeth irradiated in vitro, without any 
influences from the oral environment. Further studies are required to determine whether the 
time elapsed since the treatment has any influence on these protein changes.  
In the same pattern of McGuire et al, Hui lu et al. (2019) recently compared in vitro micro 
hardness and elastic modulus of 60 sound third molars divided into three groups, one non-
irradiated (control) and the other two groups received 30 and 60 Gy respectively. These 
specimens were exposed to a 2 Gy fraction per day, five days per week in order to reproduce 
the clinical treatment conditions and controls were kept in saline solution. Additionally, the 
microstructure was assessed using a scanning electron microscope (SEM) and the mineral 
protein ratio was determined with a Raman spectroscopy. After RT, there was a significantly 
decreased micro hardness close to the EDJ in both irradiated groups compared with the non-
irradiated. Fractures and fissures were present in the vicinity of EDJ in the irradiated groups. 
Elastic modulus of the irradiated groups followed a similar trend in the EDJ zone. SEM 
revealed a destruction of the enamel structure related to the dose of radiation. Cracks, 
irregular prisms and degeneration of the collagen network were seen in both irradiated 
groups. In contrast, protein phosphate ratio did not vary significantly in the irradiated groups 
in enamel, but in dentin the protein mineral ratio dropped in direct correlation with the 
radiation dose. Even though this is one of the few studies that analysed the possible mineral 
protein composition changes in the EDJ region after RT, the RT protocol for the patient cohort 
has not been clearly described in the study. Further necessary oral conditions during the 
radiation delivery were not reproduced such as facial hard and soft structure, presence of 
saliva (the teeth were dry), bacterial composition, food intake and oral hygiene. It is also 
important to take into consideration the cancer location and cancer staging to assess the size 
and location of the primary tumour (T), lymph nodes (N), and the possible distant metastasis 
(M).  
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This tumour stage evaluation relates to the prognosis, determine the area and size of the 
radiation beam and lastly the real amount of radiation delivered on these molars, which today 
may be outlined with specific computational programs.  
Qing et al., (2015)analysed the effects of RT on the wear resistance of enamel on 19 teeth 
collected from orthodontic patients and cut in slides which were perpendicular and parallel 
to enamel rods. Enamel specimens received 60 Grey fractioned 2Grey per day, 5 days a week; 
samples were immersed in cups with artificial saliva and changed daily. Nano scratch tests 
were conducted; X-Ray diffraction to evaluate the crystal structure of the enamel before and 
after radiation and FTIR spectrometric analysis was performed to obtain spectra of the 
enamel before and after RT. In addition, scratch resistance and micro hardness were analysed 
before and after RT. A modification of the crystallography and composition of the enamel was 
found after irradiation which would lead to a reduced wear resistance of enamel, indicating 
inferior mechanical properties. This is a possible explanation of the enamel delamination 
observed clinically after RT in H&N cancer patients. Although in this study they tried to imitate 
the oral condition, by keeping the teeth in artificial saliva, the sample number was lowered, 
and the focus was on enamel properties cutting the teeth which is not a representation of 
real-life clinical situations.  
To date, no definitive conclusion may be reached from the studies related to the direct effects 
of radiation on the mechanical properties of teeth. The reported findings indicate a decreased 
surface, micro hardness and ultimate tensile strength, as well as an increased stiffness and 
brittleness of enamel, but most of the studies irradiated in vitro extracted teeth which are not 
the conditions faced by H&N cancer patients during and after treatment. These studies also 
used a small sample size with radiation being applied directly to the teeth.  The final radiation 
dose and fractioning are not the same among the different studies. Also, the type of teeth, 
storage time and conditions, during and between RT doses, are not consistent with some 
studies ensuring the teeth are kept wet and others not. The participants’ age is another 
important factor to consider as this will affect the chemical composition of teeth.  
Additionally, there are only a few studies that have been investigating the mechanical 
properties of the EDJ proximity which plays an important role in fissure propagation. This is 
important given that the RT caries process starts with enamel shear fracture leading to a 
complete delamination from dentine.  
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Therefore, it is necessary to conduct studies on living teeth, imitating the clinical condition of 
the mouth with accurate radiation doses being delivered to larger sample sizes, in order to 
produce data that is directly translatable to the clinical practice. Additionally, quantitative 
image analysis of dentine obtained by two-photon microscopy (Second harmonic generation; 
SHG) would enable the characterisation of the collagen fibre structure (Sun et al., 2006; Kim 
et al., 2000).  It would therefore be possible to gather information about size of collagen 
fibres, their interaction with mineral components, degree of organisation and cross-linking 
(Stoller et al., 2002). High resolution two-photon fluorescence microscopies would allow for 
the non-destructive observation of tissue in 3D (z-scan mode enabling optical sectioning & 
subsequent 3D reconstruction). The mineral content of dentine samples may also be analysed 
by Raman spectroscopy (Atmeh et al., 2015).  
RT has been associated with decreased quantities of bacterial colonies in the dental biofilm, 
associated with non-cavitated stage of caries lesion non mutans streptococci (S. sanguinis, S. 
oralis, and S. mitis) and Actinomyces, which play an important role in keeping the stability of 
the microbial ecosystem in order to maintain the balance between demineralisation and 
remineralisation of the tooth surface (mineral gain vs mineral loss) (Takahashi and Nyvad, 
2011). It has been observed in children with early childhood caries (ECC) that candida spp. are 
capable of invading dentinal tubules, secreting acid and helping enamel demineralization; 
They are also capable of binding hydroxyapatite to dissolve crystals. In this group of children, 
this microorganism was relevant in caries progression (Belstrøm et al., 2016; Hemadi et al., 
2017).  
However, further studies that explore the clinical in vivo results are not fully established, with 
past studies exploring the direct impact of radiation on teeth damage and the ensuing 
micromorphological changes that result in enamel delamination and finally in aggressive 
caries formation (Gomes-Silva et al., 2017).  
In addition, the majority of the studies performed so far showed a lack of information about 
participants in relation to systemic diseases, medication, oral diseases, caries risk, caries 
lesion number, localization, teeth/surface and dental treatment. Saliva flow rate and 
composition were not taken into account in these studies, even though a diminished saliva 
flow rate might accelerates the progression of dental caries considerably (Takahashi and 
Nyvad, 2008; Kilian et al., 2016; Belstrøm et al., 2016). By performing an oral clinical 
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assessment along with the described measurements, it is possible to draw a holistic clinical 
picture of H&N cancer patients pre and post RT and to compare them with healthy matched 
patients, using internationally recognised metrics and indices of oral health (e.g. Decay 
Missed Filled Tooth (Surface), International Caries Detection and Assessment System (ICDAS) 
Periodontal probe (CPITN), gingival index and plaque index).  
1.5.4.8 Quality of Life  
 
As discussed previously, the patients’ nutritional intake, food preferences, social 
communication skills and overall mouth feel deteriorate following RT. Therefore, such 
patients often require a multidisciplinary team approach (restorative dentists, 
periodontology, endodontic, dental hygienists, radiation oncologists, medical oncologists, 
and oral surgeons) to maintain oral health, recover functional problems and improve quality 
of life (QoL) (Meurman and Grönroos, 2010; Epstein et al., 2012; Jawad et al., 2015; Murphy 
and Deng, 2015). This can involve a process of continuous recall consultations for monitoring 
purposes, following RT treatment, in order to analyse the risk of tooth breakdown, which 
becomes more severe with time (Meurman and Grönroos, 2010).  
In addition, there is an economic cost involved with follow-up care, as ancillary support teams 
of nutritionists, dietary counselling and speech therapy are required to restore a patient’s 
QoL, following cancer treatment in order to prevent depression (Wissinger et al., 2014). As 
almost 50% of cancer survivors report clinical depression or stress, in relation to xerostomia 
and their increased DMFT, which affects their ability to eat in public and has a great impact 
on their QoL (Duke et al., 2005; Osailan et al., 2012; Rieger et al., 2012; Lieshout and Bots, 
2014; Deng et al., 2015).   
1.6 Intensity-Modulated Radiotherapy 
 
In order to try to diminish the adverse side effects of the RT, three-dimensional computed 
tomography planned radiotherapy known as “Intensity-Modulated Radiotherapy” (IMRT) has 
been introduced (Pacholke et al., 2005; Pow et al., 2006; Vergeer et al., 2009; Porter et al., 
2010; Murphy and Deng, 2015; Jawad et al., 2015). IMRT permits the sparing of healthy 
tissues that are near tumours, specifically salivary glands (parotid) in order to reduce the risk 
of hypofunction.  Unlike conventional radiotherapy, in IMRT the radiation dose is delivered 
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with more precision and also different intensities can be delivered to the tumour. IMRT uses 
seven different beams, each with a regulated strength, shaping different doses and permitting 
better targeted volumes. However, it is not always possible to avoid toxicity from radiation of 
the normal adjacent tissues (Dawes et al., 2015; Brennan et al., 2017; Strojan et al., 2017). 
IMRT reduces the radiation dose on parotid glands, eyes and the cervical spinal cord, while at 
the same time maintaining clinical effectiveness to reduce the risk of under treatment of 
nearby areas of microscopic tumour spread. It is important to design an accurate target 
volume, keeping the dose distribution only on the tumour and sparing the normal structures 
reducing salivary gland damage (Vergeer et al., 2009; Porter et al., 2010; Randall et al., 2013; 
Duarte et al., 2014; Brennan et al., 2017).  
In particular, it is well established that parotid gland salivary flow decreases after 
conventional radiotherapy, in relation to the mean dose volume irradiated. However, there 
have been studies demonstrating how salivary flow rate can be improved and xerostomia 
reduced in cancer therapy, with the adoption of IMRT improving the quality of life of these 
patients (Little et al., 2012; Wang and Eisbruch, 2016; Brennan et al., 2017; Scrimger et al., 
2018). Unfortunately, the causalities of the improvements and variations in biochemical 
composition of saliva after IMRT are still not clear (Randall et al., 2013; Brennan et al., 2017), 
therefore it is necessary to quantitatively analyse the saliva components, proteins and 
microbial changes that occur in patients’ teeth/oral cavity following IMRT, in order to 
determine the aetiology and pathophysiology of the two prevalent side effects 
(caries/mucositis) to correlate with preventive measurement and appropriate treatment for 
these patients. Finally, it is also necessary to perform a complete oral assessment using 
validated indices in order to create a baseline record before treatment and a validated 
measure to compare against following IMRT and with healthy individuals.  
1.7 Saliva as A Multicomponent Fluid for Early Clinical Diagnostic of Disorders 
 
A biomarker is a biological molecule, biochemical component, gene, cell or bacteria that is an 
indicator of pathologic or physiologic conditions and pharmaceutical response to treatment. 
It must be able to be measured in order to predict, diagnose and assess the treatment of a 
disease. Additionally, it should have a high sensitivity, specificity, functionality, low cost and 
the capacity of testing a high number of samples in order to optimize laboratory services. A 
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predictive biomarker is related to clinical outcome and is measured before treatment. It will 
provide information regarding progression of a disease given certain treatment. Prognostic 
biomarkers provide information of disease development without considering any specific 
treatment ( Wong, 2011;Gao et al., 2016; Wang et al., 2016; Pedersen et al., 2018). It is well 
stablished that saliva biochemical composition is responsible for multiple functions 
(Carpenter, 2013a; Pedersen et al., 2018; Lynge Pedersen and Belstrøm, 2019). A broad range 
of saliva components may help to identify systemic conditions or detect the exposure to 
dangerous substances. These elements represent potential biomarkers to detect different 
diseases including oral squamous cell carcinoma (OSCC), autoimmune diseases, viral diseases, 
bacterial diseases, cardiovascular diseases, and HIV among other conditions. Saliva secretion 
rate and composition have been used to assess salivary gland function as a biomarker of 
hypofunction when the flow rate was reduced. Saliva biochemical constituents (proteins and 
peptides) have potential for diagnosis, monitoring the course of oral diseases and treatment 
evaluation. In addition, saliva contains a mix of products from the oral tissues affected by 
caries or periodontitis which is why could be used to monitoring diseases progression and 
treatment success rate (Chaudhury et al., 2015; Proctor, 2016; Zhang et al., 2016Pedersen et 
al., 2018). Saliva proteins are relevant in tooth protection, preventing demineralization and 
increasing remineralization, others participate in defence having antimicrobial properties or 
promoting certain bacterial colonization during biofilm formation. Protein constituents of 
saliva that are capable of regulate oral microbial composition and host defence have been 
tested as early childhood caries markers. Assessing these proteins as a potential indicator of 
dental health in children, provide information to predict caries risk and prognosis (Hemadi et 
al., 2017). Additionally, proteins such as cystatin S have been assessed for a potential marker 
of submandibular gland dysfunction in SS patients. It was stated in a study including only five 
patients diagnosed with syndromes, the possible correlation between cystatin S and 
pathological findings in submandibular gland (UWMS salivary flow rate) (Martini et al., 2017).  
Vitorino et al., (2005)studied the association between salivary protein composition and dental 
caries in 20 males, divided according to DMFTS index into caries-free and caries-susceptible. 
From the caries-free group, 6 subjects were selected to carry over 2 hours, pieces of sterilised 
enamel bonded to their molars. Afterwards, enamel pellicle was collected from the pieces 
and analysed. An increased amount of peptide fragments (sign of proteolytic activity) and 
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lower amounts of proline rich proteins, histatins and statherin were found in caries-
susceptible subjects, which could increase their risk of developing caries. 
Regarding periodontal disease presence/severity and therapy response, several studies have 
compared different salivary protein concentrations and specific oral pathogens present in 
patients with chronic periodontitis compared with healthy control subjects.  
On one hand, there are studies focused in biochemical salivary biomarkers to assess 
treatment response in adults with chronic periodontitis. These studies were focused in 
salivary immunoglobulin concentration such as IL-1b and matrix metalloproteinases (MMP-8) 
connected with extracellular matrix degradation to screen periodontal disease severity and 
treatment.  Combining host inflammatory response and molecules related with tissue 
damage signs (Miller et al., 2006; Ebersole et al., 2015). On the other hand, there are studies 
analysing periodontal pathogens associated with periodontal disease progression in order to 
improve periodontal treatment. The number and ratio of porphyromonas gingivalis, 
Prevotella intermedia and Tannerella forsythia present in stimulated saliva analysed from 85 
patients during 18 months  were found significantly correlated with presence of periodontitis 
having the potential of predicting the progression of this disease (Nomura et al., 2012).  
Lee et al., (2012) studied 30 salivary proteins related to host defences, inflammatory process 
and tissue destruction were analysed and associated with the proportion of bacteria present 
in subgingival plaque to assess gingivitis treatment, in 30 healthy subjects. Unstimulated 
whole mouth saliva was collected during and after the treatment of the provoked gingival 
disease. Increased levels of IL-6 and MMP-1 at baseline were associated with risk of 
developing a higher inflammatory response.  
Miller et al., (2006)  analysed possible biomarkers for three aspects of periodontitis 
inflammation, collagen degradation and bone turnover associating these with clinical 
characteristics of periodontal disease. Unstimulated whole mouth saliva was collected from 
28 subjects. Salivary levels of MMP-8 and IL-1β appeared to serve as biomarkers of 
periodontitis.  
Potential salivary biomarkers are being tested for identification and monitoring diseases 
including periodontitis, dental caries,  oral cancer, but also systemic diseases like Sjögren’s 
syndrome (Pedersen et al., 2018).  
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Unstimulated whole mouth saliva collection presents many advantages such as being 
minimally invasive, accessible, minimum cost, reduced anxiety and increased comfort for 
patients during collection. Moreover, unstimulated whole mouth saliva collection does not 
require special training or equipment to obtain samples. In addition is more accurate than 
stimulated saliva because the agents used to stimulate the salivary flow may change salivary 
composition (Lee et al., 2007; Vidotto et al., 2010; Franzmann et al., 2012; Chaudhury et al., 
2015). It is important to standardize the salivary sample collection to avoid circadian 
variations in salivary flow rate and composition (Dawes and Ong, 1973). During and after 
collection saliva samples must being kept on ice at 4C°, aliquoted and frozen immediately 
after collection to avoid proteolysis and deglycosylation of the proteins (Takehara et al., 
2013).  
Nowadays personalized medicine is becoming an area of interest in research in order to 
create a tailored treatment according to patients’ personal characteristics such age, 
bodyweight, body mass, gender, renal and hepatic function, local oral factors and genetics is 
the main goal of medicine in order to avoid severe and potentially life threatening drug 
toxicity for patients (Zhang et al., 2016).  
Novel ways to detect oral and systemic diseases are developing rapidly, including proteomics, 
genomics and molecular biological methods, that can be used to assess salivary protein 
components. Saliva can contain substances present in human serum due to a thin layer 
separating salivary ducts from systemic circulation enabling the exchange through the 
capillary walls into the salivary glands duct. In addition, saliva contains specific proteins that 
can be used also as a marker of different systemic diseases, instead of multiple test that are 
more invasive, expensive or in many cases non-conclusive (Osman et al., 2012). 
The discovery and use of molecular biomarkers in saliva associated with oral diseases would 
permit fast and precise diagnoses and possibly more accurate treatment as well as controlling 
of disease activity.   
Mucositis severity and frequency is related to cancer therapy, volume of irradiated mucosa, 
fractionation regime, dose per fraction and total dose. However, there are some patients with 
similar malignancies and treatment regimens results in different mucositis severities. 
Therefore, it is important to identify specific risk / predictive factors related to patients 
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comprising age, body weight, body mass, gender, renal and hepatic function, use of alcohol 
and tobacco, genetics and oral health factors (Rosenblatt 2014) Among oral factors is 
important to consider salivary flow rate, salivary composition and oral bacteria which will 
influence oral mucositis development (Sonis, 2011; Villa and Sonis, 2015).  
It is important to comment that around 20% of oral mucositis patients will have a reduced 5-
year survival rate due to the subsequent cancer treatment disruptions. Which is why research 
should be focused on prevention and treatment in order to reduce its prevalence and severity 
(McCullough, 2017).  
Unfortunately, prediction of onset and severity of oral mucositis is not possible yet, an early 
identification of high-risk patients through predictive markers would allow to create a specific 
monitoring regime and characterization of oral mucositis in order to prevent, prepare, reduce 
its severity and elimination.  
Certain molecules have been assessed to evaluate severity and progression of oral side effects 
of cancer therapy, including citrulline, calprotectin and the pro-inflammatory cytokines (Al-
Dasooqi et al., 2013).  
However, there is no definitive way of measuring the risk of developing oral mucositis before 
radiotherapy and predict severity to improve the management of such condition or prevent 
severe toxicities (Normando et al., 2017).   
In this way, it is imperative to analyse salivary proteins variation post IMR and evaluate their 
associations with oral mucositis assessment  in order to find a possible predictor of onset and 
severity of this side effect to help to develop patient customized intervention, to prevent the 








Chapter 2 Clinical Assessments in Head and Neck cancer patients  
2.1 Introduction  
 
Radiotherapy will produce a diverse range of side effects many of which are oral 
complications due to the proximity of the tumour to the salivary glands (Tschoppe et al., 2010; 
Nutting et al., 2011; Richards et al., 2017). These are interconnected with salivary gland 
hypofunction inducing a reduction in  salivary flow rate, leading to oral side effects (Wijers et 
al., 2002; Nutting et al., 2011; Belstrøm et al., 2016J; anus et al., 2017), despite the current 
support from a multidisciplinary medical and dental team pre- and post-cancer treatment and 
the use of IMRT (Walker et al., 2011; De Siqueira Mellara et al., 2014; Lieshout and Bots, 2014; 
Laheij et al., 2015).  It has been reported the occurrence of xerostomia and taste altered 
perception (Ruo Redda and Allis, 2006; Epstein and Barasch, 2010; Epstein et al., 2016; 
Spotten et al., 2016; Epstein et al., 2019) are linked to reduced salivary flow rate following 
HNC treatment (Epstein et al., 2019). Moreover, a reduced flow rate is usually accompanied 
by an altered composition, leading to an increased risk of oral diseases, as well as hastening 
the progression of dental caries and mucosal injuries along with bacterial colonization. It is 
well established that saliva is important to maintain tooth and mucosal integrity, throughout 
its protective functions (Hannig et al., 2017; Pitts et al., 2017).  
Oral mucositis has a significant negative impact in HNC patients care, altering their cancer 
treatment course, reducing quality of life and increasing the therapy cost which is why it is 
important to report its incidence and severity along with an analysis of the possible link with 
other side effects to reduce its severity because there is no effective treatment or preventive 
therapy. In addition, mucositis and its complications are often under reported due to the wide 
range of scoring criteria used to determine mucositis prevalence and intensity. This 
represents a major drawback in this research field, as the lack of an objective reliable and 
valid index to compare different clinical reporting and the fact that some studies only report 
the highest severity grades (only 3 or 4) leaving the lowest out of their scope, can 
underestimate the overall prevalence of mucositis. Therefore, is not easy to draw conclusions 
regarding the clinical evaluation of oral mucositis related to IMRT (Logan et al., 2007; Epstein 
et al., 2012; Villa and Sonis, 2015; Normando et al., 2017; Franco et al., 2017).  
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The clinical management of these deleterious RT side effects represent a challenge for the 
care team and there is a necessity to develop optimal preventive and therapeutic regimes. 
Clinicians need to understand the consequences associated to cancer treatment in order to 
develop preventive care plans and treatments for acute and chronic side effects in order to 
improve HNC patient’s quality of life. The first step is to collect data and understand the 
mechanisms; a clinical oral assessment pre- IMRT (T0) and post radiotherapy at 6 months (T1) 
and 12 months (T2) in order to determinate a baseline to compare over time.  The second 
part of this analysis was assessing the possible association among the dental and oral 
evaluation outcomes post IMRT.  
 
2.2 Aims  
 
The aim of this longitudinal trial was to assess salivary gland function and oral/ dental status 
of HNC patients pre (T0) and post IMRT (T1 and 2) and analyse the possible associations 
between the clinical outcomes.   
Null hypothesis: IMRT will not affect salivary gland functionality and oral condition.   
Objectives  
• To quantify the variations in flow rate of UWMS at T0 and compared to T1 and T2 in 
ml per minute.  
• To assess the effect of IMRT on teeth in HNC patients at different time points, and 
furthermore to associate those clinical assessments with salivary flow rate. 
• To assess xerostomia, utilising subjective dryness perception of patients at T1 and T2, 
whilst also determining whether hyposalivation has occurred in accordance to self-
reported xerostomia by patients.  
• To assess subjective taste alteration utilising questionnaire following IMRT, whilst also 
determining whether hyposalivation has occurred in accordance to self-reported taste 
changes by patients. 
• To report clinical oral mucositis presence and severity T1 and T2, whilst also 
determining whether hyposalivation has occurred in accordance to oral mucositis 
development.  
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• To analyse clinical oral mucositis presence and severity during IMRT, 2 weeks after, 6 
weeks after, 12 weeks after IMRT.  
• All of the above were related longitudinally to the baseline pre-IMRT scores where 
applicable (T0) – the patients’ acted as their own controls. 
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2.3 Materials and Methods 
 
2.3.1 Ethical Approval  
 
This study was approved by the North of Scotland Research Ethics Service (NRES) Committee 
foundation in October 2016 (16/NS/0116), the Health Research Authority NHS (IRAS Project 
ID:199100) on 21st January 2017 and finally, the confirmation of capacity and capability to 
conduct research at Guy’s and St Thomas’ NHS Foundation Trust (GSTFT) was granted in 
February 2017. 
All participants enrolled in the study gave informed consent and signed appropriate 
documentation to this effect. 
All volunteer samples for this study were obtained from the Special Care Dental Unit at Guy’s 
Dental Hospital, London, UK.   
 
2.3.2 Participants  
 
Head and Neck Cancer (HNC) Patients pre-IMRT 
Head and neck cancer (HNC) patients over the age of 18, with permanent dentition, both 
genders, at any stage of disease, except where distant metastases were present requiring 
high-dose RT treatment of the primary tumour, without systemic diseases affecting the 
salivary flow and oral host defence mechanisms (Table 1). 
 
2.3.2.1 Exclusion Criteria 
 
Volunteers younger than 18 years old (non-permanent dentition), unable to give consent and 
volunteers who were administered antibiotics in the previous 3 months (affecting oral 
microbial composition, altering and promoting the opportunistic colonization)(Willing et al., 
2011) were excluded. Volunteers with uncontrolled systemic disease were also excluded from 
this study (Carpenter et al., 2000; Gil-Montoya et al., 2008; Izumi et al., 2015; Gil-Montoya et 
al., 2016).   
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Male - Female 
Over the age of 18 




Younger than 18 
Unable to give consent 
Administered antibiotics in the previous 
month 
Patients with non-controlled systemic 
disease 
Patients with Sjogren syndrome. 
Patients with Rheumatoid arthritis  




   
 
 
2.3.2.2 Sample Size Calculation 
 
The power calculation for this study was based on comparing all the clinical and biochemical 
parameters analysed in HNC patients before and after treatment. Previous studies 
investigated salivary biochemical composition without a sample size calculation, therefore no 
previous data were available to support power calculations (Funegård et al., 1994; Almståhl 
et al., 2001; Eliasson et al., 2005; Hannig et al., 2006; Vidotto et al., 2010; Dijkema et al., 2012; 
Laheij et al., 2015; Richard et al., 2017). 
Statistical advice was obtained prior to start this study in order to determine the sample size 
required by a suitable power calculation. The power calculation was based on comparing the 
mean protein levels in head and neck cancer patients before and after IMRT. A study with 
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80% power at 5% level of significance (Chaudhury et al., 2015) will be able to detect the true 
difference in all parameters before and after cancer treatment with an effect size of 0.5 (high 
according to Cohen 1988) using two tailed test would require a total sample of 35 patients. 
The power calculation was carried out using Gpower 3.1.5. software (Franz Faul, Universitat 
Kiel) (Faul et al., 2007) 
 
2.3.2.3 Participant Recruitment 
 
Patients diagnosed with HNC at Guy’s and St Thomas’ NHS Trust were recruited and gave 
informed consent prior to sample collection. In the longitudinal study all the samples were 
collected at three time points. Firstly, 40 HNC patients were recruited before their cancer 
treatment started (pre-IMRT, T0), 38 patients were examined at 6 months after IMRT (± 1 
month, T1), and 33 patients at one-year post-IMRT (T2).  
 
2.3.2.4 Demographics and Clinical Characteristics 
 
Demographics and clinical characteristics of the volunteers participated in this study:  
Age, gender, smoking and drinking habits were reported by patients.   
Type of treatment received, total dose, fractionation of radiotherapy.  
Medical history, it was used patient records as a source of information about the medical 
experiences and current medication intake. 
 
2.3.2.5 Tumour Localization and Stage of Cancer  
 
Tumour localization and the stage of cancer prognosis is related to severity and extension of 
the disease. The staging assessment of HNC uses the rules on classifications that were publish 
by the American Joint Committee on Cancer (AJCC) which is the Tumour Node Metastasis 
(TNM) classification. TNM is based on three anatomical components, the extent of the 
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primary (T), describes the evidence of lymph nodes involvement or (N) and the possibility of 
cancer spreading to distant part of the body (M)(Chi et al., 2015; Roland et al., 2016).  
Tumor histology was recorded from the clinical history reported by the oncology team.  
 
2.3.3 Sample Collection    
 
The following samples were collected:  
• unstimulated whole mouth saliva (UWMS), saline solution rinse   
• plaque biofilm  
• mucosal swabs collecting residual saliva from the inner cheek  
• excavated carious dentine tissue and/or extracted carious teeth.   
Sample collection added 15 min to the conventional treatment time. Samples were collected 
during the day, routinely between the hours 1:30pm to 3:30pm in the dental clinic in an 
attempt to avoid diurnal variations.   
 
2.3.3.1 Unstimulated Whole Mouth Saliva Sample Collection (UWMS) 
 
Unstimulated salivary flow rate reports the basal secretion of salivary glands without external 
stimuli (Proctor 2016). All participants had refrained from food and drink for at least 30-60 
min prior to sample collection. UWMS samples were obtained by passive drooling 
(Navazesh,1993) into a pre -weighed 50 mL sterile conical polypropylene tube (Falcon; BD 
Biosciences, San Jose, CA, USA) for 10 minutes.   
All subjects were seated in a dental chair and they were instructed to swallow, prior to leaning 
their head forward and allow saliva to collect in the mouth, and let the saliva start to drain 
into the tube. All sample collections were carried out at the same time of the day and under 
similar clinical conditions in order to exclude circadian variations in salivary flow rate and 
composition (Dawes and Ong, 1973). The samples were placed immediately on ice, keeping 
the temperature at 4°C, to avoid proteolysis and deglycosylation of the salivary proteins. After 
collection, samples were transferred to the laboratory where the tubes were re-weighed and 
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the net saliva volume was calculated. Saliva samples were aliquoted into microtubes 2ml 
(Mikro-schraubrohre 2ml, PP. Sarsted AG & Co, KG, Numbrecht Germany), labelled and stored 
in – 80 °C freezers for further analysis.  
An alternate saliva sample was collected from each participant, in order to combat 
hyposalivation, a possible side effect that HNC patients may develop after radiotherapy.  Each 
participant was instructed to rinse 0.9% normal saline solution (5 ml) for 30s and then spit 
into a 50 mL sterile conical polypropylene tube (Falcon; BD Biosciences, San Jose, CA, USA).   
The samples were placed immediately on ice, keeping the temperature at 4°C, to avoid 
proteolysis and deglycosylation of the salivary proteins. After collection, samples were 
transferred to the laboratory labelled and stored in – 80 °C freezers for further analysis. 
 
2.3.3.2 Unstimulated Whole Mouth Saliva Flow Rate  
 
Flow rate was measured by reweighing the sample tubes and subtracting it from the pre-
weighed tubes to get the net saliva weight in grams, saliva density of 1.0 g/ml.(Ligtenberg et 
al., 2015). The net weight was divided by the duration of sample collection (10minutes) to 











2.3.4. Clinical Oral Assessment 
 
An oral clinical assessment was performed on all participants.  
 
2.3.4.1 Dry Mouth and Taste Report 
 
Dry mouth feeling was established based on the patients’ answers of the following questions 
extracted from the questionnaire validated by Fox et al (Fox et al., 1987): 
• Does the amount of saliva in your mouth seem to be less than normal?  yes/no  
This question was asked at every time point post IMRT in order to determine prevalence 
of this symptom longitudinally after one year of treatment. Furthermore, to assess the 
possible association with salivary flow rate, dental assessment, taste perception, oral 
mucositis and in the following chapter with salivary protein composition.   
Taste variation was established based on patients’ reports, answering the following question 
extracted from the Late Effects of Normal Tissue/Somatic Objective Management Analytic 
(LENT/SOMA) scoring system: 
• Has your sense of taste changed after IMRT? Can you taste the food in the same way 
as before radiotherapy?  yes/no 
This taste perception was measured at every time point post IMRT to assess its prevalence 
and association with the other oral/dental assessment results.  
 
2.3.4.2 Oral Mucositis Grading 
 
The most common assessment scales used are The National Cancer Institute (NCI)-Common 
Toxicity Criteria (CTC version 4.0), The European Organization for Research and Treatment of 
Cancer (EORTC), The Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) the 
criteria developed by World Health Organization (WHO) in 1979among others (Sonis, 2004b; 
De Sanctis et al., 2016; Villa and Sonis, 2016).  
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The World Health Organization (WHO) Oral Toxicity Scale, for example, combines signs of 
mucosal damages (erythema and ulceration) with functional impairment, while the RTOG 
criteria are based only on a general description of mucosal damage intensity.  
In the study clinical assessment of oral mucositis was performed by the oncology team during 
and after the radiotherapy adding three time points post IMRT (2 weeks, 6 weeks and 3 
months) using the World Health Organization (WHO) oral toxicity scale (World Health 
Organization, Handbook, 1979). This grading system is based on a clinical examination of the 
oral cavity combining signs of erythema and presence of ulcers with questioning the patient 
about pain and their diet to assess functionality.  
The scoring scale is grade 0: no oral mucositis; grade 1: erythema and soreness (no ulcer); 
grade 2: ulcer (s) present, subject able to eat solids; grade 3: ulcer (s) present, subject requires 
a liquid diet (due to mucositis); and grade 4: ulcer (s) present, alimentation not possible (due 
to mucositis) (Figure  2.1 ;WHO organization 1979 handbook).  
The WHO scale presents a complete assessment of the range of signs and symptoms of 
mucositis, but it depends on subjective physicians’ judgement and evaluation (De Sanctis et 
al., 2016; Villa and Sonis, 2016).  
 
 
Figure 2. 1 The WHO Oral Toxicity Scale. 
     Severe Oral Mucositis  
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Another important factor to take in account to choose among grading systems is which scale 
does not fatigue or increase patient pain.  
2.3.4.3 Dental Assessment 
 
The number of carious lesions present from clinically visible change of colour to dark brown 
on any surface to open lesions in the oral cavity. Number of teeth / decayed, missed or filled 
(DMFT) were included in the clinical assessment. This clinical and visual index has been used 
for more than 80 years as a diagnostic criterion in epidemiology, in order to detect and 
quantify the total number of teeth affected by carious lesion (Fejerskov, 2004; Kidd and 
Fejerskov, 2004). This method relays on clinical experience of the examiner, however it is 
rapid, economical and used around the world. In addition, it is satisfactory for detecting 
enamel lesions on accessible surfaces, dentinal lesions (non cavitated) and cavitated dentinal 
caries(Pitts, 2001; Pitts and Stamm, 2004).  
At each time point participating patients were clinically examined by the same consultant in 
the Special Care Dentistry Unit, at Guy’s and St Thomas’ Hospitals NHS Foundation Trust. 
Special Care Dentistry is the specialist unit for care of head and neck cancer patients. The 
consultant examining the patients is the clinical lead for dental oncology service and Sedation 
as well as Special Care Dentistry. Additionally, this clinician has been part of the guidelines’ 
development group for the oral management of oncology patients. The consultant 
performing the dental assessments was calibrated on caries detection (DMFT) in 2011 using 
the Adult Dental Health Survey criteria (O'Sullivan 2011). 
Visual examinations of the participating head and neck cancer patients were performed 
before cancer treatment (T0) and post IMRT at two time points (T1 and T2). Panoramic 
radiographs were done before start of radiotherapy, but at the end of the cancer treatment 
radiographs were taken only when needed to assist patient care and management decision-
making. 
Following the recommendations regarding dental care for HNC patients undergoing IMRT at 
Guy’s and Thomas a dental assessment before starting the treatment is mandatory. This is a 
baseline visit, with the multidisciplinary dental team pre IMRT, mandatory for all patients in 
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order to plan and deliver a care pathway. The assessment includes a dental exam to identify 
any oral diseases and remove infections, hygienist support and preparation for side effects of 
cancer therapy. At special dental care unit all patients will receive a prescription of a sodium 
fluoride toothpaste (Duraphat® 5000) for twice daily use. Six months after starting cancer 
therapy patients had a dental appointment in order to assess oral function, side effects and 
risk factors along with a reinforcement of oral hygiene and use of fluoride toothpaste. After 
this second appointment patients were usually discharge to primary practitioner care. 
However, in this study patients were seen 12 months after the start of IMRT adding one follow 
up to the regular care. 
Clinical diagnosis criteria of carious lesion were performed by the same calibrated consultant 
at every time point following this protocol, it was defined as a sound tooth / surface, those 
that had no visible caries after clean and dry teeth surfaces. Regarding teeth affected by 
carious lesion the threshold were defined at it follows, D1 indicating incipient enamel lesion 
with an intact surface, D2 representing cavitated enamel lesion and D3 as a clinically 
detectable dentine lesion presenting cavitated enamel and dentin exposure (Pitts, 2001; Pitts 
and Stamm, 2004; Pitts et al., 2017; Sroussi et al., 2017). Lesion were recorded at these 3 
stages.  
In addition, it was reported the number of surfaces affected by caries as it follows, it was 
analysed a total number of five tooth surfaces on the posterior teeth and four tooth surfaces 
on the anterior teeth, determining the total number of sound and carious surfaces at every 
time point through clinical visual observation (Sroussi et al., 2017).    
It is important to remark that post radiation carious lesions affect nonclassical surfaces of 
teeth such as cusp tips, occlusal and incisal edge, cervical line and buccal and oral smooth 
surfaces. 
 Radiotherapy caries clinical appearance starts as brown stain decolouration spot (incipient 
uncavitated lesion) after a rapid onset caries development and progression present a high 
destructive potential leading to amputation of crowns in a short period of time resulting in to 
edentulousness and therefore a reduced oral function and quality of life (Jansma et al., 1989; 
Silva et al., 2009; Lieshout and Bots, 2014).  
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One of the limitations of this scoring system is that depends on clinician knowledge and 
experience which could add variability among the examiners. This method of detecting caries 
is only a report whether caries is present or not, it does not provide any information regarding 
activity or carious lesion stage(Pitts, 2001; Pitts and Stamm, 2004).  
Additionally, when using this index, the missing tooth and filled components are still under 
debate, due to it does not calculate the number of teeth lost or filled for reasons other than 
carious lesion. As a result, it can overestimate caries experience in a specific group (Broadbent 
and Thomson, 2005). 
 
2.3.5 Statistical Analysis  
 
Descriptive statistics was used to summarise the sample characteristics and other clinical 
factors. The clinical parameters, protein concentration and secretion rate found in HNC 
patients before and after treatment were tested using:  
• Repeated measures Friedman test to assess variation of clinical parameters, salivary 
flow rate, total protein concentration, secretion rate and specific proteins in saliva within the 
oral cavity of HNC patients at three time point.  
• Data in different categories was analysed using Wilcoxon matched pairs test for 
testing the differences between same patient.  
• Data in different categories was analysed using Mann-Whitney test to compare 
differences between two independent groups.   
• Data of different tumour location was analysed using Kruskal-Wallis test to compare 
differences between independent groups.   
• Descriptive statistics were used to present baseline demographics, dental assessment, 
patient-reported xerostomia, taste changes and oral mucositis.  
  •         Random effects Generalized Least Squares linear regression.  
Random effects linear regression analysis in a longitudinal panel is a model which was used 
to analyse the data obtained from several measures taken from the same patients at different 
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times, in order to determine the relationship between two variables making a distinction 
between independent and dependent variables.  
Panel data refers to a group of patients that were studied recurrently over time in order to 
determinate the association between salivary flow rate, dry mouth reports taste changes 
reports and oral mucositis development at T1 (6 months post IMRT) and T2 (12 months post 
IMRT) in comparison to T0 (pre IMRT). 
All analysis was carried out using STATA 15.1 (College Station, Texas USA, www.stata.com), 
GraphPad Prism 8 software (La Jolla California USA, www.graphpad.com) and Microsoft Excel 
2018, after checking for normality. Normality of the data was tested for all the parametric 
analyses using histogram and box plots. Results were expressed as a mean ± SEM relative to 
the variables and ‘n’ represents the number of subjects, p <0.05 value was considered 





2.4.1 Patient Demographics  
 
Demographics and clinical characteristics of the HNC patients is shown is Table 2.2  
Table 2. 2 Patient Demographics. Data is expressed as mean ± S.E.M. 
Patients Recruited 40 
Age (Years)   62.562 (± 2.15)  





Smoking  Yes 28 No 8 Unknow 6 
Drinking Yes 22 No 9 Unknown 9 
  
 
Table 2.3 Tumour Histology  
Primary Tumour histology Number of patients 




Table 2.4 Treatment  
Treatment Patients Mean dose 30 fractions 20 fractions 12 fractions 
IMRT 40 62.38 36 3 1 
Chemotherapy 19 2    
Cisplatin 18     
Carboplatin 1     
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2.4.2 Tumour Characteristics   
 
The tumour localisation and the stage of cancer prognosis was evaluated using the TNM 
classification (Table 2.5 and Table 2.6). 
Table 2.5 Primary Tumour Location. 




Nasopharynx   2 
Hypopharynx   3 






Buccal mucosa 1 
Sinus 1 
  
Table 2.6 Tumour staging 
Tumour Staging        
T TX T0 T1 T2 T3 T4 Unknown 
 0 1 3 15 4 13 4 
N N0 N1 N2 N2a N2b N2c N3  
 10 3 3 2 13    4     1 4 
M M0       
 36      4 
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Table 2.7 Medication  
Medication  Number of patients 
Not reported  7 
Bisphosphonates  4 
Immunosuppressive agent  6 
Steroid  9 
High blood pressure (β- blocker) 13 
No medication  5 
 
 
 2.4.3 Dropout Rate   
 
In general, patient compliance was positive with the majority of the patients receiving their 
scheduled dosages as originally planned. 
40 HNC patients were recruited before radiotherapy started. In total, 4 patients died during 
the study, one patient died before T1, and 3 more before T2.  
The total drop-out figure was 7 participants, including one due to antibiotic usage and 2 who 
did not comply to their scheduled appointments.    
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2.4.4 Unstimulated Whole Mouth Saliva (UWMS) Flow Rate (FR) 
 
Mean salivary flow rate (SFR) of HNC patients prior to IMRT (T0) was 0.44 ± 0.04 ml/min, 
similar to the resting flow rate of healthy patients (p = 0.1253) (Figure 2.2).  
At 6 months post-IMRT (T1), the salivary flow rate was statistically significantly decreased to 
0.16 ±0.02 ml/min, (p = 0.0001) compared with pre -radiotherapy salivary flow rate 
(Figure2.2.).  
At 12 months post-IMRT (T2), the salivary flow rate was increased in comparison to T1, 
reaching 0.24 ±0.03 ml/min. The mean SFR values showed at T2 represents 52.79% of the 
original values of T0 (Figure 2.2).  
Only 6 subjects showed a full recovery of salivary flow rate values compared with T0 mean 
values, whilst 20 subjects recovered less than 50% of the salivary flow rate pre-IMRT mean 
values.  
Analysis of salivary flow rate post IMRT among different locations showed no statistical 
differences at T1 (p= 0.5564) and T2(p=0.6125) (Kruskal-Wallis test) 
Analysis of salivary flow rate post IMRT among different medication showed no statistical 
differences at T0 (p= 0.443) T1 (p= 0.452) and T2(p=0.676) (Kruskal-Wallis test)  
Analysis of salivary flow rate after IMRT showed a significant reduction compared with 


























Figure 2. 2 Salivary flow rate variation pre- (T0) and post-IMRT at 6 months (T1) and 12 months 
(T2). 
UWMS flow rate was reduced significantly at T1, compared with T0 (p<0.0001) (Wilcoxon 
matched pairs signed rank test). UWMS flow rate was decreased significantly at T2 compared 


















2.4.5 Xerostomia Perception  
 
Dry mouth feeling was assessed based on the HNC patients’ answers of the Fox et al  
questionnaire (Fox et al., 1987), this questionnaire has been used by in order to complement 
the information obtained by measuring salivary flow rate, which is essential in salivary 
hypofunction diagnosis. Additionally, determine the association between this subjective 
condition reported by patients and the objective measurement of salivary quantity and 
quality.  
Therefore, among several questionnaires fox et al (1987) developed this survey to predict 
hyposalivation (Villa et al., 2014), this particular question was selected due to the simplicity 
to identify patients with symptoms of xerostomia regarding the amount of saliva by answering 
yes or no, in order to report an overall  feeling  of  oral  dryness.  The whole questionnaire 
would add extra time to the clinical appointment, it would be needed a second examiner 
capable of collecting that information probably it would be necessary an extra session which 
in this case is not suitable for the patient’s urgency of being treated and the multiple medical 
controls that they have to attend in a short period of time.  
Dry mouth feeling was established based on the patients’ answers of the following question 
extracted from the questionnaire validated by Fox et al(Fox et al., 1987): 
• Does the amount of saliva in your mouth seem to be less than normal?  yes/no  
As a result, 92% of patients (n= 35) reported dry mouth and 8% of patients (n=3) reported no 
sensations of dry mouth post-IMRT at 6 months (T1). This is in comparison to pre-IMRT (T0) 
where no patient reported a dry mouth sensation 94% of patients (n= 31) reported dry mouth 
sensation and 6% patients (n=2) reported no sensations of dry mouth, at 12 months post-
IMRT (T2) This is in comparison to T0 where no participants at all reported dry mouth 
sensations. 




2.4.5.1 Longitudinal Associations Between Salivary Flow Rate and Dry Mouth Feeling 
Reported by Patients Post IMRT at 6months (T1) and 12 Months (T2) by using Random effects 
Generalised Least Squares linear regression 
 
Analysis of associations between UWMS flow rate and dry mouth reported by patients pre- 
and post-IMRT (Table2.8) shows a negative and significant association between dry mouth 
reported by patients and salivary flow rate post-IMRT at T1, but no significance at T2.  
 
Table 2.8 Association between salivary flow rate (SFR) and dry mouth reported by patients 




Coefficient   P [95% Conf. Interval] 
T0 -0.0973 0.220 -0.252 0.0580 
T1 -0.202 0.011 -0.359 -0.046 
T2 -0.121 0.135 -0.281 0.038 
 
Table shows significant association between dry mouth feeling reported by and salivary flow 
rate post-IMRT at 6 months(T1) (p=0.011). No significant association at 12 months (T2) and 
(p=0.135).   
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2.4.6 Hypogeusia / Dysgeusia 
 
Changes in taste perception reported by patients by answering one question extracted from 
the Late Effects of Normal Tissues (LENT)–Subjective, Objective, Management, and Analytic 
(SOMA) system (LENT/SOMA) scoring system which is a validated scoring system used by 
National Cancer Institute’s (NCI) in the UK to assess treatment side effect in cancer patients. 
this is a frame of reference for assessment and grading of IMRT side effects.  
 There is a specific one for HNC patients it has three different parts that includes demographic 
assessment type of cancer and treatment, the second part is a subjective oral assessment the 
following question was extracted from that section, which included 38 different questions. 
The last part of this questionnaire is including an evaluation of cancer treatment side effects 
including skin, mucosa and teeth (50 questions).  
Variation in taste perception was established based on the patients’ answers of the following 
question extracted from the questionnaire validated system LENT/SOMA 
• Has your sense of taste changed after IMRT? Can you taste the food in the same way 
as before radiotherapy?  yes/no   
35% of HNC patients (n=13) reported maintained sensations of taste, at T1, whereas 65% of 
patients (n=24) reportedly losing their sense of taste at T1. For comparative purposes, prior-
IMRT (T0) all patients reported ordinary levels of taste. No statistically significant difference 
regarding taste between T1 (6 months post IMRT), & T2 (12 months post IMRT), was reported 
by HNC patients.  52% of HNC patients (n=17) reported maintained sensations of taste, at T2, 




2.4.6.1 Longitudinal Associations Between Taste Reported by Patients and Salivary Flow Rate 
Post IMRT at 6months (T1) and 12 Months (T2) by using Random effects Generalised Least 
Squares linear regression 
 
Presence of taste alteration (dysgeusia) reported by patients and UWMS flow rate at T1 and 
T2, revealed a significant association between taste variation reported by patients and 
salivary flow rate post-IMRT at T1 and T2 (Table 2.9). 
 
Table 2.9 Presence of taste alteration (dysgeusia) reported by patients and Salivary flow rate 




Coefficient P [95% Conf. Interval] 
T0 0.237 0.274 -0.188 0.662 
T1 -0.570 <0.0001 -0.771 -0.368 
T2 -0.398 <0.0001 -0.584 -0.212 
 
Table shows a significant relation between taste variation reported by patients and UWMS 
flow rate in after IMRT at T1 and T2 compared with T0 (pre-IMRT). 
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2.4.7 Oral Mucositis 
 
Oral mucositis evaluation was performed by the clinical oncology team at different time 
points using WHO oral toxicity scale to quantify oral mucositis presence and severity based 
on clinical signs and symptoms and type of food intake which indicated a functional measure.  
Oral assessment at special dental care was performed pre IMRT (T0) at 6 months (T1) and 
one-year post IMRT (T2). Clinical examinations were undertaken by the same consultant 
(specialist dentist) who carried out the dental exam at Sedation and Special Care Dentistry 
Unit at Guy’s and St Thomas’ Hospitals NHS Foundation Trust. 
In addition, patients recruited were assessed during the IMRT period, 2 weeks, 6 weeks, 3 
months, 6 months and one-year post IMRT by the oncology team at Guy’s Hospital using the 
WHO index to determinate presence and severity of oral mucositis.  
Prior-IMRT (T0) at T0 there was no patients with oral mucositis, during RT 31 patients 
presented oral mucositis, two weeks after the treatment was finished 27 patients had 
mucositis. At six weeks post IMRT 15 patients still presented the condition. Finally, six months 
post IMRT, (T1), the vast majority of participants did not have oral mucositis (n= 32) and 16% 
participants (n=6) had oral mucositis, at T1. At T2, 91% of participants (n= 30) did not have 
oral mucositis and only 9% participants (n=3) had oral mucositis, 12 months post IMRT (T2) 
(Figure 2.3). There was no statistically significant difference between T1 & T2 (p= 0.625) 
(Wilcoxon matched pairs signed rank test) Percentages were rounded to nearest whole 
number percentage.  
Among the 31 patients that developed oral mucositis during IMRT, sixteen subjects reached 
grade 2 and thirteen grade 3  during and after IMRT as a maximum value (Table 2.10), at T1 
(6 months post IMRT) six patients developed grade 1 and at T2 (12 months post IMRT) three 
patients developed grade 1, showing  a significant drop in number of patients that presented 
oral mucositis (p=<0.0001) in comparison to the number of patients that presented that side 
effect during and at the early time-points (2 weeks ) after IMRT. According to WHO mucositis 
scale grade 1 mucositis is considered as a mild side effect without presenting any ulcer that 






















Total number of patients that presented Oral Mucositis

















Figure 2.3  Number of patients that present oral mucositis at different time points.  
From 6 weeks post IMRT the number of subjects presenting this condition is significantly 
reduced in comparison with the numbers observed during IMRT (p<0.0001). However, there 
was no significant difference 2 weeks post IMRT compared with during IMRT (p= 0.1486) 











Table 2.10 Oral mucositis assessment during and after IMRT by primary tumour location. 
Tumour location During IMRT  2 weeks  6 weeks  3months Max. 
Left oropharynx 3 2 2 0 3 
Bilateral oropharynx  2 2 0 0 2 
Right oropharynx 3 2 2 1 3 
Oropharynx  2 3 0 0 3 
Left oropharynx 2 3 2  2 
Left oropharynx       
Left tonsil 3 3 1  3 
Right tonsil 2 2 3 0 3 
Left tonsil 3 1 0 0 3 
Left tonsil 2 2 1 1 2 
Right tonsil 1 3 2 1 3 
Left tonsil  2 1 0 0 2 
Left tonsil 1 2 1 0 2 
Right tonsil 2 2 1 1 2 
Left tonsil 2 0 1 0 2 
Left tonsil 2 1 1  2 
Right tonsil  2    2 
Right tonsil 1 2 2 0 2 
Left hypopharynx  1 1 0 0 1 
Pharynx 0 0 0 0 0 
Left hypopharynx 3 2 1 1 3 
Bilat nasopharynx 3 2 2 2 3 
Nasopharynx      
Larynx 0 0 0 0 0 
Right larynx  2 0 0 0 2 
Larynx    2 2   2 
Right neck 1 1 0 0 1 
Left neck 3 3 1 0 3 
Parotid       
Right maligns sinus 2 2 1 0 2 
Nasal and mid ear 3 2   3 
Anterior mandibular      
Left buccal mucosa 2 1 0 0 2 
Bilateral tongue 2 2 0 0 2 
Right tongue  3 3   3 
Border tongue      
Base of tongue 2 2 2 0 2 
Right tongue  3    3 
Epiglottis   3 0 0 0 3 
Left epiglottis      
 
Table shows the different grades of oral mucositis among patients separated by primary 
tumour location during and post IMRT, and the maximum grade reached at any time point.  
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In this study there was no significant difference in the radiation dose received for these 
patients (mean 62.5 Gy), as well as the fractioning planning reporting 30 fractions in 37 
patients, the location of the tumour varied reporting mainly tonsil, pharynx (oropharynx, 
nasopharynx and hypopharynx ) and tongue reaching 28 subjects.  However, during IMRT 
there was no statistical difference in mucositis onset and severity regarding primary tumour 
location (Man-Witney test). 
 
2.4.7.1 Longitudinal Associations Between Salivary Flow Rate and Oral Mucositis Post IMRT at 
6 months (T1) and 12 Months (T2) by using Random effects Generalised Least Squares linear 
regression 
 
The outcome measures of oral mucositis status of HNC patients  post-radiotherapy along with 
a reduced volume of saliva secretion have been presented in this chapter as well as the 
relation between these two outcomes at time point 1 and 2. It was showed that the reduced 
salivary flow rate was negatively associated  to oral mucositis development.  
Analysis of oral mucositis and UWMS flow rate in at 6 months (T1) and 12 months (T2), 
revealed a significant association between oral mucositis and salivary flow rate post-IMRT 
(Table 2.11). 
Table 2.11 Presence of oral mucositis and Salivary flow rate in UWMS post-IMRT at 6 months 
(T1) and 12 months (T2).  
Mucositis/Salivary 
flow rate 
Coefficient P [95% Conf. Interval] 
T1 0.001 0.987 -0.125 0.127 
T1 -0.287 0.0001 -0.354 -0.221 
T2 -0.213 0.0001 -0.280 -0.146 
 
Table shows a significant association between oral mucositis and salivary flow rate in UWMS 
after IMRT at T1and T 2. 
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2.4.7.2 Longitudinal Associations Between dry mouth feeling reported by patients and oral 
mucositis post IMRT at 6months (T1) and 12 months (T2) 
 
Analysis of dry mouth feeling reported by patients and oral mucositis at 6 months (T1) and 12 
months (T2), revealed a significant association post-IMRT (Table 2.12). 
 
Table 2.12 Presence of oral mucositis and dry mouth feeling post-IMRT at 6 months (T1) and 
12 months (T2).  
 
Dry mouth feeling/ 
Mucositis (WHO) 
Coefficient P [95% Conf. Interval] 
T0 0.073 0.343 -0.078 0.226 
T1 0.911 0.0001 0.827 0.995 
T2 0.931 0.0001 0.846 1.017 
 
 
Table shows a positive and significant association between oral mucositis presence and dry 









2.4.8 Dental Assessments 
 
The total number of teeth present was significantly reduced at T1 (6 months post-IMRT) & T2 
(12 months post-IMRT), in comparison to T0 (pre-IMRT) (p <0.0001) (Figure 2.4). No significant 
differences were observed in the quantity of teeth between T1 and T2.  
The total number of teeth that were visibly missing, due to extraction, was significantly 





























Figure 2.4 Number of teeth present in patients’ oral cavities variation pre- (T0) and post-IMRT 
at 6 months (T1) and 12 months (T2).  
The total number of teeth present was significantly reduced at T1 & T2 in comparison to T0 
(p < 0.0001) (Wilcoxon matched pairs signed rank test). No differences were observed in the 



























Figure 2.5 Number of Teeth Missing pre- (T0) and post-IMRT at 6 months (T1) and 12 months 
(T2).  
The total number of teeth that were missing, due to extraction, was significantly increased at 
T1 and T2 in comparison to T0 (p < 0.0001, Wilcoxon matched pairs signed rank). No 
statistically significant differences were observed in the quantity of teeth missing between T1 





Dental assessment revealed the total number of teeth that were without any type of visible 
restoration and without clinical caries present was significantly decreased at T1 and T2, in 























Figure 2.6 Number of teeth visibly healthy at T0, T1 and T2.  
The total number of teeth that were without any type of visible restoration and without 
clinical caries present was significantly decreased at T1 & T2 in comparison to T0 (p = 0.0418 
and p= 0.0014) respectively. Wilcoxon matched pairs signed rank test) No statistically 
significant differences were observed in the quantity of teeth missing between T 1 and T2. 





The total number of teeth that were visibly affected by development of caries was statistically 
significantly higher at T0 in comparison to T1 & T2 (p<0.0001 and p = 0.0006). However, at T2 
the number of teeth affected by caries lesion was slightly increased (Figure2.7). There is a 
group of 7 patients at T0 that present 6 or more teeth affected by caries lesion, at T1 this 
number decrease to two patients reaching 8 and 10 teeth affected, at T2 there were 3 patients 
and the maximum number of teeth affected were 11. At T0 only 2 patients did not present 
carious lesions.  


























Figure 2.7 Number of teeth with visible signs of caries development pre (T0) and post IMRT 
at 6 months (T1) and 12 months (T2).  
The total number of teeth that were visibly affected by development of caries was statistically 
significantly higher at T0 in comparison to T1 & T2 (p<0.0001 and p= 0.0) (Wilcoxon matched 
pairs signed rank test) No statistically significant differences were observed in the quantity of 




Dental assessment pre and post IMRT also revealed the total number of teeth that had filings 
present was significantly decreased at post IMRT at 6 months (T1) and 12 months (T2) 2 in 
comparison to pre-IMRT (T0) (p <0.0001) (Friedman Test). No statistically significant 
differences were observed in the quantity of teeth with restorations between T1 and T2 
(Figure 2.8.) 
Tooth surfaces that had caries present were significantly reduced at T1 (p <0.0001) & T2 
(p<0.0001) in comparison to T0. The same clinical threshold was used to asses number of 
surfaces D1 to D3. No statistically significant differences were observed in the quantity of 
























Figure 2.8 Number of teeth with restorations at the three time points measured.  
The total number of teeth that had filings present was significantly reduced at T1 & T2 in 
comparison to T0 (p 0.0007 and p 0.0012). No statistically significant differences were 
observed in the quantity of teeth with fillings between T1 and T2. Data is represented as mean 




































Figure 2.9 Number of tooth surfaces visibly affected by caries at the 3 timepoints measured.  
The total number of surfaces on teeth that had caries lesion present was significantly reduced 
at T1 (p <0.0001) & T2 (p<0.0001) in comparison to T0. (Wilcoxon matched pairs signed rank). 
No statistically significant differences were observed in the quantity of teeth with fillings 









2.4.8.1 Longitudinal Associations Between Salivary Flow Rate and Dental Assessment 
Outcomes Post IMRT at 6 months (T1) and 12 Months (T2) by using Random effects 
Generalised Least Squares linear regression 
 
Previous studies have reported the dental status related to HNC patients regarding quality of 
life (Duke et al., 2005). The outcome measures of dental status of HNC patients comparing 
pre- and post-radiotherapy along with a reduced volume of saliva secretion have been 
presented. In order to assess the interaction between these two variables, a statistical model 
that includes the variable of time was used.  
The salivary flow rate was significantly reduced post-radiotherapy, UWMS reaching the 
lowest value at T1 (0.16 ±0.018 ml/min). At T2, showed an increase (0.24 ±0.032) ml/min 
(Figure.2.2). However, it was significantly lower than T0. 
Post-IMRT there was a significant drop in the total number of teeth present in the mouth 
(Figure 2.4) As well as total number of teeth that were without any type of visible restoration 
and without clinical caries (Figure 2.6),  both showed a strong and negative association with 
reduced salivary flow rate at T1 and T2 (p <0.0001) (Table2.13 And 2.15).  
The number of teeth missing was significantly increased at T1 and T2 (Figure 2.5) representing 
a negative and significant association with salivary flow rate at both time points (p<0.0001) 
(Table 2.14). 
There were strong negative associations between salivary flow rate and the decreased 
number of teeth that were affected by carious lesions (Figure 2.7) (p<0.0001) (Table 2.16) 
along with the total number of teeth that had restorations present (Figure 2.8.) (p<0.0001) 
(Table 2.17) at T1 and T2. Surfaces on teeth that had carious lesions present (Figure 2.9) were 
significantly reduced after IMRT and strongly associated to salivary flow rate at T1 and T2 




Table 2.13  Number of teeth present in the oral cavity and salivary flow rate post-IMRT at 6 
months (T1) and 12 months (T2). 
 
Salivary Flow Rate/ 
Number of Teeth 
Coefficient P [95% Conf. Interval] 
T0 0.004 0.102 -0.009 0.010 
T1  -0.270 0.0001 -0.339 -0.200 
T2 -0.191 0.0001 -0.263 -0.129 
 
Table shows significant association between number of teeth present and salivary flow rate 
post-IMRT at 6 months (T1) and 12 months (T2) (p<0.0001). 
 
 
Table 2.14 Salivary flow rate and number of teeth missing in the oral cavity post-IMRT at 6 
months (T1) and 12 months (T2). 
 
Salivary Flow Rate/ Number 
of Teeth Missed 
Coefficient  P [95% Conf. Interval] 
T0 -0.005 0.079 -0.011 0.00062 
T1 -0.267 0.0001 -0.337 -0.197 
T2 -0.188 0.0001 -0.2609 -0.1165 
 
Table shows significant association between salivary flow rate and number of teeth missing 




Table 2.15 Salivary flow rate and number of teeth without clinical caries or restorations 
present in the oral cavity post-IMRT at 6 months (T1) and 12 months (T2). 
 
Salivary Flow Rate/ 
Healthy Teeth 
Coefficient P [95% Conf. Interval] 
T0 0.005  0.102 -0.0010 0.0110 
T1 -0.285 0.0001 -0.349 -0.220 
T2  -0.202 0.0001 -0.270 -0.1340 
 
Table shows significant association between salivary flow rate and number of teeth without 
caries and restorations observed clinically post-IMRT at 6 months (T1) and 12 months (2) 
(p<0.0001).  
 
Table 2.16 Number of teeth that present with carious lesions in the oral cavity and salivary 
flow rate concentration post-IMRT at 6 months (T1) and 12 months (T2). 
 
Salivary Flow Rate/ 
Number of Teeth (D) 
Coefficient P [95% Conf. Interval] 
T0  5.207  0.194 -2.644 13.060 
T1  -5.627 0.002 -9.163 -2.091 
T2 -5.330 0.001 -8.605 -2.055 
 
Table shows significant association between number of teeth affected with carious lesions 
and salivary flow rate post-IMRT at 6 months (T1) and 12 months (T2) (p=0.002 and p=0.001 
respectively). 
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Table 2.17 Salivary flow rate (SFR) and number of teeth with restorations in the oral cavity 
and post-IMRT at 6 months (T1) and 12 months (T2).   
 
Salivary Flow Rate/ Number 
of Teeth (F) 
Coefficient P  [95% Conf. Interval] 
T0 -0.0015 0.736 -0.0104 0.0073 
T1 -0.296 0.0001 -0.3619 -0.230 
T2 -0.0215 0.0001 -0.2844 -0.146 
 
Table shows significant association between salivary flow rate and number of teeth with 
fillings post-IIMRT at 6 months (T1) and 12 months (T2) (p< 0.0001). 
 
 
Table 2. 18 Salivary flow rate (SFR) and number of surfaces with clinical caries present in the 
oral cavity post-IMRT at 6 months (T1) and 12 months (T2). 
 
Salivary Flow Rate /Number of 
Surfaces Caries 
Coeficient P [95% Conf. Interval] 
T0 0.0030 0.194 -0.00015 0.007 
T1  -0.270 0.0001 -0.342 -0.199 
T2 -0.192 0.0001 -0.265 -0.119 
 
Table shows significant association between salivary flow rate and number of surfaces with 




2.5 Discussion  
 
Tumour localisation and staging are two important factors regarding the IMRT beam pattern 
and final dose received by head and neck cancer patients. RT dose, fractioning and volume of 
tissue targeted are associated with the risk of developing oral and dental side effects (Villa 
and Sonis, 2016). In addition, there are patient-related risks, such as past and current dental 
care, salivary flow rate and composition, oral hygiene, smoking, diet and drinking; that might 
influence the onset and development of side effects (Sonis, 2013). Therefore, It is important 
to determine the degree of salivary flow reduction, xerostomia, taste variation and oral 
mucositis prevalence and severity, following IMRT in order to evaluate these matters further, 
potentially by even associating these parameters with the IMRT dose and fractioning 
regiment received by this study’s volunteers, along with the possible influence of the different 
first tumour sites.  
In this particular study, the majority of participants received IMRT with no difference in the 
fractioning regime, with only 4 patients receive a different fractioning regime than the rest of 
the group. Furthermore, all participants received a mean dose of 62.9 Gy with non-statistically 
differences among each participant’s dosage. Another important factor in this study was the 
use of patients with varying tumour locations and IMRT treatment sites, and in this case the 
majority of patients had sites that were in close proximity to each other and anatomically 
close to parotid and submandibular glands. Therefore, it is possible that these two salivary 
glands were affected by the toxic side effects of IMRT, with submandibular glands being the 
main contributor of UWMS (Pedersen et al., 2018).  
There were no differences in salivary flow rate among the different locations at T1 and T2 (p 
(p=0.5564 and p= 0.6125). This is line with previous studies that reported that different IMRT 
treatment sites had no effect on consequential side effects, and served as a demonstration 
of how different primary tumour sites are unlikely to affect the xerostomia prevalence when 
the radiation-dose parameters are matched between the experimental groups (Richards TM 
(2014). As shown in Figure 2.2, there were statistically significant reductions at both T1 and 
T2, in comparison T0. Whilst these findings are in accordance with previous studies that 
utilised conventional radiotherapy, as well as studies of IMRT (Pow et al., 2006; Dijkema et 
al., 2008, 2010; SHAO et al., 2011; Nguyen et al., 2018), it had been predicted by other studies 
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that IMRT would produce improved results compared to conventional radiotherapy after one 
year (Nutting et al., 2011; Nguyen et al., 2018).  
One reason for the estimates that IMRT would demonstrate improvements in comparison to 
conventional radiotherapy, is that past studies (in particular those that demonstrated 
improvements in flow rate) utilised stimulated parotid gland saliva, or stimulated whole 
mouth saliva – which contains mainly parotid secretions, which could suggest that parotid 
glands were spared by IMRT but this data does not denote whether other glands were 
affected by collateral damage. 
In this regard, it is of particular importance to utilise unstimulated whole mouth saliva for 
measurements of salivary flow rate, as unstimulated whole mouth saliva is a blend of all 
salivary gland secretions, including the major and minor glands and therefore can offer a more 
well-rounded picture of the oral environment.  Whilst UWMS is produced constantly during 
the day and night, without external influences, in contrast, stimulated saliva is produced a 
few times during the day, targeted by external stimuli. Therefore, unstimulated whole mouth 
saliva is considered more representative of the daily oral situation that head and neck cancer 
patients are facing before and after radiotherapy (NAVAZESH, 1993; Chaudhury et al., 2015; 
Proctor, 2016). Furthermore, during such measurements, it is essential to maintain 
homogenous clinical conditions on every patient visit, to avoid or reduce the circadian 
variation. Salivary flow rate and protein composition have been shown to present the highest 
levels in the afternoon (Pedersen et al., 2018) which is why in this study all the samples were 
collected at the same hour of the day, between 13:30 and 15:30 in the dental clinic.  
An advantage of unstimulated whole mouth saliva collection by passive drooling is that does 
not represent a technical challenge for the operator or for patients during the sample 
collection. This is especially important after RT because patients may develop side effects of 
cancer treatment, such as trismus reducing mouth opening and oral mucositis. Parotid gland 
stimulated saliva collection will include the use of citric acid 2% solution and the use of special 
instruments such as a Lashley cup that must be placed over the duct orifice, attached to the 
oral mucosa previously dried keeping the mouth open for 15 minutes during the collection 
period, all of which may be a challenge for head and neck cancer patients.  
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In addition to the reduction in the amount of flowing saliva, clinically a change in saliva colour 
and consistency at the moment of sample collection and later on when the samples were 
handled in the laboratory were observed subjectively, but not measured formally in this 
study.  It would be useful to measure the rheological properties of saliva (specifically 
Spinnbarkeit) of head and neck cancer patients in order to analyse adhesive and elastic 
changes after radiotherapy, to study the association with the amount of saliva, mucin 5B and 
7 protein content and dry mouth reported by patients along with the clinical changes in saliva 
colour and viscosity reported by clinicians.  
The clinical implication of a reduced salivary flow rate after radiotherapy in the early stages is 
that it will hinder daily normal functions such as eating, swallowing, speaking and the use of 
removable prosthodontic appliances due to the lack of mucosal lubrication, hydration and dry 
mouth influencing negatively the patient’s quality of life.  
Xerostomia can affect emotional physical and social functioning of head and neck cancer 
survivors. Results from this study were no different, with the “dry mouth feeling” that is 
typically associated with RT occurring to over 90% of patients at both time points, with only 
3 patients not reporting dry mouth feeling at T1, and 2 patients at T2.  
However, with such a high incidence rate, one must be cautious and seek to associate findings 
together. One possible reasoning could be that patients experience dry mouth even when 
healthy, as was shown by Eliasson et al., (2009), suggesting that that the existence of areas of 
dry mucosa, along with decreased mucin nearby, can generate a sensation of dry mouth. 
Therefore, this condition can be associated to an altered protein composition, particularly 
mucins, resulting in dry mouth sensation even if the flow rate is not reduced(Lee et al., 2007; 
Dijkema et al., 2012; Chaudhury et al., 2015; Villa and Sonis, 2016; Pedersen et al., 2018; 
Almståhl et al., 2019).  
Analysing for a potential association between xerostomia and salivary flow rate revealed that 
were significant associations for patients at T1. These results are in line with similar patterns 
found by other studies (Eisbruch et al., 1999; Wiener et al., 2010; Pedersen et al., 2018; 
Nguyen et al., 2018). However, this statistically significant association was no longer present 
at T2, with the data being statistically similar to that of baseline figures, suggesting that 
perhaps these are only short-term associations. 
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In the next chapter, these findings would be analysed regarding salivary biochemical 
compositional contents, to investigate levels of proteins that are involved with lubrication, 
such as mucins 5B and 7.  
The clinical relevance of changes in saliva quantity and quality are that they directly influence 
lubrication of the oral cavity, hydration of the oral mucosa, alter normal mouth feel and 
contribute to overall oral homeostasis. With salivary flow rate established as a generally 
reliable measure of dry mouth, and it being shown to act as such once again in this study, one 
must observe associations between xerostomia, salivary flow rate and clinical observations in 
order to identify points of potential treatment in order to help ease patients’ quality of life 
(from a clinical aspect) following xerostomia as a result of cancer therapy.  
A few studies have assessed IMRT treatment and whether there are any associations to 
observe with the impacts they may have on the quality of life post-RT. There are reports in 
the literature based on questionnaires related directly to the quality of life regarding salivary 
flow rate and dry mouth feeling (Nutting et al., 2011). Nevertheless, evidence of altered 
salivary flow rate and protein concentration related to dry mouth feeling reported by head 
and neck cancer patients treated with different modalities of radiotherapy is lacking 
(Richards, 2014; Richards et al., 2017).  
A handful of trials have collected salivary samples to measure flow rate, pH or buffering 
capacity for patients treated with IMRT, however, they were often of limited scope or a small 
number of study participants (Kwong et al., 2004; Sim et al., 2018). Furthermore, there were 
no other clinical assessments and there was a lack of salivary protein content analysis, 
specially mucins, which can make it difficult to draw conclusions as to the reasons for the 
underlying issues. 
In contrast, Nutting et al., (2011) stated that there was no association between xerostomia 
and saliva flow rate in 73 head and neck cancer survivors. Twelve months after completing 
RT, the dry mouth feeling reported was significantly lower in patients that underwent IMRT 
compared to conventional RT. Although salivary flow rate was measured, the values were not 
presented in this study and no additional saliva analysis was included for us to compare with. 
Further changes to the quality of life of patients that are attributed to IMRT, include the 
alterations to taste perception, with previous studies (Pow et al., 2006; Hawkins et al., 2018) 
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demonstrating that the use of IMRT produced oral side effects in head and neck cancer 
patients similar to those of traditional radiotherapy, as recorded using questionnaires by 
patient-reported outcomes. Similarly, this present study observed significant numbers of 
taste disturbances after IMRT, when compared with each patient’s taste perceptions before 
treatment.  
Taste changes were measured by individual patients reporting to be uncapable of 
distinguishing food flavours after radiotherapy compared to before. At T1, 65% of participants 
reported a reduced taste acuity, whereas at T2 the number of patients reporting changes was 
reduced dropping to 48%. Although this represented an improvement in taste acuity, the 
improvement was non-significant, with results of T2 not being statistically significantly 
differing from T1.  
Such findings are in accordance with past studies, with Martini et al., (2019) reporting a 
significant taste alteration after 6 months of radiotherapy in head and neck cancer patients, 
when measured using the chemotherapy-induced taste alteration scale (CiTAS), On the other 
hand, one past study evaluating taste thresholds for each taste quality, reported that there 
was a recovery of taste sensitivity at one year post-radiotherapy treatment, with taste levels 
reaching baseline thresholds(Sandow et al., 2006).  However, that study needs further review 
as it utilised 11 patients which may affect the results due to lack of variability in subjects. Such 
disparity in the findings of past studies have led Epstein et al., (2016) to conclude that the real 
impact of IMRT is not clear, with the possibility for taste alteration recovery after treatment 
to occur 6 months after therapy or the possibility for it to continue indefinitely. Furthermore, 
even when recovery is reported, there is a varying scale of whether the recovery is complete 
or partial(Oates et al., 2007; Epstein et al., 2019). 
Even though the prevalence of changes in taste after cancer treatment have been described 
the aforementioned studies, the mechanisms involved are not well understood. There is not 
enough evidence of the underlying interactions between radiation and the subjective changes 
in taste before and after radiotherapy. It is still inconclusive whether radiation toxicity acts by 
affecting threshold and/or directly producing an alteration of taste perception by epithelial 
damage (Spotten et al., 2016; Epstein et al., 2016, 2019), or whether the taste changes 
perceived are a result of the reduced salivary flow rate; it has been proposed that the lack of 
saliva will impede the transport of molecules into taste buds receptors, as well as saliva 
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protection of receptor from damage will be reduced(Epstein and Barasch, 2010; Epstein et 
al., 2016).  
This theory has been explored further by the Epstein research group, who have stated that 
that taste buds acuity requires an appropriate volume of saliva in the mouth, and with almost 
all radiotherapy studies observing a reduced salivary flow rate, including this study observing 
a reduced salivary flow rate in patients at both T1 (6 months) and T2 (12 months) and a 
significant and negative association between this reduction and taste variation reported by 
patients (Table 2.9), they conclude that this must be cause of taste alterations with the lack 
of saliva has been causing an incapacity of dissolving food molecules and transport these in 
to taste buds (Epstein and Barasch, 2010; Epstein et al., 2012, 2016, 2019).  
Apart from these changes, taste perception may also be a direct result of the damage on the 
epithelial cells caused by radiotherapy, which in this case has been related to oral mucositis 
onset during radiotherapy (Ruo Redda and Allis, 2006; Epstein and Barasch, 2010; Irune et al., 
2014). Epithelial toxicity caused by radiotherapy has been associated with taste changes in 
some past studies, along with the resultant mucosal damage(J. B. Epstein et al., 2002; Doty et 
al., 2017). Furthermore, Ogama et al., (2010) found associations between reduced salivary 
flow rate, oral mucositis and taste in head and neck cancer patients treated with 
radiotherapy.  
It is especially important to keep in mind that although these changes are significant, in all 
cases they are self-reported by patients, causing the data to be subjective. Therefore, this 
represents a limitation regarding taste variation and dry mouth reported by patients by using 
one question extracted from a full questionnaire (Fox et al., (1987) and LENT-SOMA 
questionnaire) that explore different dimensions of these two factors regarding radiotherapy 
side effects. Moreover, it was selected only one question from each survey which reduced 
the scope of the information that can be obtained, along with the division of patients in two 
groups with or without the condition only, without taking in account the severity of the 
condition and the possible differences during specific  times  of  the  day,  or  the possible  
relation  to  certain daily functional activities. Therefore, this data represents a first 
approximation regarding xerostomia and taste acuity in this group of patients, in order to 
associate with objective measurements of hyposalivation and salivary composition regarding 
mouth feel and taste after IMRT.  
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Oral mucositis presence and severity was reported by the oncology team during and after 
radiotherapy and were in concordance with the results reported by Van Gestel et al., (2011). 
It was observed that there were 31 patients that developed mucositis during radiotherapy 
and the maximum grade at any time point was grade 3 representing 40% of the patients in 
concordance with  Orlandi et al., (2018) reported severe acute OM (G≥3) during IMRT using 
the Common Terminology Criteria for Adverse Events (CTCAE) scale version 4.03. On the other 
hand, Van Gestel et al., (2011), using the RTOG scale reported grade 3 oral mucositis in 41 
head and neck cancer patients treated with IMRT, representing 85% of the total number of 
subjects studied which is twice as much that what it was reported in this study. A drawback 
in oral mucositis research is the lack of a universal scale, there is not an objective and 
standardised tool to assess oral mucositis severity in the clinic. There is available a high 
number of instruments validated, these scoring systems are subjective based on patient 
experience related to pain and functional disability, disregarding anatomy, size of ulcers and 
regions affected thorough the oral cavity. Therefore, mucosal evaluation outcomes mainly 
depend on physician clinical experience and training in order to define the categories in an 
effort to increase inter observer reliability.  
There are contradictory opinions among researchers based on these grading systems some of 
them will choose one of the existing others developed their own in order to standardize, 
validate and remove subjective observations from their research outcomes. There is no 
consensus regarding these evaluation instruments (Sonis et al., 2001). There is no universal 
validated scale and no evidence of any superiority among system to report oral mucositis 
rates. However, the WHO toxicity scale has been used since 1979 more than 40 years (Quinn 
et al., 2008).  
After radiotherapy the number of patients presenting oral mucositis were reduced at T1 and 
T2 reaching 16% and 9% respectively, similarly after RT persistent mucositis was seen in 19.2% 
in a previous report developed by Jham et al., (2008) using the WHO scale patients were 
followed by 3 months after the end of RT. These past studies have established there is a risk 
of radiation‐induced mucositis that varies with the site of radiotherapy volume of irradiated 
tissue, dosage, and fractionation (Chao et al., 2001; Pinna et al., 2015; Klein et al., 2014; Laheij 
et al., 2015; Sroussi et al., 2017).  
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This chapter’s results showed no difference among different tumour locations regarding oral 
mucositis development. It has been stablished in the literature that hypopharyngeal or 
laryngeal cancers have less risk of developing oral mucositis than patients with cancers of the 
oral cavity (Sonis, 2009). In this group, oral mucositis severity was not significantly different 
among distinct tumour location, despite the fact that the number of patients conforming each 
group were not equal, in almost every group there were patients reaching grade 2 and grade 
3 severity. Therefore, it can be concluded that the location of the primary tumour was not a 
factor of difference in severity and onset, as well as regarding IMRT dosage and fractioning 
scheme, these were no dissimilar (62.5 Gy mean dose). An explanation for this situation could 
be related to the patient’s oral conditions in response to IMRT effects(Villa and Sonis, 2016). 
It has been shown in reports that good oral hygiene and proper oral/dental health care before 
IMRT might help to reduce duration severity and even the risk of oral mucositis. Another 
factor is the microorganisms that are capable to colonize ulcers contributing to oral mucositis, 
this bacterial shift is led by the lack of protective salivary functions due to the reduced flow 
rate and altered composition of proteins related to antibacterial protection. Age is another 
risk factor, older patients are more prone of developing mucositis, in this group the mean age 
was 62 years with no statistical difference among subjects(Sciubba and Goldenberg, 2006; 
Villa and Sonis, 2016).  
This study revealed significant associations at T1 & T2 between oral mucositis and reduced 
salivary flow rate in all subjects. There were also significant associations between the dry 
mouth feeling reported by patients and oral mucositis at T1 and T2, showing a connection 
between these side effects and salivary gland dysfunction after IMRT. These associations 
report the oral environment influence, specially the role of saliva in oral mucositis course and 
severity regarding mucosal wetting, lubrication and bacterial protective functions and 
colonization (Sonis, 2009).  
Past studies have proposed that there could be a relationship between salivary gland 
dysfunction and elevated caries prevalence (Mese and Matsuo, 2007; Dawes et al., 2015; 
Pinna et al., 2015; Gao et al., 2016). When observing caries presence in the current study, it 
was found that carious lesion development was decreased significantly at both T1 and T2, in 
comparison to pre-IMRT. Similarly, when measuring the number of surfaces affected by 
caries, it was also observed that carious lesion development was decreased significantly at 
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both T1 and T2. This is keeping in line with past studies, such as Duarte at al. (2014) following 
neck and neck cancer patients every 90 days for 1 year, who concluded that both IMRT and 
conventional radiotherapy resulted in a lower number of carious lesions after treatment. 
However, this is not to suggest that IMRT / RT had halted the development of carious lesions, 
but rather, when taken in context with the number of teeth remaining (Figure 2.4), it is 
concluded that the teeth that were in the high dose radiation beam that presented with 
carious lesions that were considered non restorable or if they required significant restorative 
treatment, endodontic procedure were extracted immediately prior to radiotherapy 
treatment (Hancock et al., 2003), which can also be shown by measurements of number of 
teeth missing  at T1 and T2 (Figure 2.5). Therefore, that is main reason why the number of 
teeth missed index was significantly increased at T1 and T2 in comparison to T0. A standard 
protocol exists to extract any teeth that present with carious lesions, active periapical lesions, 
extensive and chronic periapical lesions and unrestorable teeth, prior to radiotherapy (Joshi, 
2010) - ideally 3 weeks or more prior to allow time for healing before radiotherapy begins 
(Makkonen et al., 1987). 
If the study were to have gone on for an extended period of time, it is to be expected, based 
on the past literature, that caries incidence would have returned to baseline levels within 2 
years, as studies have shown carious lesions redevelop 2 years after radiotherapy (Schuurhuis 
et al., 2011). This is because one of the factors that affects dental status is time elapsed 
following radiotherapy, with every month following the end of radiotherapy only increasing 
the odds of further tooth damage(Walker et al., 2011). However, one mitigating factor that 
might have contributed to the prevention of lesions developing within 2 years, is the daily 
fluoride treatment participants (Duraphat® 5000, twice per day) in this study, as 
recommended by the PATIENTS’ dental consultant at Guy’s hospital. Fluoride treatment has 
been shown to mitigate risks of more severe radiation caries (Andrews and Griffiths, 2001, 
Pitts et al 2017). Risk of severe radiation caries has been linked to salivary gland dysfunction, 
as measured by salivary flow rate. It should be noted that past studies have observed no single 
salivary parameter increases susceptibility to dental caries, and that several parameters 
should be taken into consideration in combination with each other, alongside other non-
quantitative factors such as socio-demographic, behavioural and clinical aspects (Gao et al., 
2016). 
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Initiation and progression of caries lesions are a result of unbalance between protective and 
pathological factors present in the mouth; protective factors stimulate remineralization while 
pathological factors will make the disease progress. (Pitts et al 2017; Featherstone et al 
2018;). In order to increase protective factors, present in the early clinical stages of caries, all 
patients under the care of the Special Care Dentistry Unit are prescribed daily use of sodium 
fluoride toothpaste Duraphat 5000 (twice per day) during the pre IMRT oral examination (RCS 
guidelines 2018). This high fluoride protocol continues indefinitely with the aim of reducing 
the frequency of complication such as radiotherapy caries (Pitts et al 2017; Pedersen et al 
2018). Patient compliance with this protocol is reviewed during the post radiotherapy T1 (6 
months) assessment. In addition, participants had an extra assessment post IMRT at T2, which 
have assisted with continued adherence to this regime, as shown by the decreased number 
of carious lesion development at both T1 and T2. However, the number of teeth extracted or 
missing post-radiotherapy (a mean of 13.5 teeth at both T1 & T2) represents the high risk of 
becoming edentulous in the long term, affecting daily functions such as mastication and 
eating. This presents another severe challenge for oral rehabilitation and one not helped by 
the reduced salivary flow rate. 
It is important to remark that the oral evaluation was conducted at each visit by the same 
calibrated clinical examiner (specialist dentist) in order to identify adverse oral and dental 
outcomes, through an appropriate diagnosis, being capable of differentiating tooth pain from 
ulcerative oral mucositis pain by exhaustive facial and intra-oral examinations at every time 
point. Additionally, at T1 and T2 oral mucositis intensity was grade 1, as characterised by mild 
clinical symptoms including erythema, without ulcerative lesions or pain. 
The reduced salivary flow rate appeared to be negatively and significantly associated with all 
the clinical parameters related to the dental assessment (DMFT), after radiotherapy at both 
T1 and T2. This is in keeping with the past studies that have shown associations between 
reduced salivary flow rates in cancer patients and with increased risk of caries or candida 
infections(Frenkel and Ribbeck, 2015; Gao et al., 2016; Pitts et al., 2017). These diseases 
would have occurred in those studies as saliva is vital in maintaining mineral equilibrium on 
enamel surfaces, providing the ions required for remineralization along with maintaining 
bacterial equilibrium (Pitts et al., 2017).  
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Salivary flow rate and composition plays a critical role in the oral ecosystem symbiosis and 
biofilm formation. In this study participants presented with a significantly reduced salivary 
flow rate. During radiotherapy lack of saliva would have resulted in soft tissue inflammation 
due to a reduced lubrication and barrier function. This would have been combined with the 
direct effect of radiotherapy on epithelial cells causing toxicity leading to a cell death and 
ulcers as well as  a shift in the diversity of oral biofilm population disrupting normal oral 
homeostasis and promoting pathogenic bacteria growth (Kielbassa et al., 2006; Jham et al., 
2008; Gao et al., 2014; Liu et al., 2014; Xu et al., 2014; Deng et al., 2015; Pinna et al., 2015). 
Participants with hyposalivation caused by radiation therapy showed differences in oral 
microflora composition compared with age-gender control patients (Almstahl et al 2001), 
which included an increased susceptibility to bacterial and yeast infections (Chaudhury et al 
2015). However, participants with hyposalivation presented with similar number of tooth 
surfaces covered with plaque compared with controls. The difference in bacterial composition 
was associated with an altered salivary protein concentration (Almstahl et al 2001), reduced 
salivary flow rate and poor oral hygiene which meant increased risks of an unbalanced oral 
microbiome mainly dominated by the microorganisms associated with oral diseases (Killian 
et al 2016).Therefore, it would be imperative to assess and monitoring the periodontal status 
of patients before and after radiotherapy given the possible association between bacterial 
periodontitis and oral mucositis severity and duration (Laheij et al 2014; Maria et al 2017). 
Furthermore, the presence of ulcers results in a natural barrier breach providing an open 
entry for microorganism and cytokines to the underlying tissues thus increasing the risk for 
secondary infections such as bacteraemia and sepsis (Laheij et al 2014; Villa & Sonis 
2015,2016; De sanctis 2016). It has been observed that during and after radiotherapy head 
and neck cancer patients can suffer severe mucositis (Sonis 2004; Vasconcelos et al., 2016; 
Richards et al., 2017) along with an altered microbial diversity, particularly an increased 
number of bacteria associated with periodontitis. Gram-negative anaerobic bacteria and 
other periodontal pathogens such as Porphyromonas gingivalis, Fusobacterium and 
Prevotella are predominantly associated with the onset of ulcerative oral mucositis and 
impact the severity. This suggests that their abundance might represent a risk factor for 
aggravation of ulcers along with a delay in mucosal healing. (Laheij et al.2012; Laheij et al 
2014; Zhu et al., 2017; Elerson et al 2018; Laheij et al., 2020). However, the role of these 
 132 
bacteria regarding host microbe interaction in promoting or modifying inflammation and 
exacerbating oral mucositis progression needs to be confirmed and elucidated in future 
studies. This in turn will inform the need for periodontal routine screening in this group of 
patients (Sonis et al 2004 etc Laheij et al.2012; Laheij et al 2014; Zhu et al., 2017; Elerson et 
al 2018; Laheij et al., 2020). 
Overall, this study concludes with several findings, starting with the fact that salivary flow 
showed a significant, transient reduction in quantity following IMRT. This was in line with past 
studies that found IMRT to not fully spare tissues surrounding  target treatment area, when 
measured in terms of salivary flow rate(Dijkema et al., 2008), xerostomia (Dijkema et al., 
2010), and other oral symptoms such as hyposalivation in general (Nutting et al., 2011; 
Nguyen et al., 2018). With over 90% of patients in this study exhibiting signs of and reporting 
dry mouth, the intensity modulated radiotherapy treatment clearly lead to a vulnerable oral 
environment and disrupted oral homeostasis, leading to deteriorated clinical outcomes, such 
as reduced number of teeth, potential edentulism, all of which was statistically significantly 
associated to the original finding of reduced salivary flow rate. There are significant 
associations between salivary flow rate and dry mouth feeling, taste alterations oral mucositis 
assessment, number of teeth present, number of teeth missing and number of carious lesions 
(as measured by both teeth and surfaces). These findings corroborate that salivary flow rate 
is an objective measure of recording salivary gland damage (hyposalivation), which clinically 
is expressed as all of aforementioned side effects.  
However, the clinical relevance of such findings is dependent on what particular changes are 
occurring within the remaining saliva, dependent on the function of proteins that make up 
the composition of saliva (Jawad et al., 2015). Therefore, perhaps the next study should begin 
to analyse the bio-composition of saliva in order to evaluate the effects of IMRT on salivary 
gland output, allowing for conclusions as to whether it is definitively the reduced flow rate 
that is affecting dental health or whether it is the altered compositions of the remaining saliva. 
So far, this has all reinforced the past studies that found IMRT does not fully spare tissues that 
surround the sites of targeted radiotherapy treatment, when measured as xerostomia or 
symptoms (Dijkema et al., 2010; Nutting et al., 2011). However, the direct causalities for how 
IMRT affect salivary gland functions is as of yet unclear, and therefore the analysis of how 






Chapter 3 Impact of Radiotherapy on The Biochemical Composition of 
UWMS  
 
3.1 Introduction  
 
Chapter 2 detailed how salivary flow rate was decreased significantly following IMRT, 
correlating with an increase in the reporting of xerostomia and taste changes, as well as a 
significant reduction in number of teeth present in the mouth post-radiotherapy and 
variations in the quantity of carious lesions at each time point. 
Previous studies have observed changes in the biochemical composition of saliva following 
both traditional therapy (Roesink et al., 2001) as well as IMRT (Richards et al., 2017), however 
there remain many unanswered questions, such as the long-term nature of the changes in 
the protein composition as well as whether there are associations  between individual salivary 
proteins and their corresponding xerostomia reporting, taste acuity, carious lesion incidence, 
and mucositis severity.  
This chapter analyses the changes of individual salivary possible molecular markers in UWMS 
composition, in order to assess major salivary gland function through assessing total protein 
concentration and secretion rate, as well as specific proteins associated with each gland.  
Analysis was performed on UWMS of 40 patients, observing organic salivary composition 
biomarker that indicate various oral functions. UWMS is a mixture of all salivary gland outputs 
and this analysis concerned proteins and glycoproteins expression with specific functions that 
are directly linked to the side effects of radiotherapy reported in Chapter 3.  
The Mucins investigated were mucin 5B and 7. Their central function is lubrication and 
hydration of oral mucosa due to their water binding capacity. Lack of these glycoproteins or 
alteration in their composition is associated with dry mouth feeling(Eliasson et al., 2005; Vijay 
et al., 2015; Proctor, 2016; Pedersen et al., 2018). It has been shown that modifications in 
salivary mucin 5B and mucin 7 affects mucosal surfaces due to reduced salivary wetting 
capability and altered lubrication. Mucosal surfaces become dry and atrophic, thus more 
prone to injury (Vissink et al., 2010).   
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In addition, mucin 5B and mucin 7 form a protective barrier preventing erosion, abrasion and 
ulceration during daily oral functions such as mastication, swallowing and speaking (Vissink 
et al., 2010; Carpenter, 2013b; H. L. Gibbins et al., 2014; Dawes et al., 2015; Proctor, 2016; 
Pedersen et al., 2018). Mucosal integrity and protection are vital in HNC patients due to the 
high rate of oral mucositis onset during radiotherapy. Therefore, it is important to asses 
concentration of these salivary proteins as well as their functionality(Dawes et al., 2015).  It 
has been suggested by Sonis, (2004) that during the formative stages of ulcers the amount of 
saliva decreases whilst mucositis progresses (Tschoppe et al., 2010; Pinna et al., 2015). 
It is well known that mucin 5B and mucin 7 are the main constituents of mucosal pellicle, 
along with IgA, forming a complex with mucin 7 (Vissink et al., 2010; H. L. Gibbins et al., 2014; 
Dawes et al., 2015). IgA is the main antibody in saliva and plays an important role in bacterial 
colonization, mucosal protection, defence against microorganism, mucosal immune system 
and mucosal pellicle forming and regulating an epithelial barrier (Brandtzaeg, 2009; Dawes et 
al., 2015; Hemadi et al., 2017; Lynge Pedersen and Belstrøm, 2019). IgA is secreted by B 
Lymphocytes in salivary glands including minor glands and parotid glands (Crawford et al., 
1975; Brandtzaeg, 2009, 2013; Lynge Pedersen and Belstrøm, 2019).  
α-Amylase is one of the most prevalent enzymes in saliva and is generally considered to be a 
reliable marker of serous cell function and can therefore act as a marker for parotid gland 
function. Past studies have shown α-amylase concentration levels can be linked to protection 
against caries (Dawes 2008, Borghi et al., 2017). 
Albumin concentration is also considered an important marker for potential mucositis, as an 
increased concentration is related to an inflammatory process and increased vascular 
permeability (Jensen et al., 2003). Past studies have also observed that albumin, statherin, 
cystatin, proline rich protein (PRP), mucins 5B and 7 form acquired enamel pellicle, reducing 
the possibility of erosion and abrasion, determining biofilm formation, keeping mineral 
equilibrium by maintaining a high concentration of calcium and buffer capacity (H. L. Gibbins 
et al., 2014; Hannig et al., 2017).   
Cystatin S is a protein related to enamel pellicle formation which has antibacterial functions, 
such as inhibiting the action of endogenous, bacterial and parasitic protozoan proteases, or 
binding bacterial lipopolysaccharides(Messana et al., 2008; Magister and Kos, 2013; Hemadi 
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et al., 2017). The cystatins family of proteins are also part of the acquired enamel pellicle 
formation and play an important role in remineralisation process, as well as taste functions 
(Gao et al., 2016; Picco et al., 2017; Hemadi et al., 2017). Cystatin S may be considered a 
biomarker in assessing submandibular glands function(Martini et al., 2017). 
Proline rich proteins are secreted by parotid and submandibular glands and contain between 
25-42% of proline amino-acids which affects this protein structure (Carpenter, 2013b). Acidic 
and basic proline rich proteins are part of the acquired enamel pellicle due to their calcium 
hydroxide binding properties. Proline rich proteins, statherin and other phosphor containing 
proteins have calcium binding properties, thereby maintaining a higher concentration of 
calcium than teeth (supersaturated saliva), in order to prevent dissolution of teeth and to 
avoid their precipitation, especially in the cervical margin causing calculus (Carpenter, 2013b; 
Hemadi et al., 2017). These proteins participate in oral bacterial clearance, by binding 
bacteria, fungi and viruses towards the stomach. Furthermore, these proteins have a 
polyphenol binding affinity, acting as polyphenol precipitators (tannins included) in the 
perception of astringency (Fábián et al., 2015).  
Statherin is a phosphoprotein secreted from parotid, submandibular and sublingual glands, 
which plays a multifunctional role in the oral cavity; maintaining calcium homeostasis, 
preventing its precipitation and crystal growth, as well as maintaining saliva supersaturation 
in order to stimulate the remineralisation process.  
Carbonic Anhydrase VI (CA VI) is an enzyme secreted by parotid and submandibular glands 
that plays a fundamental role in controlling taste sensation and taste bud growth, by 
facilitating the interaction between food particles and taste buds (Denny et al., 2008, Welton 
2012). CA VI is activated in order to counteract the excessive acidity of the tooth surface 
biofilm by catalysing the most important buffer reaction in the oral environment; the carbonic 
dioxide equilibrium in saliva (Öztürk et al., 2008; Frasseto et al., 2012; Zwier et al., 2013; 
Cardoso et al., 2017; Pedersen et al., 2018), in order to increase bicarbonate salivary levels 
especially with acidic food. Moreover, this buffer mechanism plays a role in reducing tooth 




In previous chapters of this thesis was shown in detail how salivary flow rate was decreased 
statistically significantly following IMRT at two time points, along with over 90% of the 
patients reporting xerostomia and taste changes, as well as a deteriorate dental clinical 
outcomes such as a significant reduction in number of teeth present in the mouth post-
radiotherapy. Moreover, it was demonstrated the links among dental assessments, dry mouth 
perception, taste perception and oral mucositis to a reduced UWMS flow rate following IMRT. 
Regarding salivary flow rate past studies observed that IMRT not fully spare area that 
surround tumour (Dijkema et al., 2008). In the same pattern Dijkema et al., (2010); Nutting et 
al., (2011); Nguyen et al., (2018) reported xerostomia, and other oral symptoms such as 
hyposalivation in general in patients treated with IMRT.  
The clinical relevance of protein composition variation after IMRT is dependant of the 
function of each protein (Chao et al., 2001; Jawad et al., 2015). Whilst it is important to study 
and identify the possible association between these clinical side effects that are affecting 
patient’s quality of life with the quality of UWM saliva in order to find a target that allow to 
explain its participation in onset of these side effects. Past studies have showed some of these 
biochemical changes in saliva concentration and salivary flow reduction post radiotherapy 
(Dijkema et al., 2012).   
It has been proposed by some authors that a reduced salivary flow rate is usually 
accompanied by an altered saliva composition (H. L. Gibbins et al., 2014; Hannah L. Gibbins 
et al., 2014; Hannig et al., 2017), the association between these proteins and salivary flow 
rate is still not clear specially after radiotherapy and adding the longitudinal factor including 
different time point.  
The understanding of the association between oral side effects due to radiotherapy and 
salivary protein composition alteration is not yet fully analysed in the literature, some authors 
have attempted to assess the interrelation between radiothera 
py side effects (Wijers et al., 2002; Nutting et al., 2011; Randall et al., 2013; Belstrøm et al., 
2016; Janus et al., 2017), showing the correlation between a reduction in salivary flow rate 
and the salivary gland hypofunction after cancer treatment, despite the use of IMRT and the 
current preventive measures given by the oncology and dental team in the UK(Walker et al., 
2011; De Siqueira Mellara et al., 2014; Lieshout and Bots, 2014; Laheij et al., 2015). Others 
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studies have informed prevalence of xerostomia and taste altered perception following HNC 
(Ruo Redda and Allis, 2006; Epstein and Barasch, 2010; Epstein et al., 2016; Spotten et al., 
2016; Epstein et al., 2019) and the link of these symptoms with reduced salivary flow rate 
(Epstein et al., 2019).  
There is a lack of research that evaluate the role of proteins regarding lubrication and mucosal 
protection during and after RT (Randall et al., 2013). The absence of studies that have 
evaluated the role of mucin 5B in xerostomia onset and development is an impetus for this 
analysis.  
This chapter analyses the changes of the nine aforementioned individual salivary biomarkers 
in UWMS composition of 40 patients in order to evaluate major salivary gland function 
throughout, whilst assessing total protein concentration and secretion rate, as well as specific 
proteins associated with each gland. In addition, In this chapter it assessed the possible 
association between the altered clinical outcomes reported in chapter 2 and the salivary 
compositional changes in order to determinate the dependence between these clinical and 
biochemical factors, regarding proteins functions that make up the composition of saliva 
(Jawad et al., 2015).   
3.2 Aims  
 
The aim of this longitudinal trial was to assess salivary gland function of HNC patients pre (T0) 
and post IMRT (T1 and 2) by analysing protein concentration and secretion rate and 
investigate the possible associations between these proteins and clinical outcomes.   
Null hypothesis: The hypothesis for this chapter is that IMRT will not affect the protein 
composition and secretion rate. There is no association between salivary proteins and oral 
side effects of radiotherapy.     
Objectives  
• To assess the effect of IMRT on salivary protein concentration and secretion rate of 
UWMS in HNC patients at different time points (T0 and compared to T1 and T2) 
• To analyse the possible associations between proteins concentration and secretion 
rate with salivary flow rate, self-reported xerostomia and self-reported taste changes 
by patients.  
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• To determine whether these proteins analysed have role in these clinical side effects 
expression regarding salivary gland function particular production involvement in 
UWMS.  
 
3.3 Material and Methods  
 
3.3.1 Patient Recruitment 
 
Forty HNC patients were recruited in line with the Helsinki declaration with full, written 
informed consent gained. The study was approved by the North of Scotland Research Ethics 
Service (NRES) Committee foundation in October 2016 (16/NS/0116), the Health Research 
Authority NHS (IRAS Project ID:199100) and the patient recruitment letter is appended 
(Appendix no.1).  
Recruitment was done prior to IMRT (T0) at Guy’s Hospital London in the Special Dental Care 
Unit. Patients were seen at six months post IMRT (T1) and 12 months post IMRT (T2).  40 
patients were recruited at T0, 38 patients were seen at T1 and 34 patients at T2 respectively.  
 
3.3.2 Saliva Sample Collection 
 
All saliva samples were collected from the patients by drooling method at every time point, 
and flow rate was assessed as described in chapter 2. One hundred and eleven saliva samples 
were collected and analysed.  
 
3.3.3 Sample Analysis  
 
Samples were analysed for total protein content using the Bicinchoninic Acid Assay (BCA), 
targeted protein concentration by Enzyme-Linked Immunosorbent Assay (ELISA), Periodic 
Acid Schiff (PAS) staining, Coomassie Brilliant blue and α-amylase activity by the standard 
kinetic enzyme assay (Salimetrics). 
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Prior to biochemical analysis UWMS samples were centrifuged at 10000 RPM for 5 mins at 
4°C. The supernatant was separated to be used to analyse protein content and the pellet was 
preserved to perform DNA extraction. 
 
3.3.3.1 Protein Analysis Concentration and Secretion Rate  
 
In order to determine the salivary protein composition, the total protein content /secretion 
rate, specific protein concentrations and their secretion rates were analysed. Nine proteins 
(mucin 5B mucin 7, IgA, α-amylase, albumin carbonic anhydrase VI, acidic proline rich protein 
and statherin) were selected due to their relationship to host defence, antimicrobial, bacterial 
adherence, colonization, mucosal pellicle, enamel pellicle, viscoelastic, rheological properties, 
lubrication, and remineralization.  
In summary mucin 5B mucin 7, IgA, α-amylase, albumin carbonic anhydrase VI, acidic proline 
rich protein and statherin all salivary proteins related to caries development, xerostomia, 
taste alteration and oral mucositis before and after radiation therapy in a longitudinal clinical 
study (12th months) were analysed. 
 
3.3.3.2 Total Protein Concentration (TPC) 
 
Total protein concentration of UWMS was determined using the BCA protein assay (Thermo 
fisher scientific, IL, USA), in a 96 multi-well plate according to manufacturer’s instructions. 
Results were derived from a standard curve generated using Bovine Serum Albumin (BSA) 
serial dilution incubated at the same time and protein concentrations were determined. 
UWMS samples were assessed at a dilution of 1:10 in ultra-high-quality water. The 
absorbance was measured at 540nm using a plate reader (iMark Microplate Absorbance 
reader BIORAD, UK). All the saliva samples were analysed in duplicate. Total protein 




3.3.3.3 Total Protein Secretion Rate  
 
Protein secretion rate was calculated to assess salivary gland function at every time point (pre 
and post radiotherapy) including the salivary flow rate (ml/min) and the total protein 
concentration per ml of saliva. Total protein secretion rate was calculated by multiplication 
of the salivary flow rate and protein concentration in ug / min (Carpenter et al., 2000).  
 
3.3.3.4 Sample Preparation and Gel Electrophoresis 
 
All samples were prepared under the same conditions, adding 25% NuPage lithium dodecyl 
sulphate sample buffer (LDS, Invitrogen), 10% 0.5 dithiothreitol (DTT) and boiled for 3 min at 
100 ºC. UWMS samples were analysed for protein content using sodium duodecil sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). NuPage Novex, 4-12% bis tris gels Invitrogen 
were used to assess 2-200 KDa molecular weight proteins. The gels were set up in a Xcell 
vertical electrophoresis unit (Invitrogen, Thermo Fisher Scientific, UK) with 25 ml of NuPage 
MES SDS running buffer (x20 stock) (Invitrogen, Thermo Fisher Scientific, UK) and 475 ml 
double distilled water (dd H2O)Total protein concentration of samples was measured using 
the BCA assay and the protein load was adjusted to 20μg per lane. 5 μl of SeeBlue Plus Pre-
stained marker (Invitrogen, Thermo Fisher Scientific, UK) was loaded in the first and last lanes. 
The samples underwent electrophoresis for 35 minutes at 125 mA and 200 volts constant. 
 
3.3.3.5 Mucin Detection and Quantification  
 
For the purpose of determining the effect of irradiation on mucin 5B and mucin 7 
concentration in UWMS, saliva samples were electrophoriesed, and the gels were stained 
with PAS stain for the detection of mucin 5B and mucin 7.  
3.3.3.5.1 Periodic Acid Schiff Staining of Protein Gels   
 
PAS was used to detect and assess glycoproteins. After electrophoresis, gels were fixed in a 
fixing solution 25% methanol and 10% glacial acetic acid for 60 minutes and then washed in 
UHQ water for 20 minutes and incubated in 2% (w/v) periodic acid (sigma) for 15 minutes. 
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Subsequently, gels were rinsed with UHQ water for 4 min in total and using Schiff reagent 
(VWR, Leicestershire, UK), gels were incubated in the dark with gentle agitation for up to 60 
minutes or until pink stained bands appeared. The gels were de-stained in water and scanned 
on an automated image developing system, the ChemiDoc (Bio-Rad, Hemel Hempstead, UK) 
in order to identify mucin glycoproteins.  
 
3.3.3.5.2 Mucin Semi-quantification  
 
MUC5B and MUC7 mucin glycoproteins were semi-quantified using purified mucin fractions 
of known concentrations (Malmo University, Sweden). The purified mucin fractions were 
serially diluted, underwent electrophoresis and stained with PAS. Images of the PAS stained 
gel were analysed for band intensity using the ChemiDoc. The bands were converted to peaks 
and the area under each curve gave the pixel intensity. Standard curves and linear equations 
were generated for mucins (MUC5b and MUC7) concentration against pixel intensity. The 
mucin concentrations of the samples were calculated from the known pixel intensities using 




Figure 3.1 Mucin standard-concentration curves for (A) mucin 5B (MUC 5B), (B) mucin 7 (MUC 
7).  
Purified mucins with their linear equations used to calculate the concentration of MUC5B and 
MUC7 in the different test samples. 
  
3.3.3.6 α-Amylase Kinetic Assay  
 
Detection of α-amylase concentration in UWMS samples was carried out and analysed by 
measuring the enzymatic activity of this protein expressed in units.  
α-Amylase activity was used to determine its concentration in units in saliva samples using 
the α-amylase assay (amylase kinetic assay, Sialimetrics LLC, PA, USA). UWMS samples were 
diluted with α-amylase diluent (1:200). Standard and diluted saliva samples (8μL) were added 
to each well of 96 well microtitre plate. The α-amylase substrate was heated at 37ºC for 20 
minutes and 320 μL of the α-amylase substrate was added to each well. The absorbance was 
measured at 405 nm at two time points one minute, then again two minutes later. The 
calculations were carried out following manufacturer’s instructions. 
 
3.3.3.7 ELISA Protein Detection 
 
IgA, albumin, cystatin S, proline rich protein and statherin concentration in UWMS were 
determined using ELISA. Quantification of these proteins was performed using a colorimetric 
reaction by adding a substrate chromogen reagent to a labelled enzyme to visualize in a 
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spectrophotometer in a 96 well-plate for each assay which permitted to evaluate a higher 
number of patients per assay, an advantage aspect to other available tests (Almsthal et a.,l 
2001; Dijkema et al., 2012, Thermo Fisher Scientific Hand book 2015, Glasgow, UK). 
 
3.3.3.7.1 IgA ELISA 
 
Concentration of IgA in UWMS was assessed using ELISA (Sandwich kit, Cusabio Biotech USA). 
The ELISA microplate was pre-coated with IgA capture antibody. Samples were diluted in 
duplicate along with the standard and incubated at 37ºC for two hours followed by removing 
the liquid of each well without washing. Biotinylated mouse anti-human serum IgA detection 
antibody diluted to the working concentration was added and incubated at 37ºC for 1 hour 
followed by three washes. Streptavidin conjugated to horseradish peroxidase was added for 
1 hour at 37ºC and followed by five final washes. Substrate solution consisting in a mixture 
(1:1) of H2O2and tetramethylbenzidine was added for 20 minutes at 37ºC. The reaction was 
stopped with 2M sulphuric acid and the absorbance was read within 5 minutes at 450 - 540nm 
to correct optical imperfections in the plate. 
Human IgA sensitivity was 0.24 ng/mL and the detection range were 0.24 - 1000 ng/ml. 
 
3.3.3.7.2 Albumin ELISA  
 
Concentration of albumin in UWMS samples was measured using ELISA (Duo Set Elisa R&D 
Systems, Minneapolis, USA)  
Mouse anti-human serum albumin capture antibody reconstituted with phosphate buffered 
saline (PBS) and diluted to the working concentration of 2ug/ml, was used to coat the ELISA 
microtitre plates (Thermo Scientific, UK) overnight. Three washes in phosphate buffered 
saline with 1% Tween (PBS-T) pH 7.2 were completed. The ELISA plates were blocked with 1% 
BSA in PBS pH 7.2 for 1 hour followed by three further PBS-T washes. Samples were diluted 
in duplicate along with the standard and incubated at room temperature and pressure for 2 
hours followed by 3 PBS-T washes. Biotinylated mouse anti-human serum albumin detection 
antibody diluted with 1% BSA in PBS to the working concentration of 125ng/ml, was added 
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and incubated at room temperature for 2 hours followed by 3 PBS-T washes. Streptavidin 
conjugated to horseradish peroxidase diluted with 1% BSA in PBS was added for 20 minutes 
at room temperature followed by 3 final PBS-T washes. Substrate solution was added 
consisting in a mixture (1:1) of H2O2 and tetramethylbenzidine. The reaction was stopped with 
2M sulphuric acid and the absorbance was read at 450nm and 540nm to correct optical 
imperfections in the plate.  
 
3.3.3.7.3 Cystatin S ELISA 
 
Concentration of cystatin S in UWMS was assessed using ELISA (CST4, Sandwich Cloud Clone 
Corp., USA). Cystatin S (CST4) capture antibody was pre-coated onto the ELISA microplate. 
Samples were diluted in duplicate along with the standard and incubated at 37C for 1 hour 
followed by removing the liquid of each well without washing. Biotinylated mouse anti human 
serum cystatin S detection antibody diluted to the working concentration was added and 
incubated at 37ºC for 1 hour followed by three washes. Streptavidin conjugated to 
horseradish peroxidase was added for 30 minutes at 37ºC and followed by five final washes. 
Substrate solution consisting in a mixture (1:1) of H2O2 and tetramethylbenzidine was added 
for 20 minutes at 37ºC. The reaction was stopped with 2M sulphuric acid and the absorbance 
was read within 5 minutes at 450nm. Detection range 0.156 - 10ng/ml, sensitivity 
<0.066ng/ml. 
 
3.3.3.7.4 Proline Rich Protein ELISA 
 
Concentration of Proline Rich Protein (PRP) in UWMS was assessed using ELISA (Sandwich Kit 
Thermo-scientific Pierce, USA). 
The ELISA microplate was pre-coated with a Human uPA (PRAP1) capture antibody. Samples 
were diluted in duplicate along with the standard and incubated at room temperature for 2.5 
hours followed by four washes. Biotinylated mouse anti human serum PRP detection antibody 
diluted to the working concentration was added and incubated at room temperature for 1 
hour followed by four washes. Streptavidin conjugated to horseradish peroxidase was added 
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for 45 minutes at room temperature and followed by four final washes. Substrate solution 
consisting in a mixture (1:1) of H2O2 and tetramethylbenzidine was added for 30 minutes at 
room temperature. The reaction was stopped with 2M sulphuric acid and the absorbance was 
read within 5-10 minutes at 450 - 540nm to correct optical imperfections in the plate. Elisa 
sensitivity 10pg/ml. 
 
3.3.3.7.5 Statherin ELISA 
 
Concentration of Statherin in UWMS was assessed using ELISA (Sandwich kit Cusabio Biotech 
USA). Statherin capture antibody was pre-coated onto the ELISA microplate. Samples were 
diluted in duplicate along with the standard and incubated at 37 ºC for two hours followed by 
removing the liquid of each well without a wash. Biotinylated mouse anti-human serum 
statherin detection antibody diluted to the working concentration was added and incubated 
at 37ºC for 1 hour followed by three washes. Streptavidin conjugated to horseradish 
peroxidase was added for 1hour at 37ºC and followed by five final washes. Substrate solution 
consisting in a mixture (1:1) of H2O2 and tetramethylbenzidine was added for 20 minutes at 
37ºC. The reaction was stopped with 2M sulphuric acid and the absorbance was read at 
450nm and 540nm to correct optical imperfections in the plate. 
The Detection range of this ELISA was 78 - 5000 ng/mL and the sensitivity was 19.5 ng/mL.  
 
3.3.3.8 Coomassie Brilliant blue (R250) 
 
Coomassie stain was used for the assessment of the overall protein profile of UWMS samples, 
specifically used to detect carbonic anhydrase VI protein band. Pixel intensity of the carbonic 
anhydrase band was assessed in order to determine variations at T0, 1 and 2. 
Coomassie Brilliant Blue R250 (Sigma) was diluted in acetic acid (according to the 
manufacturer’s instructions). Gels were stained for 30 minutes under agitation and de -
stained in 10% (v/v) acetic acid until clear and scanned on an automated image developing 
system, the ChemiDoc MP imaging system (Bio-Rad, Hemel Hempstead, UK). Chemidoc 
images were analysed with Image Lab software (Bio-Rad, Hemel Hempstead, UK). 
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3.3.4 Statistical Analysis  
 
Wilcoxon matched pairs signed rank test was used to indicate differences between same 
patient concentration and secretion rate at T0 (pre IMRT) in comparison to T1 (6 months post 
IMRT) and T2 (12 months post IMRT).  
Repeated measures Friedman test to assess variation of biochemical parameters, total 
protein concentration, secretion rate and specific proteins in saliva within the oral cavity of 
HNC patients at three time point. 
Wilcoxon–Mann–Whitney test to indicate the difference between different locations of 
primary tumour among patients.  
Random effects Generalized Least Squares in a longitudinal panel was the model used to 
analyse the data obtained from several measures taken from the same patients at different 
times, in order to determine the relationship between two variables making a distinction 
between independent and dependent variables. Panel refers to a group of subjects that were 
studied recurrently over time in order to determinate the association between salivary 
proteins and oral mucositis development at T1 (6 months post IMRT) and T2 (12 months post 
IMRT) in comparison to T0 (pre IMRT).  (Longitudinal and panel data: analysis and applications 
in the social sciences. EW Frees - 2004).  
All analysis was carried out using STATA 15.1 (College Station, Texas USA, www.stata.com), 
GraphPad Prism 8 software (La Jolla California USA, www.graphpad .com) and Microsoft Excel 
2018. Results were expressed as a mean ± SEM relative to the variables and ‘n’ represents the 




3.4 RESULTS  
 
3.4.1 Total Protein Concentration (TPC) in UWMS  
 
Mean TPC for patients prior to IMRT (T0) was 2.97 ± 0.31 mg/ml (±SEM). At T1 (6 months post 
IMRT), TPC was reduced to 2.59 ±0.23 mg/ml, compared with pre-radiotherapy protein 
concentration. At T2 (12 months post IMRT), the TPC was significantly increased to 3.74 ±0.32 















Figure 3. 2 Total protein concentration pre (T0) and post IMRT at 6 months (T1) and 12 months 
(T2).  
TPC changed in UWMS pre and post IMRT. Total protein concentration was lower at T1 
compared with T0 (p = 0.68). Conversely at T 2 was significantly increased compared with T0 
and T1 (p = 0.049 and p = 0.008 respectively) (Wilcoxon matched pairs signed rank test). Every 





3.4.2 Total Protein Secretion (TPS) rate in UWMS  
 
Mean TPS rate of HNC patients at T0 was 1.22 ± 0.12 mg/min. At T1 the TPS rate was reduced 
to 0.46 ±0.08 mg/min, which represented a significant reduction compared with pre-
radiotherapy (T0) protein secretion rate. At T2, the TPS rate reached 0.76 mg/min (SEM ± 
0.10) showing a degree of recovery but remained significantly decreased compared to T0 

















Figure 3.3 10 TPS rate variation pre (T0) and post- IMRT at 6 months (T1) and 12 months (T2).  
Total protein secretion rate in UWMS was reduced significantly at the T1 and T2 compared 
with T0 (p < 0.0001 and p = 0.007 respectively). TPS rate in UWMS was reduced significantly 
at T1 in comparison to T2 (p = 0.003) (Wilcoxon matched pairs signed rank test) Every colour 





3.4.3 Specific Protein Analysis of UWMS Pre and Post IMRT 
 
3.4.3.1Mucin 5B Concentration in UWMS 
 
Mucin 5B concentration was investigated in UWMS pre-IMRT (T0) and at T1 (6 months post-
IMRT) and T2 (12 months post-IMRT). Analysis of mucin 5B concentration post IMRT showed 
a significant increase at each of the two-time points (p = 0.0001) compared with T0 (Friedman 















Figure 3. 4 Mucin 5B concentration variation pre- IMRT (T0) and post-IMRT at 6 months (T1) 
and 12 months (T2).  
Mucin 5B concentration in UWMS was increased significantly at T1 and at T2 in comparison 
to T0 (p<0.0001). No statistically significant differences were observed in the mucin 5B 
concentration at T1 and T2 (p = 0.269) (Wilcoxon matched pairs signed rank test) Every colour 
represents an individual participant. Data is represented as mean ± SEM. 
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3.4.3.2 Mucin 5B Secretion Rate (Outcome) in UWMS 
 
Mucin 5B secretion rate post-IMRT was slightly increased at T1 (6 months post-IMRT) and T2 
(12 months post-IMRT), compared with pre-IMRT (T0), reaching the highest value at T2. 
However, no significant differences were found (p = 0.518) (Figure 3.5). 












Figure 3.5 11 Mucin 5B secretion rate variation pre-(T0) and post- IMRT at 6 months (T1) and 
12 months (T2).  
No statistically significant differences were observed in the in mucin 5B secretion rate levels 
were observed at T1 and T2 compared with time point T0 (p = 0.458 and p = 0.2545 
respectively) (Wilcoxon matched pairs signed rank test). Every colour represents 1 




3.4.3.3 Mucin 7 Concentration in UWMS  
 
Mucin 7 concentration was analysed pre and post IMRT. It was observed that post-IMRT the 
concentration of mucin 7 increased significantly (p = 0.005) at the two time points (T1 and T2) 















Figure 3.6 Mucin 7 concentration variation pre-(T0) and post IMRT at 6 months (T1) and 12 
months (T2).  
Mucin 7 concentration in UWMS was increased significantly at T1 and T2 in comparison to T0 
(p=0.0001 and p=0.0062 respectively) (Wilcoxon matched pairs signed rank test). Every colour 





3.4.3.4 Mucin 7 Secretion Rate in UWMS  
 
Analysis of mucin 7 secretion rate data post IMRT revealed an increase at T1 (6 months post 
IMRT) and T2 (12 months post IMRT) compared with T0 (pre-IMRT), reaching the highest value 
at time T2. However, this increase in secretion rate was not statistically significant (p = 0.4651) 














Figure 3. 7 Mucin 7 secretion rate variation pre-(T0) and post IMRT at 6 months (T1) and 12 
months (T2).  
No significant differences were observed in mucin 7 secretion rate levels between T0 and T1 
and T2 (p = 0.6653 and p = 0.3896 respectively). No statistically significant differences were 
observed in mucin 7 secretion rate between T1 and T2 (p = 0.9779) (Wilcoxon matched pairs 




3.4.3.5 Secretory IgA Concentration in UWMS   
 
Analysis of IgA concentration post IMRT showed slight increase at T 1 (6 months post IMRT) 
and T 2 (12 months post IMRT) compared with T 0 (pre IMRT). IgA concentration reaching the 
highest value at T 2, however no significant differences were found (p = 0.1699) a cross the 
three time points (Friedman Test) (Figure 3.8).   
 











Figure 3.8 IgA concentration variation pre (T0) and post IMRT at 6 months (T1) and 12 months 
(T2).  
No significant difference was observed in IgA concentration at T1 and T2 in comparison to T0 
(p = 0.339, p = 0.99 respectively). no significant difference between T1 and T2 (p = 0.8553) 
(Wilcoxon matched pairs signed rank test). Every colour represents 1 participant. Data is 




3.4.3.6 IgA Secretion Rate in UWMS 
 
Analysis of IgA secretion rate post IMRT was slightly increased at T1 and T2 compared with 
T0, reaching the highest value at T2. However, this increase was not statistically significant (p 















Figure 3.9 IgA secretion rate variation pre (T0) and post IMRT at 6 months (T1) and 12 months 
(T2).  
No significant difference was observed in IgA secretion rate at T1 and T2 in comparison to T0 
(p =0.1252 and p= 0.3053 respectively). There was no significant difference between T1and 
T2 (p =0.5088) (Wilcoxon matched pairs signed rank test). Every colour represents 1 




3.4.3.7 α -Amylase Concentration in UWMS  
 
α-Amylase concentration post IMRT was reduced at T1 (55.83 ± 9.57) reaching the lowest 
level compared with T0 (112.63 ± 16.71) and T2 (111.08 ± 15.40). Though α-amylase 
concentration variation was not significant (p = 0.073) across the 3 time points (Friedman 














Figure 3.10 α-Amylase unit variation pre (T0) and post IMRT at 6 months (T1) and 12 months 
(T2).  
α-Amylase units in UWMS was reduced significantly at T1 compared with T0 and T2 (p= 0.0003 
and p = 0.0081 respectively). No difference was observed between T0 and T2 (p= 0.7) 
(Wilcoxon matched pairs signed rank test). every colour represents 1 participant. data is 




3.4.3.8 α-Amylase Unit Secretion Rate in UWMS 
 
α-Amylase unit secretion rate (mean value) post IMRT was reduced at T1 (11.87 ± 3.99) 
reaching the lowest level compared with T0(48.51 ± 6.77) and T2(23.34 ± 4.34). α-Amylase 
unit secretion rate variation varied significantly at all 3 time points (p < 0.0001) (Friedman 

















Figure 3.11 α-Amylase secretion rate pre (T0) and post IMRT at 6 months (T1) and 12 months 
(T2).  
α-Amylase unit secretion rate was significantly reduced at T1 and T2 in comparison to T0 (p < 
0.0001 and p 0.003 respectively). α-amylase unit secretion rate was significantly reduced at 
T1 in comparison to T2 (p = 0.0291) (Wilcoxon matched pairs signed rank test). Every colour 





3.4.3.9 Albumin Concentration in UWMS 
 
Albumin concentration post IMRT was increased at T1 (98.35 ± 13.29) reaching the highest 
level compared with T0 (64.5 ± 13.01) and T2 (55.8 ± 10.8). Moreover, albumin concentration 
















Figure 3.12 Albumin concentration pre (T0) and post IMRT at 6 months (T1) and 12 months 
(T2).  
Albumin concentration in UWMS was significantly increased at T1 in comparison to T0 and T2 
(p = 0.0249 and p0.0029 respectively). No statistically significant differences were observed 
in albumin concentration between T2 and T0 (p = 0.256) (Wilcoxon matched pairs signed rank 






3.4.3.10 Albumin Secretion Rate  
 
Albumin secretion rate post IMRT was decreased at T1 (16.55 ± 3.24) compared with T0 (25.00 
± 5.45) as well as at T2 (11.29 ± 2.76). Moreover, albumin secretion rate varied significantly 
















Figure 3.13 Albumin secretion rate pre (T0) and post IMRT at 6 months (T1) and 12 months 
(T2).  
Albumin secretion rate was significantly reduced at T2 in comparison to T0 (p = 0.0057). No 
significant difference at T1 in comparison to T0 (p=0.3149). Albumin secretion rate was 
significantly reduced at T2 in comparison to T1 (p = 0.0099) (Wilcoxon matched pairs signed 






3.4.3.11 Cystatin S Concentration in UWMS   
 
Cystatin S concentration post IMRT was decreased at T1 (4.68 ±0.57) as well as at T2 (7.50 
±0.99) compared with T0 (14.25 ± 1.039). Cystatin S concentration varied significantly across 

















Figure 3.14 Cystatin s concentration variation pre (T0) and post IMRT at 6 months (T1) and 12 
months (T2).  
Cystatin S concentration in UWMS was significantly decreased at the T1 and T2 in comparison 
to T0 (p= 0.0001). Cystatin S concentration was significantly decreased at T1 in comparison to 
T2 (p=0.0096, Wilcoxon matched pairs signed rank test). Every colour represents 1 






3.4.3.12 Cystatin S Secretion Rate in UWMS  
 
Cystatin S secretion post IMRT was decrease at T1 (0.88 ±0.24) as well as at T2 (1.99 ± 0.39) 
compared with T0 (6.98 ± 0.97). Cystatin S concentration varied significantly across the 3 time 


















Figure 3.15 Cystatin S secretion rate variation pre (T0) and post IMRT at 6 months (T1) and 12 
months (T2).  
Cystatin S secretion rate in UWMS was significantly decreased at the T1 and T2 compared 
with T0 (p<0.0001, p=0.0003 respectively). Cystatin S secretion rate in UWMS was significantly 
decreased at T1 in comparison to T2 (p=0.0187) (Wilcoxon matched pairs signed rank test). 






3.4.3.13 Proline Rich Protein (PRP) Concentration in UWMS  
 
PRP concentration post IMRT was slightly decreased at T1 (0.76 ± 0.16) as well as at T2 (0.632 
± 0.11) compared with T0 (0.889 ± 0.20). PRP concentration in UWMS did not vary across the 















Figure 3.16 a Proline rich protein (PRP) concentration variation pre (T0) and post IMRT at 6 
months (T1) and 12 months (T2).  
No significant differences in PRP concentration at T1 and T2 compared with T0 (Wilcoxon 
matched pairs signed rank test). Every colour represents 1 participant. Data is represented as 






3.4.3.14 Statherin Concentration in UWMS  
 
Statherin concentration post IMRT was decreased at T1 (3.29 +0.4) compared with T0 (4.55 + 
0.48). In contrast at T2 this was increased reaching the highest values (7.57 + 1.10). There was 
no significant difference between statherin concentration across the 3 time points (p = 0.72) 















Figure 3.17 Statherin concentration variation pre (T0) and post IMRT at 6 months (T1) and 12 
months (T2).  
No significant difference in Statherin concentration seen at T1 and T2 compared with T0 (p = 
0.6982 and p = 0.1763 respectively). No difference was observed between T1 and T2 
concentration (p 0.3804) (Wilcoxon matched pairs signed rank test). Every colour represents 






3.4.3.15 Carbonic Anhydrase VI (CA VI) Pixel Intensity    
 
Post IMRT CA VI pixel intensity (mean value) showed an increase at T1 (2413 ± 418.2) as well 
as at T2 (1596 ± 227.44) in comparison with T0 (1464.97 ± 27). No significant differences in 


















Figure 3.18 Carbonic Anhydrase VI (CAVI) pixel intensity in UWMS variation pre (T0) and post 
IMRT at 6 months (T1) and 12 months (T2).  
CA VI pixels intensity in UWMS was increased significantly at T1compared with T0 (p0.0498). 
No significant difference at T2 in comparison to T0 pixels intensity (p = 0.893) (Wilcoxon 
matched pairs signed rank test). Every colour represents 1 participant. Data is represented as 






3.4.3.16 Carbonic Anhydrase VI (CA VI) Pixel Intensity Secretion Rate  
 
Post IMRT CA VI pixel intensity secretion rate decreased at T1 (427.1 ± 92.51) as well as at T2 
(269.5 ± 51.66) compared with T0 (668.2 ±132.3), reaching the lowest point at T2.  Significant 
differences in CA VI pixel intensity secretion rate were observed at T1 and T2 compared to T0 




















Figure 3.19 Carbonic Anhydrase VI (CA VI) Coomassie blue pixel intensity in UWMS variation 
pre (T0) and post IMRT at 6 months (T1) and 12 months (T2).  
CA VI pixels intensity secretion rate in UWMS was decreased significantly at the T2 compared 
with T0 (p 0.0243) (Wilcoxon matched pairs signed rank test). Every colour represents 1 






3.4.4 Longitudinal associations between clinical assessment outcomes and salivary protein 
analysis post IMRT at 6 months (T1) and 12 months (T2) by using Random effects Generalised 
Least Squares linear regression.  
 
In addition to the analysis of the influence of IMRT on these salivary proteins, it was assessed 
the possible association between clinical measures reported in Chapter 2 and total protein 
concentration, secretion rate along with these specific salivary proteins regarding their 
functions that represent clinical relevance in maintaining salivary properties. Protein variation 
in concentration and secretion rate might hasten the onset and progression of oral diseases 
along with changing saliva viscoelastic and protective properties (Hannig et al., 2017; Pitts et 
al., 2017).  
Salivary flow rate  
In this section it was investigated the probable association between altered biochemical 
composition of saliva and the significantly reduced salivary flow rate post IMRT that was 
reported in chapter 2, in order to analyse the dependence between clinical observations and 
biological composition of saliva that make up its functionality (Jawad et al., 2015).  
When comparing associations between oral salivary flow rate and total protein concentration 
and secretion rate there was a significant association at both time points post IMRT (Table 
3.1 and 3.2) 
Regarding mucins 5B and 7, there were statistically significant association between increased 
concentrations of both mucins in a reduced salivary volume. Mucins secretion rate was not 
significantly different after IMRT (Figure 3.5 and 3.7), and significantly associated with salivary 
flow rate post IMRT (Table 3.4 and 3.6) 
This study found that there were statistically significant associations for α-amylase unit and 
secretion rate and salivary flow rate at T1 and T2 (p <0.0001) (Table 3.7 and 3.8). In keeping 
with the pattern of significance at T1 and T2, a reduced cystatin S concentration and secretion 
rate (Figure3.14 and 3.15) were both significantly associated with salivary flow rate at Time 





Salivary flow rate  
Table 3.1 Association between salivary flow rate and total protein concentration (TPC) post-
IMRT at 6 months (T1) and 12 months (T2). 
 
SFR / TPC Coefficient   P [95% Conf. Interval] 
T0 -0.025 0.004 -0.043 -0.008 
T1 -0.308 0.0001 -0.373 -0.242 
T2 -0.197 0.0001 -0.265 -0.129 
 
Table shows significant association between salivary flow rate and total protein concentration 
(TPC) post-IMRT at 6 months(T1) (p=0.0001) and significant correlation at 12 months (T2) 
(p=0.001). 
 
Table 3.2  Association between salivary flow rate and total protein secretion rate (TP SR) post-
IMRT at 6 months (T1) and 12 months (T2). 
 
SFR / TP SR Coefficient   P [95% Conf. Interval] 
T0 0.146 0.0001 0.099 0.193 
T1 -0.185 0.0001 -0.255 -0.115 
T2 -0.146 0.0001 -0.211 -0.080 
 
Table shows significant association between salivary flow rate (SFR) and total protein 
secretion rate (TP SR) post-IMRT at 6 months (T1) (p=0.0001) and significant correlation at 12 






Table 3.3 Association between salivary flow rate and mucin 5B (MUC 5B) concentration post-
IMRT at 6 months (T1) and 12 months (T2). 
 
SFR / MUC 5B Coefficient  P [95% Conf. Interval] 
T0 0 .0003  0.157 -0.0001 0.0008 
T1  -0.341  0.0001 -0.426 -0.255 
T2  -0.257  0.0001 -0.341 -0.173 
  
Table shows significant association between salivary flow rate (SFR) and MUC 5B 




Table 3.4 Association between salivary flow rate and mucin 5B secretion rate (MUC 5B SR) 
post-IMRT at 6 months (T1) and 12 months (T2). 
 
SFR /MUC 5B 
SR 
Coefficient  P [95% Conf. Interval] 
T0 0.004  0.0001 0.0033 0.004 
T1  -0.315 0.0001 -0.373 -0.257 
T2 -0.258 0.0001  -.0319 -0.198 
 
Table shows significant association between salivary flow rate (SFR) and MUC 5B SR post-








Table 3.5  Association between salivary flow rate and mucin 7 (MUC 7) concentration post-
IMRT at 6 months (T1) and 12 months (T2). 
 
SFR/ MUC 7  Coefficient P [95% Conf. Interval] 
T0 0.0002 0.634 -0.0007 0.001 
T1  -0.299 0.0001 -0.366 -0.231 
T2  -0.216 0.0001 -0.283 -0.148 
 
Table shows significant association between salivary flow rate (SFR) and MUC 7 concentration 




Table 3.6 Association between salivary flow rate and mucin 7 secretion rate (MUC 7 SR) post-
IMRT at 6 months (T1) and 12 months (T2). 
 
SFR/ MUC7 SR Coefficient  P [95% Conf. Interval] 
T0 0.0002  0.674 -0.0008 0.001 
T1 -0.294  0.0001 -0.359 -0.230 
T 2 -0.217  0.0001 -0.285 -0.149 
 
Table shows significant association between salivary flow rate (SFR) and MUC 7 secretion rate 







Table 3.7 Association between salivary flow rate and α-amylase unit (U) post-IMRT at 6 




Coefficient P [95% Conf. Interval] 
T0 0.0004 0.046 -0.0008 -7.71e-06 
T1 -0.323 0.0001 -0.395 -0.251 
T2  -0.214 0.0001 -0.285 -0.143 
 
Table shows significant association between salivary flow rate (SFR) and α-amylase U post-
IMRT at 6 months (T1) (p=0.0001) and significant correlation at 12 months (T2) (p=0.001). 
 
 
Table 3.8 Association between salivary flow rate and α-amylase unit secretion rate (U SR) 
post-IMRT at 6 months (T1) and 12 months (T2). 
 
SFR/ α-
AMYLASE U SR 
Coefficient P [95% Conf. Interval] 
T0 0.002 0.0001 0.001 0.003 
T1 -0.200 0.0001 -0.276 -0.125 
T 2  -0.145 0.0001 -0.218 -0.072 
 
 
Table shows significant association between salivary flow rate (SFR) and α-amylase U SR post-





Table 3.9 association between salivary flow rate and cystatin S concentration post-IMRT at 6 
months (T1) and 12 months (T2). 
 
SFR/ Cystatin S Coefficient  P [95% Conf. Interval] 
T0 0.011 0.001 0.004 0.018 
T1 -0.196 0.0001 -0.290 -0.102 
T 2  -0.143 0.001 -0.229 -0.058 
 
Table shows significant association between salivary flow rate (SFR) and cystatin S 
concentration post-IMRT at 6 months (T1) (p=0.0001) and significant correlation at 12 months 
(T2) (p=0.001). 
 
Table 3.10 Association between salivary flow rate and cystatin S secretion rate (SR) post-IMRT 
at 6 months (T1) and 12 months (T2). 
 
SFR / Cystatin S 
SR 
Coefficient  P [95% Conf. Interval] 
T0 0.028 0.0001 0.021 0.035 
T1 -0.141 0.0001 -0.210 -0.071 
T2 -0.076 0.034 -0.146 -0.005 
 
Table shows significant association between salivary flow rate (SFR) and cystatin S SR post-





Dry mouth report  
Dry mouth feeling reported by patients through answering a question extracted from a full 
questionnaire (Fox et al., 1987) was significantly increased a post IMRT at time point 1 and 
2.  
Total protein secretion rate was significantly reduced post IMRT (Figure 3. 3) and positively 
and significantly associated with dry mouth feeling reported by patients after IMRT at time 
point 1 and 2 (Table 3. 11).  Additionally, dry mouth feeling reported by patients showed a 
strong positive association with mucin 5B and 7 concentration (Table 3.12 and 3.14) and 
secretion rate (Table 3.13 and 3.15); there were both significantly associated at T1 and T2.  
 
Table 3.11 Aassociation between dry mouth feeling reported by patients and total protein 




Coefficient P [95% Conf. Interval] 
T0 -0.035 0.302 -0.101 0.031 
T1 0.890 0.0001 0.789 0.991 
T2  0.920 0.0001 0.825 1.015 
 
Table shows significant association between dry mouth feeling reported by patients and TP 








Table 3.12 Association between dry mouth feeling reported by patients and mucin 5B 
concentration (MUC 5B) post-IMRT at 6 months (T1) and 12 months (T2). 
 
Dry mouth 
feeling/ MUC 5B 
Coefficient P [95% Conf. Interval] 
T0 -0.0002 0.349 -0.0009 0.0003 
T1 0.949 0.0001 0.835 1.062 
T 2 0.962 0.0001 0.851 1.073 
 
 
Table shows significant association between dry mouth feeling reported by patients and 
mucin 5B post-IMRT at 6 months (T1) (p=0.0001) and significant correlation at 12 months (T2) 
(p=0.0001). 
 
Table 3.13 Association between dry mouth feeling reported by patients and mucin 5B 




Coefficient P [95% Conf. Interval] 
T0 -0.002 0.1 -0.003 -0.001 
T1  0.925 0.0001 0.836 1.013 
T2  0.956 0.0001 0.864 1.048 
 
Table shows significant association between dry mouth feeling reported by patients and MUC 





Table 3.14 Association between dry mouth feeling reported by patients and mucin 7 
concentration (MUC 7) post-IMRT at 6 months (T1) and 12 months (T2). 
 
Dry mouth 
feeling/ MUC 7 
Coefficient  P [95% Conf. Interval] 
T0 0.00005 0.933 -0.0011 0.001 
T1 0.917 0.0001 0.828 1.007 
T 2 0.936 0.0001 0.847 1.024 
 
Table shows significant association between dry mouth feeling reported by patients and 
mucin 7 post-IMRT at 6 months(T1) (p=0.0001) and significant correlation at 12 months (T2) 
(p=0.0001). 
 
Table 3.15 Association between dry mouth feeling reported by patients and mucin 7 secretion 





Coefficient P [95% Conf. Interval] 
T0  0.0001 0.821 -0.001 0.001 
T1 0.918 0.0001 0.832 1.003 
T 2 0.934 0.0001 0.844 1.024 
 
Table shows significant association between dry mouth feeling reported by patients and 







Taste report  
Taste variation reported by patients through answering a question extracted from a full 
questionnaire (LENT-SOMA) was significantly increased a post IMRT at time point 1 and 2.  
CA VI concentration post IMRT (Figure 3.18) was negatively and significantly associated with 
an increased taste variation reported by patients at T1 (p=0.0001.) and T2 (p=0.003), (Table 
3.16) in the same pattern a reduced CAVI  secretion rate which appeared to be significantly 
associated at both time point  (Table 3.17).   
 
Table 3.16 Association between presence of taste alteration dysgeusia reported by patients 




report/CAVI   
Coefficient P [95% Conf. Interval] 
T0 -0.0001 0.576 -0.0003 0.0005 
T1 -0.614 0.0001 -0.0801 -0.428 
T2 -0.501 0.0001 -0.700 -0.303 
 
Table shows significant association between taste variation reported by patients and CA VI 












Table 3.17 Association between presence of taste alteration dysgeusia reported by patients 
and carbonic anhydrase VI (CA VI) secretion rate (SR) post-IMRT at 6 months (T1) and 12 




Coefficient P [95% Conf. Interval] 
T0 -0.0001 0.077 -0.002 0.0001 
T1  -0.676 0.0001 -0.853 -0.5 
T2  -0.465 0.0001 -0.661 -0.269 
 
Table shows significant association between taste variation reported by patients and CA VI SR 



















Table 3.18 Summary of protein variation post IMRT at T1 and T2. 
UWMS T1  T2   
Total protein concentration  <NS  >* 
Total protein secretion rate <****  <** 
MUC 5B concentration 





MUC 7 concentration 






IgA secretion rate 
















Cystatin S concentration 





PRP concentration <NS <NS 
Statherin concentration <NS 
 
 >NS 
CA VI Pixel intensity  


















3.5 Discussion  
 
It is important to note that there is a small number of longitudinal studies that observed the 
biochemical composition of saliva in HNC patients undergoing radiotherapy. The vast majority 
of studies in HNC patients that evaluated salivary proteins were performed during and /or 
post radiotherapy (short term follow up), collecting different types of saliva (stimulated, 
UWMS, gland separately), analysing a limited number of biochemical components and 
providing contradictory results. They attempted to draw conclusions regarding radiotherapy 
oral sequelae linked with quality of life, leaving more questions than answers. Additionally, 
many of the studies were cross-sectional and collected saliva post radiotherapy only, without 
baseline data collected prior to radiotherapy (Funegård et al., 1994; Almståhl et al., 2001; 
Eliasson et al., 2005; Hannig et al., 2006; Vidotto et al., 2010; Dijkema et al., 2012; Laheij et 
al., 2015).  
It is presumed that such study limitations were due to the challenges of sample collection in 
this group of patients, due to the lack of a steady salivary flow in HNC patients post-
conventional radiotherapy (Almståhl et al., 2001), along with the development of side effects 
during and post cancer therapy. The presenting oral symptoms and sequelae can make saliva 
sample collection difficult. In addition, cancer patients will have multiple medical and dental 
assessments pre and post radiotherapy, reducing study protocol compliance.  
Another reason for the limited scope of past studies, it is the difficulty in reproducing 
standardised conditions during saliva collection techniques. For example, it is crucial to 
maintain similar clinical conditions (drinking, eating, time of the day) to avoid circadian 
variations in salivary flow rate and composition, whilst also maintaining standardised 
methods of transport, storage and laboratory testing to assess salivary components.  
Another important factor is clinical staff availability and additional time needed during their 
dental appointment to collect samples. Moreover, usually studies analysing salivary 
composition are expressed in the concentration of proteins per millilitres of saliva present in 
the oral cavity only, without considering secretion rate of proteins which is a stronger 
indicator, due to the consideration of salivary flow rate.  
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In this context of the limited scope of past studies and to the author’s knowledge, the present 
study is one of the largest longitudinal studies in HNC patients analysing the organic 
composition and secretion rate of unstimulated whole mouth saliva pre and post IMRT, 
enrolling 40 patients, across a period of 12 months following IMRT, providing a 
comprehensive analysis of salivary component variation post IMRT, and establishing a 
baseline prior to radiotherapy. The 9 proteins that were selected for analysis are all associated 
directly with oral health, mucosal and teeth protection, antibacterial, rheological properties, 
remineralisation microbial homeostasis; therefore they can have the potential to act as 
predictive markers of the two most common acute and late radiotherapy side effects - oral 
mucositis and radiotherapy caries, as well as other oral symptoms such as dry mouth and 
taste perception.  
Given that past studies of IMRT have found that it does not fully spare the surrounding tissues, 
when measured in terms of salivary flow rate (Dijkema et al., 2008), xerostomia (Dijkema et 
al., 2010), and other oral symptoms such as hyposalivation in general (Nutting et al., 2011; 
Nguyen et al., 2018), this study proposed the hypothesis that ionising-radiation, delivering a 
high radiation dose to the tumour, with PG-sparing IMRT, has no sparing effects on the 
surrounding tissues of salivary glands, and will still affect the salivary output, specific protein 
concentrations and secretion rate profile at  6- and 12-months post -IMRT.  
Past studies have established that altering protein compositions will increase the possibility 
of disturbing the equilibrium in microbial species in the oral cavity, reducing remineralisation, 
increasing erosion, and reducing food clearance process resulting in higher risk of developing 
oral diseases (Carpenter, 2013a; H. L. Gibbins et al., 2014; Kilian et al., 2016; Hannig et al., 
2017). In order to measure these factors, UWMS, total protein concentration and secretion 
rate were measured at every time point as a general indicator of altered salivary gland 







3.5.1 Total protein Concentration and Secretion Rate  
 
Total protein concentration, at T1, was reduced (Figure 3.2) however not to a statistically 
significant extent. Furthermore, the reduction was not to the same extent as the observed 
reduction in total protein secretion rate (Figure 3.3).  
However, whilst total protein concentration recovered, and even increased to a statistically 
significant extent beyond baseline figures, at T2 (12 months post-IMRT), in contrast, the total 
protein secretion rate remained significantly reduced in comparison to baseline T0. The 
increase in concentration is explained by the significant reduction in the volume of saliva 
along with the rose in secretion rate at T2 compared with T1.  
In addition, Table 3.1 showed negative and significant correlations between these two 
parameters post IMRT at both time points.  A lower secretion rate is indicative of decreased 
protein production and could be explained by the direct toxicity from radiotherapy in salivary 
glands during cancer treatment, producing  direct DNA damage, impairing the cellular division 
leading to death and senescence of those cells that were trying to complete this process, as a 
result acinar cells will not be replenished with new ones, along with general inflammatory 
reaction and fibrosis of the gland interstitium, (Vissink et al., 2010; Pringle et al., 2013), these 
might be the causations that result in salivary gland hypofunction clinically observed as a 
reduced flow rate, altered composition and symptoms that patients reported.  However, this 
association between cell apoptosis and salivary gland altered function remains unclear in the 
literature. Another possible explanation, suggested by past studies is cell membrane damage 
induced by RT leading to lysis of acinar cells and granules leakage will induce salivary gland 
dysfunction (Vissink et al., 2010; Pringle et al., 2013).  
This study reported that salivary gland dysfunction, when observed in the form of salivary 
flow rate and total protein secretion rate, continues one-year post IMRT. Furthermore, the 
study demonstrated significant associations post IMRT at T1 and T2 (Table 3.2) between these 
two parameters. 
These outcomes are in keeping with findings from past studies that have shown biochemical 
compositional changes, as well as flow rates, are altered post radiotherapy – whether the 
radiotherapy was conventional radiotherapy or IMRT. In general, patients that have received 
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more than 30 Gy are affected by such changes (Dijkema et al., 2012; Gao et al., 2016; Richards 
et al., 2017).  
Conversely, the study conducted by Hannig et al.,(2006), analysing UWMS from 10 HNC 
patients post radiotherapy compared to 10 control subjects, reported no differences in total 
protein concentration. However, a high variation among this small group of cancer patients 
was found. The exact number of months post radiotherapy of saliva collection for each patient 
was not discussed, which is important as has been shown in this study, total protein 
concentrations are significantly different between 6- and 12-months post IMRT.  
Therefore, in order to further solidify the theory, given Hanning et al 2006 data’s, further 
analysis was carried out to identify the specific protein concentration and secretion rate 
alterations associated with specific glands. This would allow identification of the clinical 
avenues to handle IMRT follow-ups by knowing the specific glands and salivary makeup that 
are altered at each time point.  
 
3.5.2 Specific Protein Analysis of UWMS Pre and Post IMRT 
 
PAS staining of UWMS glycoproteins demonstrated how mucin 5B and mucin 7 were both 
strongly affected by radiotherapy. Analysis of each mucin noted the increased concentration 
of mucin 5B and 7 at T1 in comparison to pre-IMRT (T0). This is all whilst maintaining the same 
levels of secretion for mucin 5B and 7, at all-time points. It should be noted that variance in 
data points for mucin 7 at T2, does not change the overall observation that the salivary 
structure would have fundamentally changed for the patients. 
Past studies have proposed the possibility that the patients would have been able to feel the 
increased concentrations of mucin 5B and mucin 7, as increased levels of these mucins raise 
the viscosity of saliva and ultimately alter the rheological properties of saliva (Inoue et al., 
2008).  
In accordance with the data presented in this study, Randall et al., (2013) reported that during 
IMRT, mucin 5B concentrations in stimulated whole mouth saliva were increased in 20 HNC 
patients along with a significant reduction of salivary flow rate. However, that study only 
lasted 6 weeks, making it difficult to draw conclusions regarding protein variation post the 
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cancer treatment, and furthermore the Randall study, like most other studies that have 
assessed mucin concentrations, have utilised patients’ stimulated whole mouth saliva likely 
due to difficulties in obtaining enough UWMS post radiotherapy in order to make valid 
comparisons.  
Unlike Randall et al., (2013), some past studies have reported decreased secretion rate of 
mucin 5B in stimulated saliva collected from HNC patients (Almståhl et al., 2001; Dijkema et 
al., 2012). However, each study protocol differed, with Almståhl et al., (2001) comparing 
radiotherapy patients’ stimulated saliva with those of healthy control samples,  
rather than the same patients prior to radiotherapy; Dijkema et al., (2012)utilised stimulated 
submandibular saliva of patients in two groups – comparing those with none/mild xerostomia 
and those with severe xerostomia. Although this in and of itself may be drawing inconsistence 
conclusions, as it has long been established that mucin 5B concentrations are associated with 
dry mouth reports by patients.  
What we can infer from these results is that because the secretion rates were maintained and 
not changed for mucin 5B and 7, at all-time points, then the mucin secreting glands were 
spared, at least functionally, by IMRT in this patient cohort.  Sublingual glands are the major 
contributors of both mucins, along with minor salivary glands, so it can be inferred that at 
least one of these glands were spared by IMRT in these patients.  
It might be possible that the patients were capable of glandular recovery from the side effects 
of radiotherapy by T1, judging by their mucin secretion rates remaining similar to baselines, 
despite the fact that there was a reduced total protein secretion rate and  salivary flow rate, 
this might be a mechanic compensation of the lack of total protein or due to an altered 
functionality as a result of a different glycoprotein structure, it would be important to assess 
salivary flow rate in minor salivary glands along with mucin 5b and 7 concentration and 
secretion rate. It is important to remark that there was no significant difference in 
concentration and secretion rate of these mucins regarding different tumour location in this 
group of patients which is why it is important to study different locations through the mouth 
including palatal, buccal and labial minor glands.   
The increased concentrations of both mucins in UWMS post radiotherapy in this study may 
be connected to the xerostomia reported by patients, this was suggested by the significant 
association at time point 1 and 2 between dry mouth feeling reported with an increased 
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mucin 5B and 7concentration (Table 3.12  And 3.14) and mucins secretion rate in saliva 
observed at T1 and T2 (Table 3.3 and 3.5 respectively). Whilst the mucins alter the rheological 
properties of saliva (Inoue et al., 2008), there is also a further aspect of diminished lubrication 
of oral mucosa in the oral cavity as a result of the increased mucin 5B and mucin 7. There is a 
lack of information in relation to this phenomena in HNC patients, however it has been well 
established that the mucosal pellicle formation requires mucin- mucin interactions driven by 
mucin 1, which is secreted by minor salivary glands and it is expressed by epithelial cells 
membrane (Hannig et al., 2017). A lack of this protein will impair pellicle formation 
diminishing the possibility of binding mucin 5B and 7 to oral mucosa (Lynge Pedersen and 
Belstrøm, 2019), it would be therefore interesting to investigate the concentration of this 
protein in mucosal boundaries in future studies. Mucin 1 present in the surface of oral 
epithelium is defined as a membrane associated glycoprotein present mainly in the buccal 
and labial surfaces(Pedersen et al., 2018).   
Another possible connection between dry mouth and an increased mucin concentration is an 
altered mucin molecular composition affecting protein carbohydrate proportion, resulting in 
an altered lubrication property and making mucins more vulnerable to proteolytic 
degradation (Takehara et al., 2013). The Chaudhury group found similar results in 2015 to this 
present study, in so far as patients were suffering from dry mouth, that mucin 5B and mucin 
7 were at similar secretion levels, if not slightly higher. But they attributed signs of xerostomia, 
exhibited by patients despite the abundance of these moisture-retaining proteins, to a 
potential loss of the lubricating and retention/adhesion properties of saliva caused by 
structural changes in glycosylation ratio per unit of protein(Chaudhury et al., 2015).   
Therefore, knowing that mucin 5B is amongst the main constituents of the mucosal pellicle, 
along with the IgA forming complex with mucin 7(Dawes et al., 2015; H. L. Gibbins et al., 2014; 
Vissink et al., 2010). IgA is the next logical bio-compositional aspect of saliva to study. 
Similarly, to the mucins, IgA secretion rate did not vary at any time points post radiotherapy 
in UWMS. This could mean that there were increased quantities of IgA in relation to total 
protein secretion rate, reflecting that some salivary glands were less affected by radiotherapy 
and maintained salivary production and compensated for the disfunction of other glands. A 
negative association between this protein and flow rate has been reported (Kugler et al., 
1992; Närhi et al., 1994; Eliasson et al., 2005).  
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However, when comparing IgA concentrations, this theory might be disproven, as 
concentration levels of IgA also did not alter at any time point following IMRT. This has been 
in line with past studies that observed IgA concentrations in patients would either remain 
stable (Eliasson et al., 2005), or increased short term, returning to baseline in samples 
collected after one year (Funegård et al., 1994). More recently Richard et al 2017 studied 26 
HNC patients Pre and Post IMRT and also reported no significant variation at 3-6 months, as 
well as at 12 months post IMRT in unstimulated parotid saliva when compared with baseline 
IgA concentrations. It is well known that minor salivary glands are a major source of IgA in the 
oral cavity (Sonesson et al., 2003; Eliasson et al., 2005; Eliasson and Carlén, 2010). As IgA 
secretions were unaffected by IMRT in this study, it can be inferred that the minor glands 
were spared, or at least functionally recovered by T1. This is similar to the previous mucins 
results that inferred that sublingual gland or again minor salivary glands were probably spared 
by IMRT treatments.  
Having observed sublingual, as well as minor gland function, through mucins and IgA acting 
as possible functional biomarkers, α -amylase is the next protein to observe as it is the most 
abundant protein in saliva secreted by parotid glands (Carpenter, 2013b) as well as is the 
single most abundant protein in ductal saliva(H. L. Gibbins et al., 2014),  serving as an indicator 
of serous gland function as well as reflecting any cell damage. A reduction in secretion rate of 
this protein would be an indicator of altered functioning of the parotid gland as a result of 
radiotherapy dose (Almståhl et al., 2001; Hannig et al., 2006).  
The aforementioned reduction is precisely what occurred, with both α-amylase unit 
(measuring catalytic activity) and α-amylase secretion rate significantly reduced post IMRT, 
along with a significant association of this protein concentration and secretion rate with a 
reduced salivary flow rate at both time points (Table 3.7 and 3.8),  showing that parotid glands 
were affected by IMRT, at T1 and T2, with parotid gland secretion capacity reduced as 
demonstrated by α-amylase. The reduced α-amylase concentration in saliva post 
radiotherapy is in accordance with findings of Almståhl et al., (2001), who found that the 
reduced concentration of α-amylase along with hyposalivation may indicate a loss of serous 
cell function. Similarly, De Barros Ponte et al 2004 found a significant reduction of salivary α-
amylase activity, presented by units, post irradiation in stimulated whole mouth saliva, mainly 
secreted by parotid glands.  
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The recovery of amylase catalytic activity, as measured by units, in T2, which was to an extent 
that is statistically not-significantly different from baseline measurements, was not replicated 
in secretion rates as α-amylase secretion rate at T2 was still significantly lower than baseline 
rates. This could be associated with the slight salivary flow rate recovery at T2 reported in 
chapter 2 and corroborated by the significant association showed in this chapter at the same 
time point. This is keeping in line with similar findings in a non-cancer patient, whereby 77 
subjects affected by rheumatological diseases were reported to have shown reduced α-
amylase levels in unstimulated whole mouth saliva compared with controls (Helenius et al., 
2005).   
This recovery of α-amylase units to baseline levels is keeping in line with Hannig et al., (2006), 
who reported that there were no differences in α-amylase levels between 10 HNC patients 
treated with radiotherapy and controls. It is important to note that these patients  underwent 
to IMRT between 6 and 12 months prior the sample collection, therefore the time frame of 
the sample collection is important because this current study observed an increase in α-
amylase units per ml of saliva post 12 months of finished IMRT, as well as a slightly but not 
significantly increased secretion rate of this enzyme, therefore it can be inferred that Hanning 
et al’s findings were perhaps closer to the 12 month point of the 6 to 12months time range. 
Another known side effect of HNC radiotherapy, besides xerostomia, is stomatitis and in 
particular inflammation of the oral mucosa (Sciubba and Goldenberg, 2006), with more than  
two-thirds of radiation and chemotherapy-treated HNC patients developing severe mucositis, 
due to the cytotoxic effects of inflammation on epithelial tissue  (Sonis, 2011; Epstein et al., 
2012; Villa and Sonis, 2015). Albumin concentration in saliva can act as a good biomarker in 
detecting the presence of oral mucositis as it has been related to inflammatory process in 
salivary glands and serum leakage (Jensen et al., 2003).  
The present study found that albumin concentration was statistically significantly higher in 
UWMS in patients post IMRT at T1, whilst secretion rate remained at a statistically non-
significantly changed level. This indicates that the oral side effects of RT, particularly 
inflammation could have provoked epithelial disruption, making the oral mucosa very fragile 
causing plasma leakage and the direct side effect on salivary glands causing inflammatory 
reactions, as shown by the increase in albumin concentration.  
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However, at T2, albumin concentration was significantly reduced to levels similar to pre IMRT. 
Furthermore, secretion rate was also reduced at T2, being significantly lower than both time 
points 0 and 1, indicating a recovery of the oral mucosa over time. Moreover, the increased 
concentrations found at T1, could potentially be linked to the severe lack of saliva at that time 
point. However, this would be only 1 factor involved as salivary flow rates remained 
significantly low post 1 year (Chapter 2) whereas albumin concentrations returned to baseline 
levels. 
Past studies, albeit ones who observed stimulated saliva rather than unstimulated, also 
observed increases in albumin concentrations in HNC patients post radiotherapy in 
comparison with controls (Almståhl et al., 2001; Eliasson et al., 2005). Whereas studies of 
non-cancer patients with systemic disease who are of similar age ranges have found salivary 
albumin concentration in stimulated saliva to also be significantly higher (Meurman et al., 
2002). Clinically these hospitalized patients had worse oral health than outpatients along with 
a reduced salivary flow rate (Meurman et al., 2002; Zussman et al., 2007). 
The hypothesis that as inflammation levels died down, albumin concentrations returned to 
baseline levels is further backed by studies that observed altered salivary profiles of heavy 
smokers with diseases, such as  Nagler ( 2007 ), finding that IgG and albumin were reduced in 
smokers in comparison to non-smokers. This is explained by nicotine usage causing anti-
inflammatory reactions in the oral cavity (McQuibban et al., 2000; Nagler, 2007).  
Having observed sublingual, parotid, and minor glands functionality, through mucins, α -
amylase and IgA acting as biomarkers respectively, the next protein to observe is cystatin S as 
it can act as a biomarker for submandibular glands, it is mainly secreted by submandibular 
glands (Baron et al., 2008; Martini et al., 2017). 
This study found a severe reduction in concentrations levels of cystatin S at both time points 
1 and 2, as well as a statistically significant reduction of secretion rates at T1 and T2, possibly 
indicating that IMRT affects the submandibular glands directly leading to reduced cystatin S 
production. Furthermore, the concentration and secretion rates were both significantly 
correlated with UWMS flow rate at both time points (Table 3.9 and 3.10 respectively). 
Submandibular glands are the biggest contributor of UWMS in terms of secretion and account 
for 60% of flow rates (Pedersen et al., 2018). Therefore, the severe reduction in flow rate, 
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combined with the severe reduction in concentrations levels and secretion rate of cystatin S, 
all combine to suggest that IMRT directly affected submandibular glands (Hawkins et al., 
2018). This association between UWMS flow rate and cystatin S production has been 
previously explored (Martini et al., 2017), with studies that analysed Sjogren syndrome 
finding cystatin S was significantly decreased in patients, especially in those with 
hyposalivation (Peluso et al., 2007; Martini et al., 2017). However, another study of HNC 
patients reported no difference in cystatin S concentration post radiotherapy compared with 
controls (Hannig et al., 2006), whilst another study reported reduced salivary flow rate and 
decreased overall cystatin S in saliva from patients with dry mouth in comparison to controls, 
but increased levels of cystatin S on “residual fluids on mucosal surfaces” however these fluids 
“showed little remaining reactivity for cystatin S” (Pramanik et al., 2010)( pg. 249). Pramanik’s 
findings on residual fluids suggest that the proteins were in an altered dormant state on the 
residual fluids and not directly produced by the submandibular gland, as it has been seen that 
minor salivary glands located in the oral mucosa and consisting of a small cluster of 
seromucous cells can produce cystatin S (Siqueira et al., 2008; Eliasson and Carlén, 2010). This 
could explain the dramatic reduction after 6 months of radiotherapy and the slight recovery 
at the one-year time point. It would be helpful to asses this protein concentration and 
secretion rate during and immediately post radiotherapy, as some studies have found 
variations in shorter term time points (Laheij et al., 2015), as well as assessing production 
from minor salivary gland saliva collection, whether they are from labial or buccal surfaces as 
minor salivary glands have been identified as producing small quantities of cystatin S(Siqueira 
et al., 2008; Eliasson and Carlén, 2010).  
Analysis of PRPs could also be a good indicator for both parotid and submandibular glands, as 
PRPs, containing between 25-42% of proline amino-acids are secreted by parotid and 
submandibular glands (Carpenter, 2013b). The present study found no statistically significant 
change in PRPs levels at any time point in comparison to baseline. But this is not to diminish 
the previous inference that parotid and submandibular glands were affected by IMRT, as 
another study observing cancers also found no changes in PRPs whilst finding changes in other 
salivary composites such as α-amylase (Warner et al., 1985). Similarly, other studies utilising 
animals models have also found a lack of significant change in PRPs (Ann et al., 1987; 
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BANNISTER et al., 1989).This has been the first study of its kind to observe PRPs in humans 
post radiation therapy. 
Finally, comparing statherin levels can give an overview of the overall oral cavity homeostasis, 
as statherin is a phosphoprotein protein secreted from parotid, submandibular and sublingual 
glands. Maintaining calcium homeostasis, statherin prevents its precipitation and crystal 
growth, as well as keeping saliva supersaturated in order to stimulate the remineralisation 
process (Carpenter, 2013; Hemadi et al., 2017).  
Statherin concentration levels found not to be statistically significantly changed, similar to 
PRPs, at any time point in comparison to baseline. But once again, similar to PRPS, this is not 
to diminish the previous inference that submandibular glands were affected by IMRT, as 
similar past studies have also found no changes in statherin following biological Stress (Hannig 
et al., 2006; Laheij et al., 2015).  
As Chapter 2 reported taste disturbances by patients, along with reduced salivary flow rate, 
it is also important to analyse the levels of CA VI, which has been shown to play a fundamental 
role in controlling taste sensation and taste bud growth, by facilitating the interaction 
between food particles and taste buds (Denny et al., 2008; Hunter, 2013). 
Carbonic anhydrase levels were statistically significantly increased at T1, whilst the graph 
(Figure 3.18) demonstrating that secretion rates were reduced at T1, although not to a 
statistically significant extent. Whilst analysis of data at T2 showed that CA VI concentration 
levels had returned to those similar of controls, secretion was statistically significantly 
reduced at T2 in comparison to T0. Additionally, carbonic anhydrase concentration and 
secretion rate were significantly associated to taste alteration reported by patients at both 
time points (Table 3.16 and 3.17). These alterations in levels associated to taste acuity could 
go some way towards understanding the taste disturbances reported in chapter 2 which were 
significantly associated with a reduced flow volume , it has been showed that the lack of saliva 
reduces the moistening process leading to a reduced capacity of chemoreceptors to accept 
stimuli, causing a lack of gustatory response (Sciubba and Goldenberg, 2006). 
Furthermore, these show an altered parotid and submandibular gland function, as CA VI is an 
enzyme secreted by parotid and submandibular glands. This backs up our previous findings of 
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α-amylase indicating that parotid glands were affected by IMRT and our findings of reduced 
cystatin S suggesting that IMRT directly affected submandibular glands.  
A further element to consider, as a possible reasoning for why certain protein concentrations 
and secretion rates are providing similar outcomes, is that all patients received a similar 
radiation dose and fractioning for their cancer treatment and that their main tumour sites 
were close anatomically and the tumour stages were similar, among the patient group. 
Radiotherapy dose and fractioning regime seems to be the determinant factor regarding 
normal tissue response in this group of patients. Radiation susceptibility of salivary glands 
cells to damage, magnitude of response, functional recovery and regeneration of the gland 
are determined by a genetic component that needs to be further studied in the literature 
(Andreassen, 2010). A different explanation that has been reported in the literature is the 
exposure to radiation induced oxidative stress in cells which would cause cellular apoptosis 
and senescence. A prolonged exposition to oxidative stress due to radiation toxicity might 
harm adjacent non-irradiated cells by communication through secreted factors this is known 
as a Bystander effect (Kadhim et al., 2013; Mothersill et al., 2019).  
However, it is not possible to draw a definitive conclusion from reviewing literature regarding 
salivary composition changes post radiotherapy due to limited number of patients recruited 
for past studies, wide range of molecules investigated and short follow-up period in past 
studies, with the only consensus being that of salivary flow rate reduction post radiotherapy. 
Past studies have found IMRT to not fully spare tissues surrounding  target area, when 
measured in terms of salivary flow rate (Dijkema et al., 2008), xerostomia (Dijkema et al., 
2010), and other oral symptoms such as hyposalivation in general (Nutting et al., 2011; 
Nguyen et al., 2018). However, the clinical relevance of such initial findings changes 
depending on the function of each protein that is altered (Chao et al., 2001; Jawad et al., 
2015). Therefore, the present study analysed several salivary bio-composites individually in 
order to evaluate the effects of IMRT on each individual gland and the association of this 
proteins with clinical altered symptoms. That analysis of biomarkers for individual glands , 
made the unique finding that although IMRT can spare some tissues, it is not entirely proof, 
with parotid and submandibular glandular function affected in particular, as evidenced by 
CAVI, α-amylase and cystatin S acting as biomarkers, whilst functional markers for sublingual 
and minor salivary glands showed them to be spared from IMRT or functionally recovered, 
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being capable of secrete certain proteins. This reinforces the findings of past studies that 
found IMRT does not fully spare tissues when measured as xerostomia or symptoms (Dijkema 
et al., 2010; Nutting et al., 2011), rather than glandular functions. Whilst others have shown 
how altering certain protein compositions will increase the possibility of breaking the 
equilibrium between microbial species in the oral cavity, reducing remineralisation, increasing 
erosion, and reducing food clearance process resulting in a high caries risk (Carpenter, 2013b; 
H. L. Gibbins et al., 2014; Kilian et al., 2016; Hannig et al., 2017). The direct causations that 
IMRT may have on such oral symptoms through its effects on salivary glands, was measured 
using a longitudinal panel data statistical model to assess their associations, that have not 
previously been performed for HNC patients. Therefore, it was imperative to analyse these 
links between the aforementioned factors, because it is well known that oral radiotherapy 
side effects reported previously might be connected to an altered salivary quality observed in 
this study, as a result of salivary gland hypofunction post IMRT (Dijkema et al., 2012; Richards 
et al., 2017). Indeed, this chapter observations were able to reflect salivary dysfunction, 
moreover, altered proteins concentration and secretion rate could be a mirror of each salivary 
gland specially taking in consideration the major UWMS contributors submandibular and sub 
lingual. It could be speculated that recovered minor gland might be trying to compensate 
reduced function. There is no literature regarding these gland function in head and neck 
cancer patients related to radiation therapy threshold, flow rate and composition. However 
there are studies that showed an altered secretion rate of minor saliva and mucosal pellicle 
protein composition in patients presenting xerostomia (Pramanik et al., 2010; Chaudhury et 
al., 2015; Hannig et al., 2017).  
Overall, this study concludes that salivary flow and composition showed a significant, 
transient reduction in quantity and quality, following IMRT.  However, some of the patients 
began to recover to normal levels at T2, 12 months post IMRT, there were reported significant 
associations among protein composition, secretion rate and this reduced volume of vital fluid 
as well as dry mouth feeling reported by patients and taste acuity. 
 Another important finding was that the primary tumour location did not affect the protein 
secretion rate and concentration in saliva in this group of patients in line with the past studies. 
The potential clinical relevance of these findings needs to be further investigated regarding 
oral care protocols improvements, oral risk assessment (pre and post IMRT) and personalized 
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monitoring of these conditions progression in order to improve this patient’s quality of life. 
Finally, the possibility of developing novel therapies to help to reduce salivary gland 
dysfunction, induce recovery of function, along with promoting the use of IMRT capable to 




Chapter 4   Oral mucositis 
4.1 Introduction 
 
Chapters 2 & 3 previously reported the clinical outcomes as well as the biochemical salivary 
protein compositional variations following radiation treatments for head and neck cancers, 
specifically when localised near salivary glands and oral mucosal epithelium.  
With patients undergoing radiotherapy for cancer treatment presenting multiple functional 
impairments and clinical symptoms, usually as a side-effect of the treatments, it becomes 
more important to understand the relationships between their health and any markers that 
may indicate early onset of upcoming side-effects (Fan, 2007; Raber-Durlacher et al., 2010; 
Münstedt et al., 2019), even more  if these biomarkers can be identified prior to radiotherapy 
treatment. With saliva being the first line of defence in the oral cavity to protect tissues, saliva 
composition is essential not only to protect the oral cavity through lubricating and coating the 
epithelial surface (Asikainen et al., 2017), but also to act as a potential indicator for overall 
health of the salivary glands and the oral cavity’s homeostasis.  
One of the most common side effects, along with xerostomia, is mucositis, a morbid condition 
that occurs as frequently as 60-85% of cancer treatment patients (Sonis, 1998, 2004a; Villa 
and Sonis, 2015). Despite the high incidence rate of oral mucositis during cancer therapy and 
its clinical impact on patients and economic effect for healthcare providers, there is a lack of 
adequate treatment to reverse, control or prevent this side effect. Furthermore, the condition 
represents not only a problem for patients but also for clinicians(Rieger et al., 2012; Gao et 
al., 2015) with its management placing a strain on healthcare systems by increasing the 
financial burden of healthcare costs in comparison to the patients without oral ulceration 
(Sonis et al., 2001; Vera-Llonch et al., 2006), increasing the expenses as a result of additional 
medical attention, extended hospitalisation, increasing risks of secondary infections and 
lowering quality of life due to implementing special diets and parenteral feeding (Sonis, 2011; 
Villa and Sonis, 2016; McCullough, 2017). Therefore, from both economic and patient 
healthcare delivery perspectives, it could be a critical turning point for management of 
mucositis if early detection and/or prediction was feasible and implemented (Fan, 2007; 
Raber-Durlacher et al., 2010).  
 193 
This study used the clinical skills of physicians from the Guy's and St Thomas' NHS oncology 
group to visually assess mucositis levels using the WHO mucositis scale, at each time point of 
the experiment (prior to; 6 months and 1 year post-radiotherapy). The findings were analysed 
in comparison to salivary proteins and mucins, in order to not only assess any relationships 
between the two elements of saliva and mucositis, but in order to also form a capacity to 
predict the severity of oral mucositis, by allowing salivary composition to act as a biomarker 
prior to radiotherapy, as demonstrated in Figure 4.1. 
The WHO toxicity scale documents the severity and prevalence of mucositis, with the scale 
being one of the most commonly used in order to monitor this condition. However, there is 
no universal scale for measuring mucositis, with this being one of the biggest drawbacks in 
oral mucositis research as at the moment of writing this thesis. Other scales used include the 
Radiation Therapy Oncology Group scale (RTOG) and European Organisation for Research and 
Treatment of Cancer scale (EORTC). Whilst RTOG / EORTC are focused on patients’ levels of 
pain and suffering, in order to measure the necessity of analgesia, the WHO toxicity scale 
focuses on patients’ functionality in relation to the capacity to eat solid food (Sciubba and 
Goldenberg, 2006; Sroussi et al., 2017). However, these are all subjective measurements, with 
evaluative outcomes dependent on a physician’s clinical experience and training in order to 
clearly define categories on each relevant scale.  
The lack of a clear universal scale might act as a further barrier to development of a definitive 
predictive system for gradings of mucositis, however this study first focuses on establishing 
whether or not a clear predictive molecule for mucositis can be identified prior to 
radiotherapy treatment. If a biomarker is found, with its specificity and sensitivity rate of 
predictive accuracy analysed, then a further step can be taken to analyse each grading of 
mucositis against the diagnostic ability of predictions using a Receiver Operating 
Characteristic curve, or ROC curve. ROC curves are used in order to clearly plot the diagnostic 
ability of a binary classifier in cases where discrimination thresholds are varied (in this case 
being the ability to accurately predict oral mucositis in cases where salivary protein thresholds 
vary).  
If such a finding can be identified, analysed and proven to associate against varying severities 
of mucositis, then this not only presents an opportunity to create a clear identifier to prevent 
cancer treatment interruption (Turner et al., 2013) but also the opportunity to create 
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personalised preventative care regimes in order to reduce the debilitating effects on 








Figure 4. 1 Identifies the clinical problem and the process followed to find a possible marker of 









4.2 Aim  
 
The aim of this study focuses on establishing a predictive model for mucositis prior to 
radiotherapy treatment by analysing the possible associations between salivary protein 
concentration and secretion rate and clinical outcomes.   
Null Hypothesis: There is no longitudinal association between IMRT-induced changes in 
salivary markers with oral mucositis severity. 
There are no pre-operative salivary indicators for potential risk prediction of the severity of 
mucositis suffered during therapy 
Objectives  
To associate salivary protein concentration and secretion rate pre and post- IMRT with the 
clinical assessment of mucositis.  
To assess specific proteins in saliva pre-IMRT as a potential risk predictor of the presence of 
mucositis suffered during therapy in head and neck cancer patients. 
To assess specific proteins in saliva pre-IMRT as a potential risk predictor of severity of 




4.3 Material and Methods 
 
4.3.1 Patient Recruitment 
 
Forty HNC patients were recruited in line with the Helsinki declaration with full, written 
informed consent gained. The study was approved by the North of Scotland Research Ethics 
Service (NRES) Committee foundation in October 2016 (16/NS/0116), the Health Research 
Authority NHS (IRAS Project ID:199100) and the patient recruitment letter is appended 
(Appendix no.1).  
Recruitment was carried out prior to IMRT (T0) at Guy’s Dental Hospital, London in the Special 
Care Dentistry Unit. Patients were followed up six months post-IMRT (T1) and 12 months 
post-IMRT (T2).  Forty patients were recruited at T0, 38 patients were seen at T1 and 34 
patients at T2 respectively. 
 
4.3.2 Saliva Sample Collection 
 
All saliva samples were collected from the patients by drooling method at every time point, 
and flow rate was assessed as described in detail in Chapter 2. One hundred and eleven saliva 
samples were collected and analysed.  
 
4.3.3 Sample Analysis 
 
Samples were analysed for total protein content using the Bicinchoninic Acid Assay (BCA), 
targeted protein concentration by Enzyme-Linked Immunosorbent Assay (ELISA), Periodic 
Acid Schiff (PAS) staining, Coomassie Brilliant blue and α-amylase activity by the standard 
kinetic enzyme assay (Salimetrics). The assays were carried out as set out in the 
manufacturer’s guidelines.   
Prior to biochemical analysis UWMS samples were centrifuged at 10000 RPM for 3 mins. The 
supernatant was separated to be used to analyse protein content and the pellet was 
preserved to perform DNA extraction. 
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4.3.3.1 Protein Analysis Concentration and Secretion Rate  
 
In order to determine the salivary protein composition, the total protein content /secretion 
rate, specific protein concentrations and their secretion rates were analysed. Nine proteins 
(mucin 5B, mucin 7, IgA, α-amylase , albumin, cystatin S, carbonic anhydrase VI, acidic proline 
rich protein and statherin) were selected due to their relationship to host defence, 
antimicrobial, bacterial adherence, colonization, mucosal pellicle, enamel pellicle, 
viscoelastic, rheological properties, lubrication, and remineralization.  
In summary, mucin 5B, mucin 7, IgA, α-amylase , albumin, cystatin S, carbonic anhydrase VI, 
acidic proline rich protein and statherin are all salivary proteins related to caries 
development, xerostomia, taste alteration and oral mucositis before and after radiation 
therapy in the reported longitudinal clinical study (12 months). 
4.3.3.2 Oral Mucositis Assessment 
 
In the study clinical assessment of oral mucositis was performed by the oncology team during 
and after the radiotherapy using the World Health Organization (WHO) oral toxicity scale 
(World Health Organization, Handbook, 1979).  
This grading system is based on a clinical examination of the oral cavity, in the case of oral 
mucositis there were added three extra time points due to the acute nature of this toxicity 
that appears once the cancer treatment started.  
Clinical assessment was recorded during radiotherapy and after 2 weeks, 6 weeks 3 months 
and the regular time points 6 months (T1) and 12 months (T2).  
 
4.3.4 Statistical Analysis  
 
Random effects Generalized Least Squares linear regression.  
A random effects linear regression analysis in a longitudinal panel was used to analyse the 
data obtained from the patients over time. Panel refers to a group of subjects that were 
studied recurrently over time in order to determinate the association between salivary 
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proteins and oral mucositis development at T1 (6 months post-IMRT) and T2 (12 months post-
IMRT) in comparison to T0 (pre-IMRT).  
Receiver Operating Characteristic (ROC) curve  
ROC analysis was used to analyse sensitivity and specificity of certain salivary proteins to 
predict the development and severity of oral mucositis during IMRT prior to commencement 
of the radiotherapy treatment.  
The true positive rate (sensitivity) is plotted in function of the false positive rate (100-
specificity) for different cut-off points of a parameter. Each point on the ROC curve represents 
a sensitivity/specificity pair corresponding to a particular decision threshold.  
ROC curve is an analysis tool used to evaluate the performance of a diagnostic test, based on 
sensitivity and specificity for every possible cut point for a test. It is a plot of the true positive 
rate (sensitivity) in function of the false positive rate (100-specificity) for different cut-off 
points of a parameter. Each point on the ROC curve represents a sensitivity/specificity pair 
corresponding to a particular decision threshold. In addition, it would reveal the area under 
curve (AUC) which is a measure that represent the whole performance of the test being the 
sensitivity average value for all specificity values, demonstrating how well a parameter can 
discriminate between disease and non-disease subjects. The higher the AUC, the better the 
model is at distinguishing between patients with or without disease. Therefore, a test with a 
higher accuracy will have a higher AUC, the lower limit should be 50% in order to keep an 
optimal test performance to distinguish between patients that present the disease from those 
without the disease and not relying on pure chance. AUC is not dependent on disease 
prevalence (Metz, 1978; Bradley, 1997; Obuchowski, 2003; Park et al., 2004; Zhou et al., 
2011). Sensitivity is defined as a true positive rate (TPR) expressed as a percentage, being the 
proportion of positive samples that present with the disease and specificity true negative rate 
(TNR) expressed in percentages being the proportion of negative samples that were correctly 
classified as non-disease subjects (Tharwat, 2018).  
A test sensitivity and specificity is chosen in the context of the type of disease to be diagnosed; 
for potentially life threatening diseases the cut point range for a positive test would provide 
a high sensitivity in order to reduce false negative subjects, as a false negative test could have 
serious inplications for survival of the patients (Park et al., 2004). 
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All analyses were carried out using STATA 15.1 (College Station, Texas USA, www.stata.com), 
GraphPad Prism 8 software (La Jolla California USA, www.graphpad .com) and Microsoft Excel 
2018. Results were expressed as a percentage for sensitivity, specificity and AUC, cut point 







4.4 Results  
 
4.4.1 Longitudinal Associations Between Oral Mucositis Outcomes and Salivary Proteins 
Concentration and Secretion Rate Post IMRT at 6 Months (T1) and 12 Months (T2) by 
using Random effects Generalized Least Squares linear regression. 
 
This study found that between the 31 patients who developed mucositis during IMRT, there 
were significant associations had formed, beginning to associate total protein concentration 
and oral mucositis at T1(p=0.009) (Table 4.1). Furthermore, there appeared to be statistically 
significant associations formed between oral mucositis and total protein secretion rate at 
Time Point 1 (p=0.017) (Table 4.2). 
When comparing associations between oral mucositis assessments and mucins 5B and 7, 
although there were no statistically significant associations formed in comparing 
concentrations of the mucins with oral mucositis at both time points post IMRT, there were 
statistically significant associations for mucin 5B’s secretion rate at Time Point 1 (p=0.017) as 
well as mucin 7’s secretion rate at Time Point 1 (p=0.015) (Table 4.4 and 4.6) 
In keeping with the pattern of significance at Time Point 1, α-amylase units and secretion rate 
were both associated with oral mucositis assessments at statistically significant levels at Time 
Point 1 (p=0.040 and p=0.037 respectively). Similarly, albumin concentration and secretion 
rate were both significantly associated to oral mucositis presence at Time Point 1 (p= 0.007 
and p= 0.014 respectively), whereas for all comparisons of oral mucositis with Albumin and 
α-amylase, there were no statistically significant associations at Time Point 2. 
Cystatin S concentration was significantly associated with oral mucositis at Time Point 1 
(p=0.039), keeping in line with cystatin S secretion rate which appeared to have a borderline 
associated at Time Point 1 (p=0.057). The associations of cystatin, α-amylase , albumin, 
mucins 5B and 7 and oral mucositis all becoming statistically significant at Time Point 1 is in 
keeping with the results of Chapter 2 that found that following IMRT, between Time Points 0 
and 2, there were significant drops in the number of patients that presented with oral 
mucositis (p=<0.0001).  
Immunoglobulin A concentration uniquely presented a significant association at both Time 
Points 1 & 2 in relation to oral mucositis (p=0.007 and p= 0.03 respectively). IgA secretion rate 
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was also significantly associated at Time Point 1 (p= 0.009) with a borderline association to 
oral mucositis at Time Point 2 (p=0.052).  
Table 4.1 Oral mucositis assessment in the oral cavity and total protein concentration in 
unstimulated whole mouth saliva (UWMS) at T1 (6 months post-IMRT) and T2 (12 months 




Coefficient  P [95% Conf. Interval] 
T 0 0.027 0.052 -0.0002 0.055 
T 1 0.153 0.009 0.038 0.267 
T 2 0.071 0.237 -0.046 0.188 
 
Table shows the significant relation between oral mucositis and total protein concentration 
(TPC) in UWMS after IMRT at Time Point 1. 
 
Table 4.2 Oral mucositis assessment in the oral cavity and total protein secretion rate in 
unstimulated whole mouth saliva (UWMS) at T1 (6 months post-IMRT) and T2 (12 months 




Coefficient P [95% Conf. Interval] 
T 0 0.0182 0.667 -0.064 0.101 
T 1 0.156 0.017 0.0281 0.283 
T 2 0.097 0.111 -0.022 0.217 
 
Table shows the positive and significant relation between oral mucositis and total protein 
secretion rate in UWMS after IMRT at Time Point 1.  
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Table 4.3 Oral mucositis assessment in the oral cavity and mucin 5B concentration in UWMS 
at T1 (6 months post-IMRT) and T2 (12 months post-IMRT) in comparison to T0 (pre-IMRT). 
 
Oral Mucositis/ 
Mucin 5B   
Coefficient  P [95% Conf. Interval] 
T0 0.0005 0.157 -0.0002 0.0013 
T1 0.078 0.272 -0.0617 0.219 
T2 0.036 0.605 -0.1011 0.174 
 
Table shows non-significant relation between oral mucositis and mucin 5B concentration in 
UWMS after IMRT at Time Point 1 and Time Point 2.  
 
Table 4. 4 Oral mucositis assessment in the oral cavity and mucin 5B secretion rate in UWMS 
at T1 (6 months post-IMRT) and T2 (12 months post-IMRT) in comparison to T0 (pre-IMRT).  
 
Oral Mucositis/ 
Mucin 5B SR 
Coefficient P [95% Conf. Interval] 
T0 -0.000046 0.954 0-.0016 0.0015 
T1 0.138 0.017 0.0247 0.252 
T2 0.088 0.139 -0.0289 0.206 
 
Table shows the significant relation between oral mucositis and mucin 5B secretion rate in 





Table 4.5 Oral mucositis assessment in the oral cavity and mucin 7 concentration in UWMS 




Coefficient  P [95% Conf. Interval] 
T0 0.0038 0.0001 0.0025 0.0051 
T1 0.051 0.330 -0.0512 0.153 
T2 0.072 0.155 -0.0275368 0.172 
 
Table shows no significant association after IMRT at Time Point 1 and 2 between oral 
mucositis and mucin 7 concentration in UWMS after IMRT.  
 
Table 4.6 Oral mucositis assessment in the oral cavity and mucin 7 secretion rate in UWMS at 




Coefficient  P [95% Conf. Interval] 
T0 0.0007 0.381 -0.0009 0.0025 
T1 0.135 0.015 0.026 0.244 
T2 0.079 0.167 -0.033 0.193 
 
Table shows significant relation between oral mucositis and mucin 7 secretion rate in 






Table 4.7 Oral mucositis assessment in the oral cavity and α-amylase unit in UWMS at T1 (6-
months post IMRT) and T2 (12 months post-IMRT) in comparison to T0 (pre-IMRT). 
 
Oral Mucositis/ α-
amylase  U  
Coefficient  P [95% Conf. Interval] 
T0 0.0003 0.266 -.0002 .0008 
T1 0.107 0.04 .004 .208 
T2 0.069 0.177 -.031 .169 
 
Table shows a significant relation between presence of mucositis and α-amylase unit in 
UWMS after IMRT at Time Point 1. 
 
Table 4.8 Oral mucositis assessment in the oral cavity and α-amylase unit secretion rate in 




amylase  U SR 
Coefficient  P [95% Conf. Interval] 
T0 0.0008 0.290 -.0006 .002 
T1 0.118 0.037 .007 .229 
T2 0.088 0.104 -.018 .195 
 
Table shows a significant relation between oral mucositis and α-amylase unit secretion rate 





Table 4.9 Oral mucositis assessment in the oral cavity and albumin concentration in UWMS at 




Coefficient  P [95% Conf. Interval] 
T0 -0.0002  0.500 -0.0009 0.00045 
T1 0.151  0.007 0.040 0.262 
T2 0.064  0.264 -0.048 0.177 
 
Table shows a significant relation between presence of mucositis and albumin concentration 
in UWMS after IMRT at Time Point 1.  
 
Table 4.10 Presence of mucositis in the oral cavity and albumin secretion rate in UWMS at T1 





Coefficient  P [95% Conf. Interval] 
T0 -0.0007 0.466 -0.0028 0.0012 
T1 0.136 0.01 0.027 0.245 
T2 0.056 0.344 -0.060 0.172 
 
Table shows a significant relation between presence of mucositis and albumin secretion rate 






Table 4.11 Presence of mucositis in the oral cavity and cystatin S concentration at T1 (6 




Coefficient  P [95% Conf. Interval] 
T0 0.002 0.638 -0.008 .012 
T1 0.171 0.039 0.008 .334 
T2 0.125 0.103 -0.025 .277 
 
Table shows the positive and significant association between presence of mucositis and 
cystatin S concentration in UWMS after IMRT at Time Point 1. 
 
Table 4.12 Presence of mucositis in the oral cavity and cystatin S secretion rate at T1 (6 
months post-IMRT) and T2 (12 months post-IMRT) in comparison to T0 (pre-IMRT). 
 
Oral Mucositis/ 
Cystatin S SR 
Coefficient P [95% Conf. Interval] 
T0 -0.0003  0.966 -0.0147 .014 
T1 0.143  0.057 -0.004 .291 
T2 0.105  0.161 -0.041 .253 
 
Table shows the positive and significant association between presence of mucositis and 






Table 4. 13 Presence of mucositis in the oral cavity and IgA concentration in UWMS at T1 (6 




Coefficient  P [95% Conf. Interval] 
T0 -0.00067 0.597 -0.003 0.001 
T1 0.156 0.007 0.041 0.271 
T2 0.140 0.030 0.013 0268 
 
Table shows a significant association between presence of mucositis and IgA concentration 
in UWMS after IMRT at Time Point 1 and at Time Point 2. 
 
Table 4.14 Presence of mucositis in the oral cavity and IgA secretion rate in UWMS at T1 (6 





Coefficient  P [95% Conf. Interval] 
T0 0.004 0.153 -0.001 0.0101 
T1 0.154 0.009 0.0385 0.269 
T2 0.126 0.052 -0.0009 0.254 
 
Table shows the positive and significant association between presence of mucositis and IgA 
secretion rate in UWMS after IMRT at Time Point 1 and a borderline significant relation at 





4.4.2 Receiver-operating characteristics curves (ROC) 
 
Following analysis of associations between assessments of oral mucositis with different 
protein concentrations and secretion rates at all time points, it is possible to take the next 
step of analysing the presence of mucositis (as well as grading of oral mucositis) against the 
previous associations, with the specificity and sensitivity rate of predictive accuracy analysed, 
allowing a diagnostic ability of predictions using a ROC curve.  
The summary of analysis of sensitivity (true positives) and specificity (true negatives) 
measured before IMRT, as a point of prediction of mucositis onset, revealed that α-amylase  
unit concentration can be an accurate predictor of oral mucositis onset during IMRT on 
occasions where α-amylase  units are more than 30.14 pre-IMRT (when measured in units per 
ml of unstimulated whole mouth saliva).  
The analysis of sensitivity and specificity measured before IMRT, as a point of prediction of 
mucositis severity, revealed that mucin 5B concentration and secretion rates assessed before 
cancer treatment can be very accurate predictors of oral mucositis severity grades 1 & 2, 
showing correct classification rates of 92.31%, with an area under the ROC curve of 90.91% 
for concentration and 86.36% for secretion rate. 
Furthermore, analysing the ROC curve of results 2 weeks after IMRT revealed that α-amylase 
unit concentration can also be an accurate predictor of oral mucositis grades 1 & 2, showing 









4.4.2.1 Analysis of Salivary Proteins Collected at Time 0 as A Molecular Predictor of Mucositis 
Development During Radiotherapy 
 
Table 4.14 Oral mucositis presence during radiotherapy. 
 
 
4.4.2.2 Analysis of Salivary Proteins Collected at Time 0 as A Molecular Predictor of Oral Mucositis 
Severity During Radiotherapy  
 
Table 4.15 Oral mucositis severity during radiotherapy. 
ROC curve analysis 
of proteins in 
UWMS 





α-amylase unit /ml 
of UWMS 





Protein at Time 
point 0 






MUC 5B ug/ml  ≥16.16     100.00% 50.00% 92.31% 90.91% 
 
MUC 5B ug/min  ≥4.65619     100.00% 50.00% 92.31% 86.36% 
Mucositis grade 
2 during IMRT 







≥ 1.94487    90.00%         50.00%        62.50% 62.27% 
 TPC sec rate 
mg/min 
≥1.134      70.00%         59.09%        62.50% 65.45% 
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4.4.2.3 Analysis of Salivary Proteins Collected at Time 0 as A Molecular Predictor of Oral Mucositis 
Severity Post IMRT Radiotherapy 
 





ROC curve analysis 
of proteins in 
UWMS 
Protein at Time 
point 0 
Cut point    Sensitivity        Specificity    Correctly Classified  AUC 
OM grade 1 & 2 
2weeks post IMRT 
α-amylase U/ ml ≥22.77    100.00% 50.00% 87.50% 91.67% 
OM grade 2  
2 weeks post-IMRT 
MUC 5B secretion 
rate ug/min 
≥ 27.97      76.92%         63.16%        68.75%    65.18% 
 MUC 7 secretion 
rate ug/min 
≥ 1.103      57.14%         54.55%        55.56% 57.47% 
 α-amylase   U/ml ≥56.84    92.86%         40.00%        61.76% 65.36% 
 α-amylase  U/ml  ≥ 78.14   71.43%         55.00%        61.76% 65.36% 
 α-amylase  
secretion rate 
U/min 
≥31.25      92.86%         60.00%        73.53% 70.71% 
 IgA secretion rate 
ug/ml 
≥4.090   75.00%         60.00%        65.63% 57.5% 
 Albumin secretion 
rate ug/min 
≥ 16.33    64.29%         54.55%        58.33% 56.17% 
OM grade 2 
6 weeks post-IMRT 
α-amylase  U/ml  ≥108.619       85.71%         47.06%        58.33%    58.82% 
 α-amylase  
secretion rate 
U/min 
≥42.7959    71.43%         41.18%        50.00% 60.50% 
 IgA secretion rate 
ug/min   
≥4.177     66.67%         58.82%        60.87%   54.9% 
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4.5 Discussion  
 
Over the past two decades, the diagnostic value of oral fluids has become recognised, in 
particular for oral diseases, such as periodontal diseases (Miller et al., 2006), assessing caries 
risk (Spielmann and Wong, 2011), and cancers (Gualtero and Suarez Castillo, 2016). More 
recently, the combination of emerging biotechnologies has allowed salivary diagnostics to 
extend beyond the traditional range to predict wholly physiological risks to the entire oral 
cavity.  
As set out in Chapter 1, the carefully regulated homoeostasis of a multitude of proteins in the 
oral environment provide functional lubrication and dehydration, as well as protection from 
colonisation by pathogenic organisms. Previous studies have established that the volume of 
saliva and its composition are vital to maintain oral homeostasis and reduce the possibility of 
developing oral diseases, such as mucositis (Carpenter, 2013b; H. L. Gibbins et al., 2014; Kilian 
et al., 2016; Hannig et al., 2017). 
This study has been the first, as of this writing, to identify potential links between salivary 
biomarkers and the potential onset of oral mucositis, within the largest longitudinal and most 
comprehensive biochemical analysis of saliva from head and neck cancer patients spread 
across 1 year.  
This is of particular note, with oral mucositis being a very frequent side effect of head and 
neck cancer radiation therapy treatment, occurring as frequently as 60 – 85% of patients  
(Fan, 2007; Raber-Durlacher et al., 2010; Münstedt et al., 2019), causing a huge measurable 
impact on patient welfare and the overall healthcare system (Vera-Llonch et al., 2007; Rieger 
et al., 2012). Therefore, in cases such as this where a patients quality of life can be so severely 
impacted (Villa and Sonis, 2016; McCullough, 2017), not only is early detection vital, but 
analysis of salivary fluids presents a great opportunity to create personalised preventive care 
regimes in order to mitigate potential suffering using non-invasive sample collection and 
simple processing.  
Whilst Chapter 3 found that CA VI, mucins, α-amylase  and cystatin S an act as biomarkers for 
glandular function, revealing whether or not particular salivary glands are spared from 
radiotherapy toxicity  during IMRT, here this process can be taken one step further to analyse 
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the same salivary compositional collection for use as a preventative diagnostics tool – 
essentially identifying the accuracy of predicting future onset of oral mucositis, as well its 
potential severity.  
The data presented in this study showed the radiotherapy effects on salivary glands resulting 
in a decreased oral function that remains after one year of completed IMRT. This study 
contributes to oral mucositis research by identifying the difference in protein signature of 
UWMS from HNC patients post-IMRT up to one year after the treatment has finished along 
with the onset of side effects, suggesting the possibility of an association between clinical 
outcomes regarding oral mucositis onset /severity and saliva functional and protective 
biochemical composition including total protein concentration and secretion rate followed by 
specific salivary proteins mucin 5B, mucin 7 and IgA as a part of the mucosal protection barrier 
and hydration layer, along with α-α-amylase  that play a role in bacterial colonization, cystatin 
S as an antibacterial  protein and part of pellicle, and albumin as marker of inflammatory 
processes. All these proteins were taken into account as patient-related contributors of 
developing this adverse side-effect and its severity.   
Therefore, a comprehensive analysis of these molecular changes in saliva and the association 
with oral mucositis might allow the targeting of certain proteins that might be suitable as a 
predictor for early identification of patients prone to develop severe mucositis. In addition, 
this would allow a prompt and frequent monitoring of this side effect and in the long run 
would help to provide information to predict the risk of every patient of developing oral 
mucositis and customize their care to avoid reaching the highest severities and finally to 
reduce the chance of cancer treatment interruptions. 
This chapter revealed significant positive associations when measuring total protein secretion 
rates, as well as concentrations, with oral mucositis at T1. This is of particular note as the 
findings in chapter 3 revealed that total protein secretion rate parameter was significantly 
reduced post-radiotherapy along with a reduced total concentration at T1, thus altering 
salivary properties and ultimately salivary flow rates. Salivary flow rate (negatively) and total 
protein secretion rate (positively) are associated with xerostomia reported by patients as 
previously reported in Chapter 2 and 3 and xerostomia was also found to be potentially 
positive and significantly associated with oral mucositis in Chapter 2. In summary, this 
demonstrates the positive and strong association between salivary gland hypofunction 
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caused by IMRT and oral side effects and the influence that this altered fluid might have on 
onset and severity regarding oral mucositis as well as in an altered mouth feel due to a 
reduced volume along with an altered salivary quality.  
This all links to the previous findings that whilst total protein secretion rate was significantly 
reduced post-radiotherapy, a reduced concentration was associated to diminished salivary 
flow rate along with oral mucositis onset and development were increasing comparatively, 
with approximately 20% of all patients presenting mucositis at Time Point 1.  
Furthermore, when analysing the protein composition on an individual basis, significant 
associations were found between oral mucositis and mucin 5B secretion rates, as well as 
mucin 7 secretion rates, all at Time Point 1. As previously shown in Chapter 3, the analysis of 
changes to mucin 5B and 7 revealed increased concentrations, which have been shown to 
affect saliva’s viscoelasticity, effectively making saliva have a “sticky effect” and reducing its 
functional value (Veerman et al., 1989; Ligtenberg and Almståhl, 2015). The combination of 
these findings point to the previous links associated with altered flow rates and salivary 
composition  that can negatively influence the occurrence and severity of mucositis (Eliasson 
et al., 2009), especially in head and neck cancer patients undergoing radiotherapy(Sonis, 
2004a, 2011, 2013; Villa and Sonis, 2016; De Sanctis et al., 2016; Normando et al., 2017; 
Franco et al., 2017; Orlandi et al., 2018). In order to maintain mucosal integrity oral surfaces 
should be covered by a strongly retained, protective protein layer which can be able of 
providing adequate hydration and lubrication which are the key function of both mucins.  
Thus, the increased mucin 5B and 7 concentrations had increased viscosity, reducing mucosal 
wetness capability and leaving oral surfaces unprotected. In order to corroborate this 
assumption, it should be investigated the presence of these molecules adjacent to oral 
mucosa, by collecting residual saliva.  
Another possibility that could be explored in future studies is the underlying causalities 
behind the alterations of mucins, with a possibility that the radiotherapy has caused an 
alteration of the cellular structure of the superficial epithelial cells that are decorated with 
numerous membrane ridges, termed microplicae (MPLs). The MPL structure is typical of the 
epithelial surfaces that are covered with protective mucus (Asikainen et al., 2015) and 
alterations in MPLs affect the adhesion of mucins to oral mucosa and ultimately suggest a loss 
of mucin retention (Dijkema et al., 2012; Asikainen et al., 2017). A recent study, albeit one 
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performed on animals, not humans, has observed that radiotherapy does cause structural 
modification, even one year after radiotherapy, to MPL (Asikainen et al., 2017). The MPL is a 
fundamental part of the interaction of mucins to form and hold a highly hydrated gel mucus 
layer to cover and protect this tissue (Asikainen et al., 2012; Ukkonen et al., 2017). Without 
the proper protective barrier, this leads to a diminished defence against mechanical and 
chemical substances, increasing risk of inflammation, erosion and ultimately chances of oral 
mucositis onset (Dawes, 2008; H. L. Gibbins et al., 2014; Hannig et al., 2017).  
Furthermore, it has been established that when mucin 5B levels are affected due to external 
stimuli, there are also concurrent changes to secretion of α-amylase  and other proteins 
(Ligtenberg and Almståhl, 2015), which corresponds with the current analysis of comparisons 
with oral mucositis and the protein composition on an individual basis that revealed positive 
and significant associations with a significantly reduced α-amylase  unit concentration, α-
amylase  secretion rates, cystatin S concentration, and cystatin S secretion rate; all at time 
point 1. 
With the co-operation of cystatin S and α-amylase  in forming the mucosal pellicle being well 
established (Bradway et al., 1992; Ployon et al., 2016; Hannig et al., 2017), as well as cystatin 
S acting as a potential reaction agent with bacteria (Isemura et al., 1984) alongside α-amylase  
playing an important role in bacterial colonisation on oral surfaces by selectively maintaining 
the normal flora providing nutrients (Borghi et al., 2017; Cardoso et al., 2017), it stands to 
reason that their altered presence could be a reason for the oral mucositis severity 
determined by the reduced  concentration and secretion rate of these aforementioned 
proteins, as further demonstrated by their significant associations with mucositis at Time 
Point 1. The cause of this being that altering both α-amylase  and cystatin S could reduce 
microbial protection and increase the risk for secondary infections and pathogen bacterial 
colonisation, contributing to the mucositis inflammatory process (Sonis, 2011; Vanhoecke et 
al., 2015; Vasconcelos et al., 2016; Maria et al., 2017; Lynge Pedersen and Belstrøm, 2019). 
This microbial unbalance could be further affected by the altered salivary viscosity, related to 
both mucins’ increased concentration, which impairs clearance of dietary carbohydrates and 
microorganisms from the oral cavity, in addition mucin 7 is capable of impeding the 
adherence of bacteria to oral surfaces being able to aggregate oral bacteria resulting in an 
efficient clearance by swallowing (Lynge Pedersen and Belstrøm, 2019). 
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Further analysis of comparisons of the protein composition on an individual basis revealed 
that albumin concentration and secretion rates were both positive associated with oral 
mucositis at T1. A possible explanation for this could be the findings from Chapter 3 that 
demonstrated albumin concentration was significantly elevated at T1, whilst secretion rate 
remained stagnant. This would go hand-in-hand with the significant association of this 
mentioned albumin with oral mucositis at this point (T1) , as during cases of mucositis, the 
oral mucosa will remain fragile, leading to plasma leakage and thus increasing this protein 
concentration in saliva (Almståhl et al., 2001; Eliasson et al., 2005).  
In all the aforementioned cases, there appeared to be a distinct lack of statistical significance 
at T2. This could be potentially explained by the findings in Chapter 2 – whereby the low 
incidence rate of mucositis at time point 2 (mucositis presence was 9%) does not allow for 
any statistically significant associations to be formed. The cause of the low incidence rate of 
mucositis at T2 being the recovery of patients, which is to be expected as based on past 
literature showing recovery of oral health status within 1 to 2 years (Schuurhuis et al., 2011; 
Walker et al., 2011).  
Immunoglobulin A was the one unique molecule observed that went against this trend, by 
presenting a statistically significant and positive association between IgA concentration and 
oral mucositis at both time Points 1 and 2, with IgA secretion rate also positive and 
significantly associated at Time Point 1, with a borderline association to oral mucositis at T2.   
However, the cause of Immunoglobulin A’s nonconformism to remain significant at T2 can be 
explained by the fact that, as shown in Chapter 3, concentration levels of IgA also did not alter 
at any time point following IMRT, in line with past studies that observed IgA concentrations 
in patients remain stable (Eliasson et al., 2005; Richards et al., 2017). One potential theory for 
their stability, or even potential increase during recovery (Martinez et al., 2007), is that IgA 
has been linked to mucosal pathologies, playing a role in mucosal defence (Engström and 
Engström, 1998; Joel B. Epstein et al., 2002; Hooper et al., 2012). Therefore, it may be linked 
to the recovery from oral mucositis rather than the onset of it. Furthermore, as Chapter 3 
revealed that minor salivary gland functions are potentially spared from IMRT or recovered 
functionally, and previous studies have shown that minor buccal glands secrete IgA (Eliasson 
et al., 2006; de Paula et al., 2017), this could be the main origin of IgA that is allowing its levels 
to remain stable and facilitate these changes.  
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The presented correlative clinical and biochemical data provide insights in to the profiles of 
patients following head and neck cancer intensity-modulated radiation therapy and allow 
determination of potential cases that can serve as a reference for monitoring response to 
therapy. However, the utility of such associations for acting as predictive or diagnostic 
biomarkers is limited, therefore it is important to further utilise the data points to establish a 
model that could be used as a comprehensive analysis point to create diagnostic biomarkers, 
using a Receiver Operating Characteristic curve, or ROC curve. ROC curves are used to plot 
the diagnostic ability of a binary classifier in cases where discrimination thresholds are varied 
(in this case being the ability to accurately predict oral mucositis in instances where salivary 
protein thresholds vary).  
It is important to note that a handful of past studies have utilised predictive salivary 
biomarkers to act as diagnostic tools for oral diseases (Miller et al., 2006; Gualtero and Suarez 
Castillo, 2016), and some have even evaluated the therapeutic opportunities of  
removing / substituting proteins (albeit inflammatory cytokines or chemokines, rather than 
regularly identifiable salivary proteins) in head and neck cancer patients (Elashoff et al., 2012; 
Sultani et al., 2012). However, as of yet, there are no studies to the author’s knowledge, that 
have evaluated the possible associations among salivary protein variations in head and neck 
cancer patients and oral mucositis assessments. Oral mucositis research has been mainly 
focused on mucositis prevalence and severity, whether that be regarding quality of life of 
patients, patient suffering and consequences in cancer treatment alteration affecting its 
results regarding survival rates and relapse (Sonis, 2004a; Maria et al., 2017), or focused on 
therapeutic agents, studying effects of mitigation, delaying onset or limiting severity(Nomura 
et al., 2013; Villa and Sonis, 2016).  
The current study proposed the use of novel salivary protein biomarkers for the early 
diagnosis of oral mucositis in head and neck cancer patients based on the analysis of ROC 
curves. Furthermore, this predictive model allows for identifying the potential severity of 
oncoming mucositis. The importance of the ability to predict and define a group of patients 
that might be in risk of developing a severe mucositis before IMRT would allow healthcare 
professionals to detect sufficiently early, to make decisions and plan an early intervention 
that must be effective to improve their quality of life, to minimize harm and reducing the 
economic burden related to additional care of palliate patient suffering (Park et al., 2004).  
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When using ROC diagnostic models, the performance of the model should be judged in the 
context of the analytic situation to which the test is applied. In this study, a salivary protein’s 
cut-off point was chosen with a high sensitivity and a specificity over 50% for each protein 
analysed. In regard to AUC, every protein presented over 60% of this factor in concordance 
with the reports of Bradley (1997).  
To date, no singular predictive model has been presented for accurately predicting the risk of 
developing and grade of severity in oral mucositis before radiotherapy. Therefore, this novel 
clinical model that analyses unstimulated whole mouth saliva by using quantitative 
experimental methods to detect certain proteins concentration and secretion rate pre-
treatment (T0) in head and neck cancer patients to be compared with cut off points chosen 
from the ROC curve of the predictive model. The specific proteins concentration and secretion 
rate cut off points were selected with regards to their sensitivity and specificity to target this 
condition and classify patients in the clinic. 
 In this context, it was found that α-amylase with a cut-off point ≥30.14 units/ml had a rate of 
93.1% correctly identify whether a patient would get mucositis with a high sensitivity rate of 
92.59% and a specificity rate of 100%. Which is desirable in order to predict the possibility of 
experiencing an event if his/her estimated risk is above this given threshold. In addition, the 
area under the curve which integrates the curve over all cut off was AUC = 92.5%, indicating 
the best discriminatory power for that protein to differentiate between patients that present 
and not present the side effect, which is why it was selected. 
Mucin 5B, both in terms of concentration and secretion, was also found to be an accurate 
predictor of severity of mucositis. More specifically, the ROC curves analysed mucin 5B 
concentration at Time Point 0 in order to predict the severity of the upcoming mucositis, with 
a cut-off point >16.16 µg/ml, it could predict with a 92.31% rate of correct classification for 
mucositis grades 1 & 2 (according to The WHO oral mucositis scale) with a sensitivity rate of 
100%, specificity rate of 50%, and an area under the curve of 90.91%. Mucin 5B secretion rate 
with a cut-off point >4.65 µg/min could correctly classify 92.31% of mucositis grades 1&2 with 
a sensitivity rate of 100%, specificity rate of 50%, and an area under the curve of 86.36%.  
Analysis to find an accurate predictor for oral mucositis severity grade 3, revealed that total 
protein concentration could be potentially used as a biomarker at Time Point 0 for upcoming 
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oral mucositis, with a correct classification rate of 62.5% when the cut-off point is >1.94 
mg/ml, with a sensitivity rate of 90%, specificity rate of 50% and an area under the curve of 
62.27%. It should be noted that this study could not be used to predict severity grade 4 of oral 
mucositis as none of the participants of this study manifested severity grade 4; however, it 
stands to reason that the study could be recreated with patients in the life-threatening 
condition of grade 4 and a biomarker found for the most severe grade of oral mucositis.  
Whilst all the aforementioned analytical models identified potential onset and severity of oral 
mucositis during IMRT, ROC curves were also used to analyse salivary proteins collected at T0 
as a possible molecular predictor of mucositis severity (grades 1&2) two weeks after IMRT 
and found that α-amylase  with a cut-off point > 22.77 units/ml could accurately predict these 
severities with a correctly classified rate of 87.5%, a sensitivity of 100% and specificity of 50%, 
and an area under the curve of 91.67%. 
The data found here demonstrates that whilst no single parameter could be utilised to fully 
elucidate the possibility of occurrence and severity of oral mucositis, the potential exists for 
combinations of certain protein concentrations and secretion rate signatures, more 
specifically total protein concentration, α-amylase  concentration, mucin 5B concentration 
and mucin 5B secretion rate; to be utilised as a suitable suite for the early detection of oral 
mucositis prior to IMRT in a routine clinical situation. This possibility of finding a non-invasive 
and cost effective diagnostic method that can discriminate between patients with a high 
accuracy presents a crucial new discovery in the fight to reduce the serious side effects of 
head and neck cancer treatments, allowing for the reduction of risks for severe mucositis 
clinical outcomes and freeing up of extra resources for patient aftercare (Raber-Durlacher et 
al., 2013; Normando et al., 2017).  
This goes against the grain of past studies, which did not focus on diagnostic biomarkers for 
severity or onset of this highly prevalent cancer treatment side effect, with the main bulk of 
research dedicated to efforts of reducing intensity and duration (Sonis, 2011; Epstein et al., 
2012; Duarte et al., 2014; Franco et al., 2017; Normando et al., 2017), as symptoms still appear 
over 8 weeks after completion of treatment (Bensinger et al., 2008)and duration of oral 
mucositis in relation to radiotherapy can range from 3 to 12 weeks (Rosenthal and Trotti, 
2009). The current model can predict mucositis prior to IMRT, as well as the potential severity, 
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which can allow for an increased range of treatments for achieving effective clinical results 
(Charalambous et al., 2018).   
For such a condition with high prevalence in head and neck cancer patients, as well as the 
wide variety of further symptoms that affect sufferers of oral mucositis across the most 
severe cases (Sonis, 2011; Epstein et al., 2012), it becomes important to further validate these 
diagnostic models. The theoretical validation of the novel predictive method developed in 
this study was based on statistical procedures to determine the possibility of developing 
mucositis and severity predictor, on the basis of specific salivary proteins with this side effect 
at Time Points 0, 1 and 2. However, this method will need further experimental validation in 
prospective clinical studies, whether they be with a new range of patients, with patients who 
also exhibit more severe cases of oral mucositis, or with patients of more diverse age ranges. 
This would further validate these findings, as the ability to predict the risk of onset, as well as 
the severity, of oral mucositis in head and neck cancer patients undergoing IMRT could be of 
supreme importance, because it would allow healthcare workers to identify patients who are 
more at-risk, providing them with tailored oral care education along with development of 
appropriate preventive and supportive care for this high-risk group in order to keep them in 
the lowest severity, ultimately reducing pain and discomfort.  
Such preventive measures would begin to take place prior to IMRT, by allowing the oncology 
team to keep patients in lower grades of severity for mucositis, reducing the probability of 
hospitalization, improving treatment outcome and quality of life. Clinical methods would 
include not only educational measures for maintaining oral health, but also detailed 
personalised care plans to reduce risk factors such as controlling oral infections in order to 
maintain bacterial homeostasis, dental and periodontal health, oral hygiene and nutritional 
intake monitoring. This has been demonstrated previously, with a study of paediatric cancer 
patients revealing that the degree of mucositis and pain levels diminished when children and 
their parents were educated regarding mouth care before chemotherapy(Yavuz and Bal 
Yılmaz, 2015). A further study concluded that providing a saline mouth rinse regimen and 
education programme on radiation‐induced oral mucositis patients increases their social-
emotional quality of life, in comparison to standard treatments for head and neck cancer 
patients(Huang et al., 2018). 
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Therefore, it is important to identify at-risk groups of patients prior to radiotherapy, in order 
for them to start with care actions, monitoring and even education programs for parents or 
next of kin; in an attempt to reduce the severity and risk of onset for oral mucositis (Yavuz 
and Bal Yılmaz, 2015; Huang et al., 2018).  
All these measures may promote better physical and social-emotional quality of life, which is 
deeply impacted by oral mucositis symptoms, for example palliative measures for xerostomia 
such as no sugar chewing gums or mouth washes. This would all be done with the main aim 
of not only increasing patients’ well-being but also increasing patient compliance with cancer 
treatment. Lack of compliance can typically lead to treatment interruptions, delays, altered 
dosages and fractioning due to regular visits to the emergency room and hospitalization to 
manage debilitating oral pain, receiving parenteral feeding and secondary infection 
treatment. This is of particular importance, not only because cancer treatment interruptions 
will threaten survival rate and remission (Scorsetti et al., 2010) but also because one of the 
key aspects behind oral mucositis is the multifactorial origin and pathobiology nature of this 
condition. 
The multifactorial origin of oral mucositis is also one of the biggest drawbacks in a study to 
develop risk prediction models, with specific patient factors prevalent in this cohort such as 
smoking history and alcohol intake, both of which have been shown to dramatically affect 
immunological profiles and microvascular changes resulting in altered inflammatory 
responses (Al-Dasooqi et al., 2013). Oral mucositis has been defined as a complex cascade of 
biological events that includes microvascular damage, inflammatory and extracellular matrix 
alterations along with host microbiome interactions (Al-Dasooqi et al., 2013). 
Another limiting factor of this study is that in order to establish a truly recognised predictive 
model – one that serves as a diagnostic tool to corroborate the direct relation with the 
condition and specific salivary proteins - it would require extensive validation with 
collaborative efforts from healthcare professionals. Currently, such predictions are made ‘off 
the cuff’ based on each particular clinician’s past experiences. Furthermore, oral screening 
and physical examinations in this group of patients were not easy to obtain before and after 
IMRT,  due to the number of appointments that they undergo before cancer therapy as well 
as the multitude of examinations to fulfil cancer treatment requirements which may 
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complicate the possibility of adding extra bodily fluid collection tests to the regular 
appointments.  
However, there are also many advantages to take in to consideration, in comparison with 
existing methods of diagnostics. One such advantage is the use of saliva for testing specific 
proteins before radiotherapy, with sample collection being relatively simple, pain-free, stress-
free and cost-effective in comparison to blood or serum tests, making such a screening 
method performed before radiotherapy suitable to be validated in large clinical studies.  
Another advantage of the methods of this study is that the proteins utilised are salivary 
components related to lubrication and protective functions, therefore they could be collected 
with relative ease in order to identify other oral injuries such as xerostomia or taste palate 
changes, alongside the possibility to predict oral mucositis at the time of examination which 
can be reported using the same scale during radiotherapy.  
This novel method of diagnosis that measures quantitatively specific salivary proteins in head 
and neck cancer patients before IMRT can make an important contribution in developing 
preventive therapeutic measures to diminish the impact of IMRT on quality of life of these 
cancer survivors along with improving treatment compliance.  
Hence, through these findings we developed a working predictive model to use for future 
clinical applications and thus rejected our null hypothesis that there are no longitudinal 
associations between IMRT-induced changes in salivary markers with oral mucositis severity. 
We reason that the most probable links with oral mucositis at T1 are total protein secretion 
rate, as well as concentration, mucin 5B secretion rate, mucin 7 secretion rate, α-amylase 
concentration, as well as secretion rate, Albumin concentration, and Albumin secretion rate. 
This is of note, because whilst it is known that there are compositional changes to saliva in 
cases of oral mucosal diseases (Hassona and Scully, 2016), these associations have not been 
explored previous to this study and thus this was  the first report of the combined application 
of salivary protein analysis and oral mucositis assessments, with the observations and clinical 
findings presenting potential implications in the pathophysiology of radiation-induced side 
effects.  
Furthermore, links were identified at time Points 1 & 2 with both IgA secretion rate and 
concentration. However, these were dismissed as not likely links. The first set of findings were 
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then further analysed to reveal potential diagnostic biomarkers of oral mucositis, even prior 
to IMRT, in the analysis of total protein concentration, α-amylase concentration, mucin 5B 
concentration and mucin 5B secretion rate. These findings should be explored further in a 
wider study of participants, to validate the predictive models by assessing UWMS proteins 
collected before IMRT compare these outcomes with ROC curves cut-off points, classifying 
patients regarding their risk of presenting this side effect. Finally, comparing the predictive 
results with oral mucositis clinical onset and severity monitored by oncology team.  
Such predictive models present a truly novel innovation in the preventative care of these 
groups of at-risk patients, making the potential personalised care plans and preventative 
measures a realistic possibility in order to modify risk factors. All of these preventive and 
educational care regimes would allow for patients to maintain a quality of life and social-
emotional well-being similar to that of prior to treatment (Yavuz and Bal Yılmaz, 2015; Huang 
et al., 2018).   
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Chapter 5  
5.1 Thesis Summary  
 
Whenever new radiotherapy delivery treatments are introduced, they are evaluated both 
experimentally and clinically in relation to existing technologies, as well as in relation to 
further alternatives. However, an omission is that they are often not evaluated for their ability 
to partner with existing protocols to treat the well-documented side-effects of such 
treatments (Davidson et al., 2011; Heijkoop et al., 2014).  
This study quantitatively evaluated Intensity-Modulated Radiation Therapy (IMRT) for their 
purported ability to spare non-cancer tissues in head & neck cancer therapy. More 
specifically, to assess salivary gland function, using non-invasive analysis, as traditional 
radiotherapy treatments produce a range of disruptive side effects due to the proximity of 
the tumour to the salivary glands (Tschoppe et al., 2010; Nutting et al., 2011).  
Whilst previous studies have observed the changes involved following IMRT with the 
biochemical composition of saliva (Richards et al., 2017),  xerostomia (Nutting et al., 2011), 
salivary flow rate (Hawkins et al., 2018), altered taste perception (Sio et al., 2016) and oral 
mucositis (Kouloulias et al., 2013), there still remain many unanswered questions, such as the 
long-term nature of these changes, as well as whether there are any associations between 
them. This study not only observed all the changes mentioned above, but also brought into 
scrutiny the clinical dental assessments, clinical observations and associations between all the 
aforementioned factors. In particular, analysing each factor and salivary protein composition, 
allowed identification of salivary biomarkers and their corresponding link to oral mucositis 
presence and severity.  
The aim of this study was to analyse and evaluate the medium-term nature of oral side effects 
and changes in nine salivary protein composition, as well as their possible associations, in 
order to develop a clinical and laboratory-based model, built on these connections, for the 
prediction of the incidence and severity of  oral mucositis in particular as it is one of the most 
frequent and more severe side effect of radiotherapy for head and neck cancer patients 
(Sonis, 1998, 2004a). Often defined as the dose-limiting side effect of RT, oral mucositis 
impairs daily activities such as the ability to swallow and feed normally, consequently 
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necessitating parenteral feeding, systemic analgesics, including opioids for pain control (Elting 
et al., 2008; Villa and Sonis, 2016).  
The findings of this study revealed that despite IMRT’s capacity to spare the parotid glands 
during treatment, it still provoked some persistent changes in UWMS flow rate, protein 
concentration and secretion rate, along with the appearance of clinical oral side effects 
related to radiotherapy that were seen longitudinally until one year post cancer treatment. 
This study also addressed the longitudinal associations of sialometry and protein composition 
of saliva on clinical symptoms, xerostomia and taste alteration, along with signs and 
symptoms of carious lesion and oral mucositis onset and severity.  
These findings rejected the original the null hypothesis of the study – that ionising radiation 
has no effect on UWMS saliva composition at both time-points following IMRT. Overall, it was 
revealed that all side effects of radiotherapy were interconnected using statistical modelling 
of longitudinally processed data. This demonstrated that there were associations among a 
group of clinical symptoms, as well as clinical and biochemical salivary composition variation, 
that will affect the patient’s quality of life, such as salivary gland function - which was 
observed clinically as a significant reduction in salivary flow rate resulting in xerostomia and 
altering taste perception. Additionally, a decreased salivary volume was accompanied and 
significantly associated with an altered protein composition/secretion rate, in addition it was 
reported the significant relationship between both and oral mucositis onset and severity. The 
associations found between reduced salivary volume and these clinical side effects are in line 
with past studies that observed saliva as a critical element in maintaining oral homeostasis 
and host protection (Hannig et al., 2017; Pitts et al., 2017).  
The results of chapter 2 revealed that the clinical, and quality of life, side effects of IMRT, such 
as xerostomia, number of teeth, taste perception, were all in line with the existing 
radiotherapy literature (Almståhl et al., 2001; Dijkema et al., 2012; Laheij et al., 2015; Richards 
et al., 2017). These observations of significantly reduced salivary flow rate, which is a vital 
factor in maintaining oral health and functionality (Dawes et al., 2015), are backed up by the 
principle that an alteration of optimal properties of saliva will lead to a disequilibrium, 
increasing oral disease risk (Pitts et al., 2017).  
Therefore, the next step was to analyse the biochemical properties of the saliva, with salivary 
proteins and mucins selected to be observed. 
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It was demonstrated that the total protein secretion rate was significantly reduced after 
IMRT, along with a reduced salivary volume. These changes were long lasting, without 
reaching baseline levels even after 1year post cancer treatment. However, total protein 
concentration significantly reduced at T1 showed a significant recovery at T2.  Additionally, 
this study observed the influence and dependence of flow rate and protein concentration and 
secretion rate being significantly associated post IMRT.   
The individual salivary proteins to be studied were selected according to their functions 
regarding oral homeostasis and their importance of maintaining a harmonious mutually 
beneficial relationship with microorganism, along with facilitating daily functions and directly 
or indirectly influencing the risk of developing oral diseases(Carpenter, 2013b; Proctor, 2016; 
Lynge Pedersen and Belstrøm, 2019). 
Mucins were selected due to their ability to alter the wetting capacity and lubrication of 
mucosal surfaces (Vissink et al., 2010), with mucosal integrity being vital in HNC patients, due 
to the high rate of oral mucositis onset during radiotherapy along with xerostomia. Mucin 5B 
and 7 are vital molecules regarding mucosal pellicle to maintain a protective barrier 
,hydration and bacterial adhesion (Hannig et al., 2017; Lynge Pedersen and Belstrøm, 2019). 
Mucins are capable of forming complex with IgA which is the main antibody in saliva and plays 
an important role in bacterial colonization (Dawes et al., 2015; Hemadi et al., 2017). If 
secretion of these glycoproteins in a functional state is not preserved, then it is unlikely 
further improvements in oral mucosa integrity and xerostomia are to be made. 
α-Amylase was chosen to be observed as it is one of the most prevalent enzymes in saliva and 
is generally considered to be a reliable marker of serous cell function (therefore acting as a 
marker for parotid gland function (Proctor, 2016), along with its influence in oral biofilm 
formation and bacterial colonization. 
Changes in concentrations of albumin have been linked to inflammatory processes and 
increased vascular permeability (Jensen et al., 2003), whilst cystatin S may be considered a 
biomarker in assessing submandibular glands function (Martini et al., 2017). PRPs can also act 
as biomarkers for submandibular and parotid glands, as they are secreted by parotid and 
submandibular glands and contain between 25-42% of proline amino-acids (Carpenter, 
2013b).  
Carbonic anhydrase VI plays a fundamental role in controlling taste sensation and taste bud 
growth, by facilitating the interaction between food particles and taste buds (Hunter, 2013).  
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 Statherin was selected as it is secreted by all 3 major glands, being a phosphoprotein secreted 
from parotid, submandibular and sublingual glands. Furthermore, past studies have also 
observed that albumin, statherin, cystatin S, PRP, mucins 5b and 7 form acquired enamel 
pellicle, reducing the possibility of erosion and abrasion, determining biofilm formation, 
keeping mineral equilibrium by maintaining a high concentration of calcium and buffer 
capacity (H. L. Gibbins et al., 2014; Hannig et al., 2017). Therefore, all of these salivary bio-
composites were observed, as it is important to assess concentration and secretion rate of 
these salivary proteins in order to evaluate overall functionality (Dawes et al., 2015).   
Overall, the variation of biochemical composition of UWM saliva in HNC patients undergoing 
radiotherapy were in line with other authors outcomes (Dijkema et al., 2012; Richards et al., 
2017). However, this study added more results, including secretion rate of 9 proteins and a 
longer follow-up period with a baseline outcome to compare. Moreover, there was analysed 
the associations between these proteins regarding its functions with clinical oral side effects 
reported in previous chapter. 
The outcomes revealed that there were significant protein concentration and secretion rate 
variations in saliva as a side effect of the cancer treatment. These findings altered normal 
feelings in each individual’s mouth and led to an increased risk of oral diseases regarding oral 
tissues (Chaudhury et al., 2015; Frenkel and Ribbeck, 2015; Vijay et al., 2015; Hemadi et al., 
2017). This was demonstrated with the significant associations between the 9 proteins 
analysed and dry mouth feeling, taste acuity, as well as salivary flow rate as reported in 
chapter 3. Such number of proteins longitudinal association analysis have not been performed 
in the literature. Regarding mucin 5B associations with salivary flow rate are similar to past 
findings, such as the Dijkema research group reporting trends of xerostomia after 
radiotherapy with only protein, mucin 5b levels, in submandibular saliva from patients 
(Dijkema et al., 2012). 
These side effects were observed in this particular study mostly in the form of oral mucositis, 
a morbid condition that occurred in 77% of this study’s participants, as shown in Chapter 2, 
with 45% of those exhibiting Grade 2 mucositis and 51% exhibiting Grade 3 mucositis. These 
grades were recorded according to the WHO oral mucositis scale, a grading system that 
documents the severity and prevalence of mucositis, with the scale being one of the most 
commonly used in order to track this condition. However, there is no universal scale for 
measuring mucositis, with this being one of the biggest drawbacks in oral mucositis research. 
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Other scales used by others include the Radiation Therapy Oncology Group scale (RTOG) and 
European Organisation for Research and Treatment of Cancer scale (EORTC). Whilst  
RTOG / EORTC are focused on patients’ levels of pain and suffering, in order to measure the 
necessity of analgesia; the WHO oral mucositis scale is focused on patients’ functionality in 
relation to the capacity to eat solid food (Sciubba and Goldenberg, 2006; Sroussi et al., 2017). 
However, these are all subjective measurements, with evaluative outcomes dependent on a 
physician’s clinical experience and training in order to clearly define categories on each 
relevant scale. This presents a clear limitation of all studies observing oral mucositis as it 
makes it more arduous to perform validation studies because these instruments are 
vulnerable to misinterpretation and clinical subjectivity.  
Furthermore, questionnaire-based points of data collection, such as surveying for “dry mouth 
sensations” in order to determine xerostomia, are another limiting factor for this study as the 
survey’s respondents are not clinical experts. This leads to subjectivity, misinterpretations and 
omission errors during data collection, whether that be due to two subjects having different 
subjective value points or whether a subject might submit rushed/false data to speed up their 
experience as a result of the length of the surveys. Thus, these measurement scales require 
adaptation for patient use, as almost all scales are designed for physician use (Ho et al., 2010). 
This has been demonstrated in past literature that reported differences between patient-
reported data and clinically observed data (Bentzen, 1998; Davidson et al., 2007). Despite the 
aforementioned limitations, the methodology used in this instance for determining potential 
xerostomia is one that has been long established and used by others for decades (Fox et al., 
1987). The questionnaire used for taste variation is an extract from the Late Effects on Normal 
Tissues (LENT), Subjective, Objective, Management, Analytic (SOMA) survey (Davidson et al., 
2007; Ho et al., 2010). The use of LENT-SOMA is, once again similar to our xerostomia 
methodology, well established and has even been included into the National Cancer 
Institute’s (NCI) documented methodologies (Davidson et al., 2007; Ho et al., 2010).  
The lack of uniformity in measurement scales for such clinical oral studies could be one 
limiting factor affecting long term comparative reviews, which is of particular importance due 
to the fact that, at the present time, there are no effective, direct treatments to reduce oral 
mucositis onset, severity and duration. Also, there are no medications to prevent oral 
mucositis, even though there are numerous studies testing different products, promoting oral 
hygiene, food advice, reducing alcohol intake and quitting smoking, these are only palliative 
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measures (Park et al., 2004). However, more recently, there have been studies focussed on 
the use of antibodies in IMRT patients to neutralize the inflammatory response of mucositis, 
as well as increasing defensive response (Villa and Sonis, 2016; Normando et al., 2017). 
Another important factor in this study was the enrolment of patients with several tumour 
locations and IMRT treatment sites. It was revealed that despite the fact that each individual’s 
tumour location was different, IMRT’s capacity to spare the glands, and therefore the salivary 
protein profile and secretion rates, were still affected in all patients, along with development 
of clinical side effects. The primary tumour sites were mostly tonsillar (n=12), oropharynx 
(n=6) and tongue (n=5), which are closely proximate, affecting more than 50% of the 
examined group, with the minority divided into five different subsites. Another study that 
supports the current findings that different IMRT treatment sites had no effect on 
consequential side effects, is a demonstration of how different primary tumour sites are 
unlikely to affect the xerostomia prevalence when the radiation-dose parameters are 
matched between the experimental groups (Richards, 2014).   
Furthermore, the current study’s radiation dosage and fractioning regime were delivered in a 
range that was quite narrow, varying between 55-65 Gy with an average fractioning of 2Gy 
per day. This reduced the probability of tumour sites affecting the prevalence of side effects, 
as backed up by a previous study that observed how site specific post-radiotherapy 
treatments were of no difference when the radiation dosage to the salivary gland remained 
below a certain level (Pringle et al., 2013) this could be is explained by the bystander effect, 
which consider the Reactive Oxygen Species (ROS) as the possible source of the signal and in 
the propagation of radiation effects from irradiated cells to adjacent unirradiated cells 
(Mothersill et al., 2019). 
This is similar to our findings of oral mucositis, whereby it was observed that there were no 
differences in onset or grading, in contrast to prior literature that stated that the risk of this 
side effect varies with the site of the primary tumour, (Chao et al., 2001; Pinna et al., 2015; 
Strojan et al., 2017; Sroussi et al., 2017).  
 
Chapter 4 focussed on establishing whether a clear predictive biomarker for mucositis can be 
identified prior to the commencement of radiotherapy treatment. Once such potential 
biomarkers were identified, their specificity and sensitivity rate of predictive accuracy were 
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analysed, then a further step was taken to analyse each grading of mucositis against the 
diagnostic ability of predictions using a Receiver Operating Characteristic (ROC) curve.  
The findings revealed that α-amylase concentration, mucin 5b concentration and secretion 
rate, as well as total protein concentration, can all be suitable as biomarkers for the detection 
of oral mucositis, prior to IMRT by collecting UWMS. Such predictive biomarkers present new 
possibilities in oral mucositis research and represent an opportunity for clinical trials with this 
novel method allowing for speeding up research and routine laboratory techniques, as they 
were found to be reliable, as well as allowing for non-invasive sample collection and cost-
effective diagnostic methods during a routine clinical appointment. This represents not only 
an opportunity to create a clear identifier to prevent cancer treatment interruption (Turner 
et al., 2013) but also the opportunity to create personalised preventive care regimes in order 
to reduce the effects on mucositis, prior to even the development of oral mucositis symptoms 
(Normando et al., 2017).   
However, such conclusions should be observed further and further evaluated, as salivary 
components display redundancy of function, each often having more than one (Dowd, 1999). 
This suggests that the findings of Chapter 4, whilst important as a base point to begin further 
evaluations to find biomarkers for oral mucositis prior to IMRT taking place, could also be 
affecting other functions or indicating other protein pathway networks in place that are acting 
on these oral functions. Therefore, it is important that such predictive models are extensively 
tested and validated in a longitudinal prospective randomised clinical trial including more 
patients, perhaps multicentre, maintaining the robustness and reproducibility of the saliva 
collection, storage and laboratory assays along with keeping the oral mucositis assessment 
and adding more clinical features to have a full characterization of this condition during and 
after IMRT (Elashoff et al., 2012).   
The evaluation of salivary components revealed a relationship between oral mucositis and α-
amylase concentration, mucin 5b concentration and secretion rate, as well as total protein 
concentration. However, it has not been able to articulate the reasoning behind these 
findings, as to the role of each salivary component and how they could be acting within the 
relationship with oral mucositis. The determination of the role of each biomarker would be 
an important part in the translation of these laboratory diagnostics into clinically applicable 
tests (Podzimek et al., 2016), but until each biomarker has been evaluated in longitudinal 
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studies across a large pool of patients, as well as evaluated for the causalities behind them, 
they are not considered truly clinically applicable markers (Podzimek et al., 2016).   
Once such evaluations are concluded, the next steps would be for the development of a 
protocol to guide clinical diagnosis, deliver accurate prognostic information and monitor 
disease progression, allowing for dentists and clinicians to develop not only pre-emptive care 
plans but also educational programs tailored for each patient. Studies reveal that 
development of such personalised care programs based on individual diagnostics can help 
lower the severity of mucositis, potentially delay onset and progression in head and neck 
cancer patients, along with reducing a plethora of symptoms which combined effect can 
drastically reduce quality of life of these patients (Sonis, 2011; Epstein et al., 2012), as well as 
the ease for the patients’ families (Yavuz and Bal Yılmaz, 2015; Huang et al., 2018).  
In conclusion, whilst the patient’s role in mitigating the toxic side effects of head and neck 
cancer therapy is increasingly acknowledged, allowing for the potential implementation of 
personalised educational and care plans that can drastically reduce quality of life of these 
patients (Dowd, 1999; Sonis, 2011), without the diagnostic ability of biomarkers it is nigh-on-
impossible to determine which therapeutics are necessary ahead of treatment. Therefore, 
this study evaluated all aspects of saliva and the oral cavity’s eco-system and determined not 
only functional insights into nine proteins and their relationship with clinical observations 
(such as taste perception changes), but also revealed that salivary α-amylase  concentration, 
mucin 5B concentration and secretion rate, as well as total salivary protein concentration, can 
all be suitable on their individual basis to be used as molecular markers for the detection of 
oral mucositis, prior to IMRT by collecting UWM saliva. And whilst it has been known that 
there are compositional changes to saliva in cases of oral diseases (Hassona and Scully, 2016), 
this has been the first report of its kind to combine the application of salivary protein analysis 
and oral mucositis assessments, with the observations and clinical findings presenting 
potential implications in the pathophysiology of radiation-induced side effects, and even 
finding a biomarker that could correctly classify 92.31% of cases ahead of IMRT, which may 




5.2 Summary and Suggestions for Future Work 
 
The   outcomes   of   this   thesis   suggest   the   need   for   further   clinical and   biochemical 
investigations, regarding IMRT side effects in the oral cavity. Despite the advances in 
evaluations of side effects that were reported in the literature, it is evident that radiation-
induced salivary gland hypofunction remains in sizable quantities of the patient group, which 
affects the oral cavity environment significantly. 
1. Biochemically, from the data presented in this thesis the next steps regarding salivary 
composition variation post IMRT should be assessed mucin functionality. This is based 
on their structure composition:  Analysis of the molecular composition of Mucins 5b 
and 7 from UWMS and assessing the glycosylation protein rate in order to analyse 
mucin hydration capacity – which is an important component in mucin functionality 
and structure (Chaudhury et al., 2015). Periodic acid–Schiff staining directly on protein 
gels is capable of detecting mucin glycosylation structure. Furthermore, to detect the 
protein core of the mucins, western blot analysis using antibodies is required. The 
relative proportion of glycosylated mucin to mucin protein (glycan/protein 
proportions), allowing the estimation of glycosylation per unit protein, can be 
calculated by dividing PAS staining– detected mucins with antibody-detected mucins. 
2. Increase the length of follow-up periods of the clinical trial participants. This involves 
clinical oral assessment and biochemical analysis of saliva composition, adding time 
points up to 2.5 years. A singular follow up after just one year is insufficient to detect 
changes in teeth integrity regarding radiation caries onset and development, along 
with the possible associations with volume and biochemical (proteins) composition of 
saliva that are relevant protective/modulating factors that modify the caries process.  
3. It would be useful to determine the exact dose of radiation received by each salivary 
gland, including the left and the right as well as the volume of the gland irradiated. 
This information can be obtained for each patient from the radiation treatment 
planning software, by manually contouring salivary glands using a 3D pencil beam. The 
delineation permits to obtain a three-dimensional dose distribution for each gland in 
each patient and the average of the mean and the maximum point doses for each 
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defined region. These dosimetric values allow for more accurate determinations of 
the influence of radiation on clinical outcomes and salivary proteins.   
4. Design a new prospective clinical trial - including new patients and extra time points 
during and early after IMRT to the 3 investigated in this study. 
The data of this thesis highlights potential implications of oral mucositis regarding 
assessment and characterization during and after IMRT, along with the validation of 
possible markers for this side effect.  Clinical evaluation will incorporate new factors 
to the WHO scale, such as anatomy, size of ulcers and report the regions affected 
throughout the oral cavity in order to have an accurate picture of this side effect.   
Clinical assessment along with UWMS sample collection before IMRT, during IMRT, 2 
weeks post IMRT, 6 weeks post IMRT and 3, 6, 12 months. Biochemical analysis of 
proteins before IMRT in order to compare with cut off points obtained from the ROC 
curves, for each protein, classification of patients whether they are or not in risk of 
developing of oral mucositis as well as severity. Follow-up of these patients during and 
after the cancer treatment to corroborate our findings with the clinical outcomes, to 
validate the predictive model proposed in this thesis.   
5. Assessing outcomes of xerostomia without the use of patient reported surveys. 
Despite the fact that IMRT is purported to spare salivary glands during treatment, this 
study showed a high prevalence of xerostomia reported by patients along with a 
significant reduction of flow rate and altered mucin 5B and 7 composition and 
secretion rate.  It has been established that sublingual and minor salivary glands are 
the sole sources of Mucins 5B and 7 in the oral cavity (Carpenter et al., 2014; Proctor, 
2016). If secretion of these glycoproteins in a functional state is not preserved, further 
improvements in dry mouth perception would be unlikely. Therefore, the outcomes 
of xerostomia, to assess the level of radiation side-effects on these salivary glands, 
should be assessed using one of the multiple objectives and analytical techniques, to 
assess oral-dryness and the functional integrity of saliva. One such method is assessing 
the extensional properties of saliva via Spinnbarkeit (stringiness) measurements using 
the Neva Meter (IMI-0501; Ishikawa Ironworks Co., Kobe, Japan). 
6. Analysis of minor salivary glands via the new prospective clinical trial designs. 
Current data on minor salivary glands in head and neck cancer patients seem to be 
limited, thus it is imperative to analyse minor salivary glands flow rate and protein 
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concentration regarding mucosal pellicle. The prospective trial models should contain 
detailed assessments of quantitative and qualitative measures of mucin function and 
patient symptoms. Residual mucosal saliva collection from different locations in the 
mouth such as anterior hard palate, buccal and lower labial surfaces. This collection 
will utilise filter paper discs, Sialo Paper strips (Oraflow Inc., Smithtown, NY, USA) and 
measured using Periotron 8000 (Oraflow Inc). This would allow for analysis of cases 
whereby patients still report “dry mouth sensation” despite steady salivary flow rates, 
caused due to a depravation of surface mucosa of its salivary wetting characteristics 
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Tel: 020 7188 7188 
 
Conditions of confirmation of capacity and capability to conduct research at Guy’s and St Thomas’ NHS 
Foundation Trust (GSTFT) 
 
1. Recruitment reporting: 
It is mandatory that all research participants at Guy’s and St Thomas’ NHS FT are entered into the research 
management system ‘Edge’. Your R&D contact will have created you (or your nominated delegate) an account 
for the system. Please refer to the ‘Quick Help Guide’ already provided. Participants must be uploaded into the 
system in real-time or weekly as a minimum, in order for the Trust to maintain a real-time record of its 
recruitment into clinical research studies. Please contact edgesupport@gstt.nhs.uk if you have any problems. 
The R&D department hosts regular training sessions on the system. Please enquire about these via the same e-
mail. 
 
2. Safety reporting  
All investigators should ensure that they elicit information regarding adverse events from participants at each 
study visit. If a Serious Adverse Event (SAE) is discovered, the investigator must alert the Sponsor immediately 
(within 24 hours) to ensure that events are reported to ethics and regulatory bodies within the timelines. 
 
Please refer to the HRA guidance on safety reporting: 
http://www.hra.nhs.uk/research-community/during-your-research-project/safety-reporting/ 
 
For Trust/KCL sponsored Clinical Trials of Investigational Medicinal Products, please refer to the King’s Health 
Partner Clinical Trials Office Standard Operating Procedures: 
http://www.khpcto.co.uk/SOP/SOP.html 
 
3. Protocol deviations and breaches in GCP 
If there is a breach of the study protocol or Good Clinical Practice, likely to affect to a significant degree:  
- the safety or physical or mental integrity of the subjects of the trial and or; 
- the scientific value of the trial 
This must be reported within 24 hours to the R&D department. 
 
For Trust/KCL sponsored Clinical Trials of Investigational Medicinal Products, please refer to the King’s Health 
Partner Clinical Trials Office Standard Operating Procedures: 
http://www.khpcto.co.uk/SOP/SOP.html 
 
4. Protocol Amendments  
Investigators should alert the R&D Department if there is an amendment to the study.  An amendment may 
include changes to study documentation, a decision to use advertising, changes to staff or revisions to study 
timelines.  
  
Where studies are sponsored by GSTFT, changes to the protocol and/or other study documents must be 
submitted to the R&D Department for review prior to ethics submission if applicable. Trust confirmation of 
capacity and capability must be issued prior to the implementation of any amendment.  
 
5. Training 
Please ensure all researchers for the study have the appropriate study specific training. For Clinical Trials of 
Investigational Medicinal Products, each member of the team is required to have up to date training on Good 
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Appendix 3: Clinical trial participant’s information sheet 
 
                                                     
 
 
Information sheet  
 
1. Study title 
“The characterisation of therapeutic radiation-induced dental caries: the 
histopathological, ultra-structural and microbial changes affecting its prevention 
and treatment” 
 
2. Invitation paragraph 
You are being invited to take part in a research study.  Before you decide whether 
or not to participate, it is important for you to understand why the research is 
being carried out and what it will involve.  Please take the time to read the 
following information carefully and discuss it with friends, relatives and your 
general dental practitioner.  Please ask us if there is anything that is not clear or 
if you would like more information.   
Take the time to decide whether or not you wish to take part. Thank you for 
reading this. 
 
3. What is the purpose of the study? 
The first treatment option in head and neck cancer is radiation therapy, which 
entails, in simple words, high-energy X-rays.  All of the head and neck cancer 
patients who take part in this study are going to receive this therapy, with the 
dose and duration of the treatment being determined by the oncologist; the 
exposure that you will receive as part of your care will not exceed the normal 
dose. As part of your treatment pathway, you are going to attend a dental 
appointment at Guy’s Hospital (on floor 26) and receive routine dental X-rays, 
which involve small exposure to ionising radiation; this is not above what would 
be received routinely as part of your dental treatment before starting cancer 
therapy.  
Patients treated for head and neck cancer may suffer both short-term and long-
term side effects around the area for which they are receiving the therapy, which 
can include speech defects, difficulties in eating, dry mouth, dental problems, 
sore mouth, and limitation of mouth opening.  
The aim of the study is to identify oral side effects of radiotherapy for head and 
neck cancer patients in order to assess whether specific changes in oral 
microbiota, saliva quality and teeth following radiation therapy are associated with 
both the severity and the increased risk of caries. 
We will also follow up with participants at 12 months post-enrolment in the trial. 
At their routine follow-up appointments we will add two more visits after they finish 
their regular dental appointments at the special dental care clinic at Guy’s 
Hospital.  
If successful, outcomes of this project will be used to change the service that we 
offer to patients to improve patients’ experience of treatment and to improve 
patients’ long-term quality of life. 
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This study is being carried out in partial fulfilment of the requirements for the 
degree of Doctor of Philosophy (PhD) of Ms. Maria Ines Gonzalez Agurto.  
 
4. Why have I been chosen? 
We are inviting you to take part in this study because you are about to start 
treatment for head and neck cancer. This makes you a suitable person for this 
study. 
 
5. Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part, 
you will be given this information sheet to keep and be asked to sign a consent 
form. If you decide to take part, you are still free to withdraw at any time and 
without giving a reason.  This will not affect the standard of care that you receive 
in any way. 
 
6. What will happen to me if I take part? 
If you decide to take part in this research, your treatment for cancer and your 
dental treatment will proceed as normal. There will be a further two visits, and the 
two regular visits to the special dental care clinic will be slightly longer.  
The aim of the study is to find out the most appropriate treatment regime to limit 
side effects of radiotherapy on oral health, therefore improving patients’ quality of 
life after treatment for head and neck cancer.  
We will follow up with participants at 18 months post-enrolment in the trial. At your 
appointments, we will conduct a clinical evaluation of the dental status and 
periodontal status. After an initial oral evaluation, samples of whole mouth saliva 
will be collected. Supragingival dental plaque, a mucosal swab from the inner 
cheek and, finally, carious dentine samples will be collected using two different 
methods: either from extracted teeth or directly from dentinal carious lesions of 
teeth that will be restored. 
This will be repeated three times, after the completion of cancer treatment. This 
would involve four extra visits for patients beyond current practice.  
 
7. What do I have to do? 
Patients who agree to take part in this study will be required to attend four extra 
visits to Guy's Hospital for follow-up during an 18-month period, which are free of 
charge. 
 
8. What is the drug or procedure that is being tested? 
We are not testing any new procedure or material.  
 
9. What are the side effects of taking part? 
There are no side effects of taking part other than those expected from routine 
dental care. 
 





There are no risks in taking part. The only disadvantage of taking part is a slightly 
longer-than-normal dental appointment of perhaps an extra 30 minutes 
approximately. 
 
11. What are the possible benefits of taking part? 
There are no advantages of taking part. The information that we obtain from this 
study may help us to treat future patients better. 
 
12. What if something goes wrong? 
If you have a concern about any aspect of this study, you should ask to speak to 
the researchers, who will do their best to answer your questions. Please contact 
the principal investigator: Professor Avijit Banerjee, avijit.banerjee@kcl.ac.uk, 
telephone number (+44) 07470223082.   If you remain unhappy and wish to 
complain formally, you can do this through the Guy’s and St Thomas’ Patients 
Advice and Liaison Service (PALS) on 020 7188 8801, pals@gstt.nhs.uk. The 
PALS team are based in the main entrance on the ground floor at St Thomas’ 
Hospital and on the ground floor at Guy’s Hospital in the Tower Wing. 
In the event that something does go wrong and you are harmed during the 
research, you may have grounds for legal action for compensation against Guy’s 
and St Thomas’ NHS Foundation Trust and/or King’s College London, but you 
may have to pay for legal costs. The normal National Health Service complaint 
mechanisms will still be available to you (if appropriate). 
 
13. Will my taking part in this study be kept confidential? 
All information collected during the course of the research will be kept strictly 
confidential. We would also inform your general dental practitioner about your 
health with your permission.  
 
14. What will happen to the results of the research study? 
Results of this research will be published in appropriate dental and scientific 
journals. No personal information or other information that could be identified as 
relating to you will be published. You will be informed of the results of the study. 
 
15. What will happen to my samples?  
All of the samples collected from you would be labelled and stored in the 
microbiology laboratory on the Waterloo campus for further microbiological and 
biochemical analysis. The teeth collected will be placed in the bio-photonic 
laboratory for further microscopy image analysis. The samples will be disposed 
according to the Human Tissue Act protocol.  
 
16. Where my personal data will be kept?  
 
The Principal Investigator will maintain a database of the patient’s personal data 
clinical notes and treatment records. The data will not be transferred outside UK 




















Physical personal data collected in the course of research will be stored under 
controlled access in a locked cabinet, in a clear filing systems in chief investigator 
office on 26 floor at Guy’s campus. (Safe from flood, fire, burglary and pest) 
 
17. How long will personal data be stored or accessed after the study has ended? 
The data will be stored 3 years, after that time the data will be destroyed.   
 
18. How long will research data generated by the study be stored? 




19. Who is organising and funding the research? 
King’s College London. 
 
20. Who has reviewed the study? 




21. Contacts for further information 
For further information please contact: 
Avijit Banerjee  
PhD student: Maria Ines Gonzalez  
King's College London Dental Institute 
Biomaterials Research Group 
Floor 17, Guy's Tower 
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Version 2                               25 October 2016                                           IRAS Project ID: 199100 
 
 
                                                                               
 
 
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES. 
 
Title of Project: The characterisation of therapeutic radiation-induced dental caries; the 
histopathological, ultra-structural and microbial changes affecting its prevention and treatment” 
 
Name of Researcher: Avijit Banerjee 
Thank you for considering taking a part in this research. The person organising the research 
must explain the project to you before you agree to take a part. If you have any question arising 
from the information sheet or explanation already given to you, please ask the researcher 
before you decide whether to join in. You will be given a copy of this consent form to keep and 
refer to any time.                                           
Please              
Tick or Initial 
I confirm that I understand that by ticking/initialling each box I am consenting to 
this element of the study. I understand that it will be assumed that 
unticked/initialled boxes mean that I DO NOT consent to that part of the study. I 
understand that by not giving consent for any one element I may be deemed 
ineligible for the study.                
 
 
1. I confirm that I have read and understand the information sheet dated 25 October 2016 
Version 2  for the above study and I have had the opportunity to ask questions, which have 
been answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible 
individuals from [Guy’s hospital] or from regulatory authorities where it is relevant to my 
taking part in research.  I give permission for these individuals to have access to my records. 
 
4.  I consent to the processing of my personal information for the purposes explained to me. I 
understand that such information will be handled in accordance with the terms of the UK 
Data Protection Act 1998 
  
5.  I understand that confidentiality and anonymity will be maintained and it will not be possible 
to identify me in any publications 
 
6. I understand that the research team may use registered external organisations for the 
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Appendix 8: ROC curve Graph 
ROC curve Graph  
ROC curve graph is a visual tool for evaluating the diagnostic power of the test - in this case of 
selected salivary proteins (concentration\secretion rate) to predict oral mucositis onset and severity. 
ROC curve provides visual information regarding the relationship between sensitivity and specificity 
of every cut off point for each protein selected. Every cut off represents a different value for 
sensitivity and specificity, generating a point on the graph on the ROC curve that indicates whether a 
patient is likely to be diseased or not. The accuracy of the test is represented by the shape of the 
slope, which is more accurate when the curve is closer to the top and left-hand borders. The area 
under the curve (AU ROC) of a test can be used as a criterion to measure the test's discriminative 
power, the maximum value is 100%, on the other hand when the curve is closer to the diagonal 
located from the bottom left corner to the upper right of the graph is less accurate having a 
discriminatory power of 50 % (50 % sensitivity and specificity) which represents pure chance (Park et 
al., 2004; Zhou et al., 2011;Tharwat, 2018).  
 
Analysis of amylase units/ ml collected at Time 0 as a predictor of Oral mucositis grade 1 and 2 two 
weeks post IMRT.    
 
The graph of 2 weeks after IMRT shows that α-amylase unit concentration can be an accurate 
predictor of oral mucositis grades 1 and 2, with an area under the ROC curve of 91.67%, true-
positive rate is high, and the false-positive rate is low, true Positive Rate represents the y-axis and 
False Positive Rate is the x-axis. α-amylase cut-off point that maximises sensitivity and specificity is > 
22.77 units/ml, with a sensitivity of 100% and specificity of 50%. 
 
AUC 
 273 
 
